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A series of 1,4-diaminobutane poly(propylene amine) (DAB-PPI) dendrimer-based ligands 
were prepared with the aim of developing ligands that will permit the synthesis of 
multinuclear technetium-99m (99mTc) radiolabeled complexes. The ligands were synthesized 
by incorporating N,N-donor atom functionalities, at the periphery of DAB-PPI dendrimers, as 
potential 99mTc chelates. Monomeric ligands were also synthesized as model compounds to 
aid with the characterization of macromolecular structures.  
The first (DAB-G1dendr-(NH2)4) and second (DAB-G2dendr-(NH2)8) generation DAB-PPI 
peripheral amine end-groups were functionalized using appropriate aldehydes, bearing either 
2,2’-bipyridyl or 2-picolylamino entities, via a single step reductive amination reaction. The 
monomeric and new dendritic ligands were comprehensively characterized using 
spectroscopic (1H NMR, 13C{1H} NMR, infrared) and analytical techniques (mass 
spectrometry and elemental analysis). Furthermore, the 2-picolylamino-functionalized 
ligands were found to be water-soluble, S25 °C = 0.01 mg/µL.  
A series of non-radioactive (‘cold’) neutral mononuclear and novel multinuclear dendritic 
rhenium(I) complexes of the form fac-[Ren(CO)3(N,N-bidentate)Xn] (n = 1, 4 and 8 for 
monomer, G1 and G2, respectively. X = Cl- or Br-) were prepared and characterized. The 
complexes with the fac-[Re(CO)3Br] core were synthesized at room temperature using the 
(Et4N)[Re(CO)3Br3]. One of the 2-picolylamino monomeric complexes, fac-[Re(CO)3(N,N-
bidentate)Br], was additionally characterized by X-ray crystallography and the 
crystallographic structure confirms the facial arrangement of the three CO ligands together 






The fac-[Re(CO)3(OH2)3]+ precursor was used to synthesize a range of cationic monomeric 
and new multivalent dendritic complexes of the type fac-[Ren(CO)3(N,N-bidentate)OH2]n+ (n 
= 1, 4 and 8 for monomer, G1 and G2, respectively) as 99mTc surrogates. The Re(I)-aqua 
complexes were characterized by spectroscopic and analytical methods.  
In order to evaluate the stability and reactivity of the known labile aqua ligand in fac-
[Ren(CO)3(N,N-bidentate)OH2]n+ (n = 1, 4 and 8 for monomer, G1 and G2, respectively) 
systems, the 2-picolylamino complexes with the fac-[Re(CO)3OH2]+ core were dissolved in 
methanol and the substitution of the water/methanol ligand at the sixth coordination site by a 
range of neutral and cationic monodentate ligands was monitored by stopped-flow 
spectrophotometry. The dendritic fac-[Ren(CO)3(N,N-bidentate)MeOH]n+ (n = 4 and 8 for G1 
and G2, respectively) complexes, containing more than one Re(I) metal centre, were found to 
labilise the fac-[Re(CO)3MeOH]+ core effectively than the monomeric analogue. This was 
supported by an increase in forward second-order rate constants (kn) obtained for the 
substitution of MeOH, by monodentate nucleophiles at 25.0 ˚C, in the dendritic complexes 
compared to the monomeric analogue.  
The water-soluble first generation 2-picolylamino DAB-PPI dendritic ligand was 
radiolabeled with generator-eluted radioactive sodium pertechnetate (Na99mTcO4). The direct 
labeling approach under acidic conditions, afforded satisfactory labeling efficiency at pH 5.5, 
as confirmed by iTLC-SG and Whatmann cellulose paper using a gamma-detector.  
Metalation of the first generation dendritic ligands with fac-[99mTc(CO)3OH2]+ core was 
accomplished using fac-[99mTc(CO)3(OH2)3]+. The regioselective radiolabeling of the 
dendrimers was evaluated using the first generation ‘cold’ fac-[Ren(CO)3(N,N-
bidentate)OH2]n+ (n = 4) surrogates. The similarity in the UHPLC-UV/vis and UHPLC-





picolylamino)OH2]n+ (n = 4, M = Re(I) or 99mTc(I)) dendritic complexes confirmed a similar 
mode of complexation of the metal centres (Re(I) and 99mTc(I)) at the DAB-PPI periphery. 
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 1.1. General introduction 
According to the International Agency for Research in Cancer (IARC) under the World 
Health Organization (WHO), in 2012 there was an estimate of 14.1 million cancer cases, 8.2 
million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) 
worldwide.1,2 Breast cancer is the most common cause of death among women (522 000 
deaths in 2012).1,2 Colorectal and lung cancers are most notable in less developed countries 
of sub-Saharan Africa. The fourth most common cancer affecting women is cervical cancer 
(528 000 cases every new year).1,2  
Overall, the most recent estimates for leading types of cancer dating from 2012, in both 
sexes, worldwide are: 
  Lung (1.59 million deaths), 
  Liver (745 000 deaths), 
  Stomach (723 000 deaths), 
  Colorectal (694 000 deaths), 
  Breast (521 000 deaths),  
  Oesophageal cancer (400 000 deaths).2 
 
Based on statistical data, the WHO has postulated a substantive increase to 19.3 million new 
cancer cases per year by 2025.1 Therefore, effective screening tools and technologies for 
cancer diagnosis and therapy are an increasing demand. 
 




 1.2. Cancer treatments 
There are different medical procedures/therapies that a cancer patient may undergo to 
counteract the effect(s) of the disease. Depending on the state of the cancer upon diagnosis, 
there are prominent tools towards treating cancer, to mention a few: surgery, chemotherapy 
and radiation therapy. Surgery is used to remove or diagnose cancerous cells in an invasive 
manner, whereas, chemotherapy involves the use of synthetic drugs to treat cancerous cells.  
 1.2.1. Radiation therapy (Radiotherapy) 
Radiotherapy involves the use of energy waves or energy particles to target cancer including 
non-cancerous diseases.3 The types of radiation therapy include: external radiation therapy, 
3D-conformal radiation therapy, intensity modulated radiotherapy (IMRT), stereotactic 
radiation therapy or radiosurgery, and internal radiation therapy or brachytherapy (implant 
radiation) where a high dose of radiation is given inside the body within a close proximity to 
the oncogene.3 For years radioisotopes (radioactive isotopes) have been known as causative 
agents of cancer and now they have found routine applications in medical procedures. 
 1.3. Radioactivity 
During a radioactive process, electromagnetic radiation or particles are emitted from an 
atom’s nucleus and this can either occur naturally or be induced. Atoms are termed 
radioactive if their nuclei are unstable and randomly emit stray particles or energy waves 
namely: alpha (α), beta (β), and gamma (γ) radiation.4-7 Approximately 270 of the existing 
isotopes are stable and 50 are naturally occurring radioisotopes. Artificial radioisotopes can 
be produced via nuclear bombardment reactions in a cyclotron, nuclear reactors, and/or 
nuclear generator.6 Chemical reactions exploit the electron cloud (electron orbitals and 
hybridization) around the nucleus of an atom to form a stable compound, in contrast to 
nuclear reactions. Nuclear reactions focus on the features of the nucleus (i.e. protons and 




neutrons: nucleons) to form a new isotope. The nucleus is held together by a strong nuclear 
binding force stronger than the repulsive force.7 Thus, competition between the binding force 
and the repulsive electrostatic force determines the stability of an atom.  
 1.3.1. Alpha (α) particle emission 
Alpha (α) decay is the emission of an α-particle (a helium atom) which consists of a two 
protons and two neutrons as shown in Figure 1.1.4,7 
                                                        
Figure 1.1: The emission of alpha particle (a helium atom, red encirclement) consists of two protons 
and two neutrons. 
Figure 1.2 shows the alpha (α) decay scheme of the radioactive isotope [226Ra]radium-226—
derived from uranium—leading to the stable chemical element lead-206 (206Pb).7 The 
radioactive decay pathway can be a protracted process (up to years) or take up to seconds for 
completion, explaining that most naturally occurring chemical elements are regenerated with 
time. 
 




                             
Figure 1.2: The emission of an alpha particle from radium-226 nucleus leads to cascading events of 
radioactive decay to form lead-206. The radioactive decay may last for a protracted period or a short-
period of time dependant on the nature of a radionuclide.13 y = years, d = days, m = minutes and ms = 
milliseconds. 
 1.3.2. Beta (β) particle emission 
Beta (β) decay involves the emission of an electron (β-) or a positron (β+) from the nucleus.7 
The former is not the same as the emission of an orbiting electron. An example of electron 
emission is the decay of carbon-14 to nitrogen-14 (such as neutron turning into a proton).7,8 
The decay of carbon-11 to boron-11 defines positron emission (such as proton turning into a 
neutron within the nucleus with the positron carrying off the positive charge).7,8 
 1.3.3. Gamma (γ) photon emission 
Cobalt-60 decays to nickel-60 by β- decay, however the nickel nucleus is formed in an excited 
state that subsequently emits two gamma (γ)-ray photons (very high energy photons, 
approximately 105 as energetic as visible light), known as γ-decay.7,8 The nuclei that emit 
gamma-rays are the daughter nuclei of another radioactive decay. The difference between X-
rays and gamma-rays, is that X-rays typically result from certain transitions of electrons 
surrounding the nucleus in the atom; whilst gamma rays are emitted from the nucleus itself.8  




Rutherford discovered that the energies of the emitted particles and photons can penetrate 
tissue and can be halted by certain physical objects as shown in Figure 1.3.7 The 
radionuclides that emit γ-photons and positron (β+) particles are used in diagnostic nuclear 
medicine, whereas α-emitting and electron (β-)-emitting isotopes confer therapeutic 
properties.6,9 
                    
Figure 1.3: Schematic representation of three kinds of ionizing radiation. The α- particles include two 
electrons and two protons, they can be shielded by a piece of paper or human skin. The β- particles 
involve high energy speed electrons and can be shielded by aluminium foil or wood. The γ-rays are 
essentially pure energy and are the most penetrating and can be shielded by a thick concrete or lead 
wall. 
Currently in nuclear medicine, the design of tumour-targeting carriers to deliver radioactive 
metals (radioisotopes or radionuclides) selectively at target site in vivo is being exploited for 
both cancer therapy and diagnosis.  
 1.4. Metals in medicine 
In the 1930s, the first experimental use of phosphorus-32 (β-emitting cyclotron produced 
radionuclide) for treatment of haematological disease, expanded the use of radionuclides in 
targeted therapy and for diagnostic imaging.6 Radioisotopes of elements from the periodic 
table, when properly harnessed, find both clinical and research applications in radionuclide 
molecular imaging and therapy.6 Radioisotopes are characterized into two classes: (i) 
therapeutics (e.g. 223Ra, 90Y, 47Sc, 212Pb, 225Ac, 186/188Re, 212/213Bi, 114mIn, 177Lu) which are 
β- and α-emitters used in radionuclide-based therapy, and (ii) diagnostics (e.g. 99mTc,67/68 Ga, 




111In, 86Y, 89Zr, 44Sc, 64Cu, 117Lu) which are β+ and γ-emitters used in nuclear imaging.9 
Figure 1.4 highlights elements (shaded) with radioisotopes applied in clinic and research.6  
            
Figure 1.4: Chemical elements (shaded) with radioisotopes used in radiotherapy are shown with a 
letter T (therapy, using beta/β--, alpha/α- or Auger-emitting radioisotopes). Radioisotopes used in 
nuclear imaging are identified by symbols γ (gamma) and β+ (positron).6 
The availability of radiometals makes it possible to select desired specific nuclear properties 
like emission types, half-lives, energies and coordination ratios, for nuclear medicine 
application.6,10,11 For instance, a radionuclide’s half-life should be long enough (for 
maximized biodistribution) to reach the target site after patient injection, but short enough to 
minimize radiation dose to the patient. Furthermore, the half-life should be long enough to 
allow transportation of the radionuclide between production site and examination room, but 
short enough to prevent long-term waste-handling issues for the hospital.11 A selection of 
radionuclides (shaded in Figure 1.4) with eminent and imminent clinical and research 
applications will be discussed. 




 1.4.1. Organometallic (radio)pharmaceuticals 
Organometallic drugs (carbon containing inorganic drugs) derived from stable (non-
radioactive) isotopes have paved a way for radiometals in medicine. In 1910, Paul Ehrlich 
discovered arsphenamine (Salvarsan®, proposed structures shown in Figure 1.5) an arsenic-
based antimicrobial compound, which demonstrated curative properties against syphilis (a 
sexually transmitted bacterial infection).12 
                               
Figure 1.5: The proposed model of arsphenamine, a mixture of cyclic species.12 
Therapeutic radiopharmaceuticals (drugs containing a therapeutic radioisotope coupled with a 
targeting biomolecule) are carriers designed to deliver a quantum of therapeutic ionization 
radiation (α-, β- particles and/or secondary electrons) to specific diseased sites.4-6 Ideally, they 
should be localized in diseased sites in sufficient concentration to deliver the cytotoxic 
radiation dose, while minimizing radiation damage by rapidly clearing from the blood stream, 
organs and tissues.6 
1.4.2. Therapeutic radiopharmaceuticals  
 1.4.2.1. Rhenium-186/188 
Elemental rhenium is polymeric and exists as rhenium-186/188 and these isotopes are 
therapeutic analogues of technetium-99m (a diagnostic radionuclide).6,13 The precise isolation 
of these isotopes is based on their half-lives differing. The beta-emitting nuclear properties of 




rhenium-186 (186Re, β-, 92.5% abundance, half-life = 90 hours) and rhenium-188 (188Re, β-, 
100% abundance, half-life = 17 hours) affords prominent therapeutic properties.6  
Though 186/188Re over time converts to perrhenate, [ReO4]-—which is taken up in the thyroid 
and is excreted renally—biodistribution studies, using indium-131 as a control, have shown 
the radiation characteristics of rhenium to confer a high dose deposition at the tumour site, 
and lower whole body radiation dose burden, making it a prominent therapeutic 
radionuclide.13,14 Studies by Blower et al. accentuated the 188Re-dimercaptosuccinic acid 
complex [188Re(V)DMSA] (an analogue of [99mTc(V)DMSA] used for tumour imaging) as a 
potential palliative radionuclide treatment for bone metastases, in patients with prostate 
cancer.15 Furthermore, the study of bisphosphonate ligands as prominent rhenium chelates to 
treat osteoblastic bone metastasis, with minimum bone marrow toxicity, has afforded 
186/188Re-HEDP (HEDP = hydroxyethylidinedisphosphonate) and 188Re-Dipicolylamine 
(DPA)-Alendronate (Figure 1.6) utility in management of pain palliation and disorders 
related to metastatic prostate cancer.16 The bisphosphonate groups have a multimodal effect 
which is targeting the bone and binding the radioisotope.13,16  
        
Figure 1.6: Radiolabeling protocol of the bone targeting rhenium-188 bisphosphonate complex 
[188Re]Re(CO)3-DPA-Alendronate.16 




The high prospect to exploit a potential cost-effective 188W/188Re generator through the 
development of 188Re radiopharmaceuticals will be subjected to the identification of an 
appropriate business model.6 
 1.4.3. Diagnostic radioisotopes 
Diagnostic radioisotopes (emit gamma photons or positrons) are used for exploiting the tissue 
penetration depth of the gamma rays derived from either nuclear decay or during positron 
annihilation.6 Diagnostic radiopharmaceuticals are compounds labeled with γ or β+-emitting 
radioisotopes and their clinical applications include diagnosing, staging, and detecting the 
progression or recurrence of a disease.5,6 
 1.4.3.1. Technetium-99m 
Stable technetium has not been reported to confer any biological significance like its 
radioactive counterpart technetium-99m (99mTc, γ-emitter, half-life = 6.01 hours).6 The 
chemistry of 99mTc developed significantly in the 1970s and today 99mTc is the ‘workhorse’ of 
diagnostic nuclear medicine and is routinely used in hospitals.6 Table 1.1 lists selected FDA 
approved diagnostic radiopharmaceuticals.17 The importance of 99mTc in nuclear medicine is 
attributed to its low cost production, 99Mo/99mTc generator availability (as cyclotron 
production has distribution problems) and a 6 hour half-life. The single gamma photopeak at 
141 keV with 89% abundance offers a close to ideal balance of attenuation and gamma 
camera sensitivity including resolution in the imaging of tissue.6,18,19 Imaging agents like 
99mTc-sestamibi, used for myocardial perfusion and breast cancer imaging, have found 
routine clinical application.17 




Table 1.1: Selected FDA approved technetium-99m radiopharmaceuicals17 
 
Synthetic advances in organometallic chemistry have enabled a simple one-step ‘kit’ process 
(e.g. isoLink® kit) towards the preparation of 99mTc radiopharmaceuticals. Several oxidation 
states exist for technetium with different chemical features.6 The isoLink® kit offers the 
tricarbonyl core, fac-[99mTc(CO)3]+ isomer (present as fac-[99mTc(OH2)3(CO)3]+), which has 
been found to be: (i) a low spin d6 inert complex and is a ‘soft’ acid, (ii) lipophilic—which 
may possess affinity to myocardial tissue—and organometallic in nature, (iii) chemically 
robust and maintains its integrity under harsh conditions, and (iv) the fac-
[99mTc(OH2)3(CO)3]+  complex is obtainable under reducing conditions, in aqueous media 
from pertechnetate ([99mTcO4]-), with the aqua ligands susceptible to nucleophilic substitution 




by entering ligands (allowing for facile coordination to biomolecules and efficient 
radiolabeling).20-24  
Since technetium is a rhenium congener, non-radioactive (‘cold’) Re(I) analogues are used in 
characterization of radioactive (‘hot’) 99mTc(I) adducts.6 Technetium and rhenium complexes 
with tricarbonyl ligands, nitride-dithiocarbamate ligands or oxo-ligands (e.g. MAG3 and 
tetraamines) are relatively similar in chemical reactivity (although they require different 
reaction conditions) and chemical structures.6 The latter can be confirmed, using 
chromatographic techniques, by comparing retention times of the ‘cold’ and ‘hot’ complexes. 
The major difference between ‘cold’ and ‘hot’ metal ion chemistry is that radiochemistry is 
performed under extremely dilute conditions, with the radiotracer present in nanoMolar to 
picoMolar concentrations.9  
 1.5. Non-invasive nuclear imaging modalities 
The year 2000 represents an important milestone in nuclear imaging.11 In the US, the number 
of PET procedures increased from 0.2 million to 1.85 million in 2012.11 Between year 2005 – 
2012, a 21% increase was observed in Europe.11 The popularity of PET scan over SPECT 
scan can be attributed to the way the isotopes are produced (i.e. in a reactor or cyclotron), 
packaged (i.e. radiolabeled molecules or generators) and distributed.11 PET scans may offer 
increased accuracy and sensitivity by two to three orders of magnitude compared to SPECT, 
and can give a resolution of approximately 4 millimetres or more in a 3D output.25 
 1.5.1. Single Photon Emission Computed Tomography (SPECT) scans 
Gamma-ray emitting radionuclides (i.e. heavy isotopes) are used in SPECT. The radiation is 
measured directly by gamma cameras during radioactive decay.25 SPECT offers a prolonged 
observation window owing to prolonged half-lives of single photo emitters.26 This allows for 




observation, at about 1 cm resolution, of biological processes (e.g. blood flow to the brain) in 
vivo, several hours or days after introduction of an appropriate nuclear imaging compound.26 
Recent innovations in SPECT procedures include combined modality imaging by 
incorporating a radioisotope and a magnetic resonance contrast (most common are 
SPECT/CT procedures).6 This has created interest in developing contrast agents that support 
both imaging modalities (SPECT/MRI-magnetic resonance imaging) for clinical applications. 
One clinical application of this combined approach includes sentinel lymph node imaging 
(SPECT used to identify a location in vivo and MRI to provide soft tissue contrast and 
structural elucidation) to identify lymph nodes draining tumours prior to surgery, and a 
fluorescent contrast as a guide during surgery.6 Table 1.2 lists some physical properties of 
SPECT radiometals. 
Table 1.2: Physical Properties of Some Common SPECT Radiometals27 
 
 1.5.2. Positron Emission Tomography (PET) scans 
PET is similar to SPECT as both imaging modalities require the use of radioactive nuclides 
and detection of γ-rays. Short-half-life radionuclides are used in PET. Table 1.3 lists some 
physical properties of PET radiometals. 
 
 




Table 1.3: Physical Properties of Some Common PET Radiometals27 
 
When a positron is ejected from the nucleus it travels a distance (termed positron range), 
finds an electron and the pair annihilate.11,28 Prior to the annihilation, the radioisotope loses 
energy by emitting ionizing radiation.11 Depending on the isotope, the positrons that represent 
a fraction of the total amount of decays (branching ratios) are emitted in a continuous kinetic 
energy spectrum defined by the maximum energy available.11 In vivo, the positron loses its 
initial energy by colliding with the atoms in the surrounding tissue. Once the positron 
becomes sufficiently small, the particle instantaneously finds a free electron and the pair 
collide producing mass energy which is converted into two gamma photons (511 keV).11 
These photons contain momentum and the conservation of momentum requires that they 
travel in opposite directions (180 °C opposed) as illustrated in Figure 1.7 top.25,28 
 




                     
                                     
Figure 1.7: Schematic representation (Top) of a positron and an electron annihilate producing two 
back-to-back photons of equal energy to be detected (Bottom) by a circular gamma ray detector in the 
PET scan shown. 
 
These photons are then detected by detectors on a PET camera, Figure 1.7 bottom.25 PET 
scans can have approximately 2048 detecting crystals in the ring of the dome of the camera, 
making these scans costly and possess higher resolution images than SPECT scans. 
 1.5.3. Advancements in nuclear imaging scans 
Radionuclides like 34mCl, 44mSc, 52Mn, 86Y, 94Tc and 152Tb give a gamma-photon emission 
accompanying the positron emission which results in a total of 3 gamma – rays.11 The two 
back-to-back γ-rays at 511 keV (due to annihilation, Figure 1.7) are detected by classical 
PET methods giving a line of response (the line along the photons’ path, Figure 1.7). The 
third γ-ray is then detected and located by an additional camera (currently under 
development).11,28 This additional emission increases radiation burden to the patient. Thus, 
dedicated cameras are under development to simultaneously measure the lines of response 




generated by the annihilation and the third photons.28,29 The intersection of the two lines will 
decrease the uncertainty on the annihilation position, increase signal-to-noise ratio and 
provide a decreased overall radiation exposure of the patient.11 
 1.6. Coordination compounds 
Radiotracers are sequestered from aqueous media by coordinating Lewis bases. Chelating 
ligands encapsulate a radiotracer and insulate it from the surrounding environment.9 In 
addition, the chelator must effectively transport the radiotracer to selective biological target 
sites.9  
 1.6.1. Ligand design 
A diagnostic radiopharmaceutical may comprise a radiotracer of specific emission type (γ for 
SPECT and β+ for PET) and a chelator that gives optimal complex stability.9 H2dedpa (a 
member of the ‘pa family’ due to the central picolinic acid ‘pa’ binding moieties, Table 1.4) 
is one of the common ligands frequently reported in literature as a prominent chelate to form 
kinetically inert complexes with certain radioisotopes.9 Radiolabeling of the acyclic 
hexadentate scaffold of H2dedpa with 67/68Ga can be performed at room temperature in less 
than 10 minutes, with no decomposition observed after 2 hours post labeling, to afford 
products with distorted octahedron coordination geometry.30,31 The complex stability 
constants (log KML) obtained from potentiometric titration studies indicate high 
thermodynamic stability, and affinity of H2dedpa for 67/68Ga(III) (log KML = 28.1) over 
64Cu(II) (log KML = 19.2).30 
 
 




Table 1.4: H2dedpa and its bifunctional derivative with corresponding relevant 
radiotracers, radiolabeling conditions, thermodynamic stability constants (logKML), 
and coordination geometries9,30 
 
 
Current progress in ligand design of tumour-targeting metal chelates involves the 
incorporation of hyperbranched polymeric structures, such as dendrimers, which permit 
multivalent attachment possibilities of metal ions.32 
 1.6.2. Dendrimers 
In 1978, Vӧgtle et al. were the first to report on dendrimers (initially termed ‘cascade’ 
molecules).32 The term ‘dendrimer’ (from Greek: dendra, tree and meros, part of) describes a 
class of tree-like structure, as shown in Figure 1.8, of polymeric macromolecules.33 
Dendrimers are synthetic nanosized (~10-20 nm) macromolecules that emanate from a 
central core (Figure 1.8), with covalently linked branch units that fan out in well-defined 
globular architectures in 3D.33-35 
 
 
 = best match,  = suitable or potential match 




                   
Figure 1.8: A typical dendrimer structure (left) is made of three units: a multifunctional central core 
(O), branched units(Y) and external capping groups (E). The branched unit, dendron, resembles the 
structure of a tree (right).33 
The tree-like architecture (Figure 1.8) enables multifunctional modification at the periphery 
permitting functionalization with various drug molecules or metal ions.34 Dendrimers have 
found utility in catalysis, electronics, and medicine.34-37 They have been found to function as 
drug solubility enhancers (e.g. Conjugation of Paclitaxel® to a dendrimer moiety increased 
drug solubility from 8µg/100 ml to <35mg/100 ml), to release modifiers as well as platforms 
for drug targeting.38,39 
 
Figure 1.9: Proposed generations of monodispersed dendritic architecture. (a) Examples of 
commercialy available generations (G1 = generation 1, G3 = generation 3,etc) of monodispersed 
poly(propylene imine) dendrimer (PPI) where diaminobutane (DAB) is the core and (b) The 
polyamidoamine (PAMAM) dendrimer showing dendritic scaffolds leading to generation 2 PAMAM 
dendrimer. PAMAM has found application in Magnetic Resonance (MRI) imaging.40-43 




In light of this, dendrimers can be viewed as discrete platforms of tunable and controlled size 
(e.g. to allow crossing of the capillary barrier and urinary elimination), efficient carriers, and 
their biodistribution and pharmacokinetic traits can be controlled with respect to surface 
functionalization.4,44 
 1.6.3. Biocompatibility studies on dendrimers 
Macromolecules such as dendrimers have been found to accumulate at tumour sites as a 
result of an increase in blood vessel permeability and poor lymphatic drainage within 
diseased tissue than in healthy cells (also known as the ‘enhanced permeability and retention’ 
(EPR) effect), Figure 1.10.42-45 Dendrimers have found application in Magnetic Resonance 
Imaging (MRI), they have been investigated in gene therapy, as radiation sensitizers, and 
carriers for therapeutic drugs.4 
                                
Figure 1.10: The EPR (‘enhanced permeability and retention’) effect of a polymer-drug conjugate in 
a tumour.45 
The biocompatibility of amine-terminated dendrimers (Figure 1.9) has been investigated 
before. A study by Zinselmeyer et al. to evaluate poly(propylene imine) (PPI) dendrimers as 
gene delivery systems showed that the fifth generation (G5) PPI dendrimer DAB-dendr-
(NH2)64 has an IC50 < 5 μg mL−1 when tested against A-431 (epidermoid carcinoma) cell 
line.46 The second generation (G2) PPI dendrimer was found to have sufficient level DNA 




binding with low level of cell cytotoxicity affording it optimum in vitro gene transfer 
activity.46 Malik et al. reported haematoxicity studies on rat blood cells using protonated 
PAMAM and PPI dendrimers, bearing amine (-NH2) termini at the periphery, to show an 
increased haemolytic effect with increasing dendrimer generation number.47 In contrast, when 
these dendrimer generations were functionalized with carboxylate end groups at the periphery 
they conferred no cytotoxic and haemolytic activity up to a concentration of 2 mg/mL.47 In 
general, cationic dendrimers displayed IC50 values ranging between 50 – 300 µg/mL 
dependent on dendrimer-type, cell-type and generation.47 This suggests the overall toxicity of 
dendritic architectures is determined by termini functional groups and can be attributed to the 
charge-charge interactions between the cell membrane and the dendrimer.43,48 In addition to 
the PAMAM and PPI dendrimers, the peptide-functionalized poly(lysine) dendrimers were 
also found to be biocompatible.49 
 1.6.4. Metallodendrimers 
When dendrimers are functionalized with transition metals at the dendritic core, tether 
termini, dendritic branches, or at the branching point they are termed metallodendrimers 
(Figure 1.11).42 Metallodendrimers with metal centres at different positions have been 








                                         
Figure 1.11: Schematic representation of metal decorated dendrimers (a) at the periphery (b) 
interspersed throughout the framework(c) encapsulated within the framework.42 
The use of metallodendrimers in drug delivery is an attractive strategy. Their multivalency 
allows multiple copies of therapeutic metals to be attached, as shown in Figure 1.11, for 
biological recognition processes. The concept of multinuclearity to increase bioactivity has 
been attempted before. Jansen et al. synthesized and evaluated a tetranuclear dendritic 
platinum complex in Figure 1.12, DAB(PA-tPt-Cl)4.50 This compound was designed to 
overcome problems linked with cisplatin in the S-phase of the cell cycle. However, the 
compound evaluation studies showed low cytotoxic activity (associated with high charge of 
the complex at blood pH) against cancer cell lines and poor cell membrane diffusion.50  
                               
Figure 1.12: The proposed structure of DAB(PA-tPt-Cl)4 a multinuclear cationic platinum complex.50 
Another example is BBR 3464, Figure 1.13, a trinuclear platinum compound which 
completed phase I clinical trials overcoming cisplatin resistance mechanism.51 Even though 




this compound was unsuccessful in phase II clinical trials, it has paved the possibility to 
combine dendritic cores with various metal units at once.51 
                            
Figure 1.13: BBR 3464, a multinuclear cationic trans-platinum(II) compound.51 
 1.7. Metallodendrimers in nuclear imaging – the development of 
dendritic diagnostic radiopharmaceuticals 
The enhanced sensitivity of imaging modalities permits injection of radiopharmaceuticals at 
very low concentrations, ~ 10-6 – 10-8 M, and they are not intended to confer any 
pharmacological effect.4 Conventional nuclear imaging with radiolabeled tumour-specific 
probes often suffers from slow signal localization and clearance.4 In cancer imaging and 
therapy, the current focus is on the development of theranostics - novel tumour-specific 
probes supplying image-guided therapy.4 The multivalent nature of dendrimers can afford 
attachment possibilities of diverse metallic radionuclides to deliver radiotherapy and 
diagnostic imaging for efficacy treatment follow up, surgical biopsy guidance and automated 
pathologic analysis of cancer biopsy and surgical samples.4  
99mTc-labeling has been proven to be an effective approach in evaluating organ distribution 
studies of drug carriers for therapy and diagnosis.4 Pioneering work in demonstrating the 
potential of radioactive metallodendrimers as tumour imaging and diagnosis agents is by 
Subbarayan et al.52 This group was able to radiolabel water-soluble dendritic architectures 
bearing porphyrin cores with terminal iminodiacetic acid groups serving as 99mTc (a 
diagnostic radioisotope) chelates.52 Chromatography of the radiolabeled products showed 




radiochemical purity of greater than 95% (an accepted limit by the European Pharmacopoeia 
for radiochemical purity of a radiopharmaceutical is ≥ 95%). Scintigraphic imaging and 
biodistribution studies on C6-glioma tumour-bearing Wistar rats showed the radiolabeled 
dendrimers to accumulate in the tumour rather than in the surrounding muscles.52  
Agashe et al. used the 99mTc-labeling technique to radiolabel mannose or lactose coated 
generation 5 PPI dendrimers.53 When the carbohydrate ‘free’ 99mTc-dendrimers were used as 
standards, the biodistribution studies in mice demonstrated that they cleared from the 
systematic circulation slower than the 99mTc-labeled carbohydrate-coated dendrimers. The 
protracted retention times of the 99mTc-glycodendrimers were notable in the liver, attributed 
to lectin receptor-carbohydrate interactions.53 This is a great indication of carbohydrate-
coated dendrimers as potential radionuclide delivery vehicles to lectin-rich organs.4,53 
Parrot et al. used 99mTc to perform core metalation of high-generation polyester dendrons 
covalently linked to a tridentate bis(pyridyl)amine ligand, Figure 1.14 (synthesis of the ‘cold’ 
technetium complex).54 Using a dynamic small-animal SPECT/Computed Tomography 
(SPECT/CT) scan, the distribution studies of the radiolabeled dendrons in healthy adult 
Copenhagen rats showed higher dendrimer generation 5 to 7 to be rapidly eliminated from the 
blood stream and excreted through bladder 15 minutes post-injection.54 The rapid clearance 
of the dendrons is likely attributed to their molecular weights (generation 5 = 4.1 kDa, 
generation 6 = 7.8 kDa and generation 7 = 15.2 kDa) being below the renal filtration cut-off 
of 40 – 60 kDa.4 





Figure 1.14: The structure of generation 5 99mTc-labeled poly(2,2-bis(hydroxymethyl)-propionic acid) 
Dendron based on the HPLC of the ‘cold’ technetium complex shown in the scheme.54 
This study demonstrates the possibility to prepare well-defined/site-specific diagnostic 
radiopharmaceuticals by radiolabeling the focal point of high generation dendrons suitable 
for SPECT imaging through the incorporation of a single high affinity 99mTc ligand.4 In 
principle, this should assist in minimizing the impact of the radiotracer in interfering with the 
dendrimer periphery–receptor binding interactions during blood and tissue circulation.55 
To target folate receptors over-expressed in cancer cells, Zhang et al. used generation 5 
PAMAM dendrimers functionalized at the primary amines periphery with diethylenetriamine 
pentaacetic acid (DTPA, an aminopolycarboxylic acid) as 99mTc chelate and folic acid (FA) 
as the receptor binding moiety (Figure 1.15).56 The radiolabeled PAMAM-FA conjugate was 
stable in phosphate buffer (pH 7.4) and serum over a period of 6 hours after labeling 
(radiochemical purity ≥ 95%), biodistribution studies in nude mice confirmed accumulation 
at the tumour site within 6 hours and rapid blood clearance.56 
 




                          
Figure 1.15: Representation of the chemical structure of [99mTc]Tc(CO)3-G5-FA-DTPA.56  
Subsequent studies on radiolabeled PAMAM-FA conjugate in the presence of a spacer group 
polyethylene glycol (PEG) for indirect conjugation of FA with fifth generation PAMAM 
resulted in increased tumour uptake.57 PEG is structurally flexible and lipophilic in nature, 
potentially allowing for escape from phagocytosis by macrophage cells in the lymphatic 
system. Thus, FA modified with the spacer group PEG is able to trigger receptor-mediated 
endocytosis by selectively binding to metastatic tumour-cells.4,57 For cancer diagnosis, such a 
study confirms the potential of FA-dendrimer conjugates as potential imaging 
radiopharmaceuticals.4 
 1.8. Perspectives 
The integration of a diagnostic radionuclide with a target-specific dendrimer either modified 
at the periphery, covalently bonded to a spacer group or conjugated with receptor binding 
moieties (like folic acid) affords optimization of diagnostic efficacy in targeting diseased 
sites. Application of dendrimers as prominent radiopharmaceutical chelates in nuclear 
imaging (and therapy) is still under research and holds promising results. Based on the 
dendritic architectures which permit multinuclearity, the ability to tune the ratio between the 




macromolecule and the radiometal for enhanced biodistribution and image quality can be 
exploited. Studies have shown the radiolabeling of dendrimers and dendrons with fac-
[99mTc(CO)3]+ isomer including purification (based on radiochemical yields) as being 
achievable.52-57 The nature of functional groups (‘hard’ or ‘soft’ donor atoms) at the periphery 
of the dendrimer is essential for the synthesis of kinetically inert radiolabeled complexes. The 
commercial availability of some dendrimers and accessibility to 99mTc (cheaper production) 
in most regions of the world will lead to the discovery of novel dendritic diagnostic 
radiopharmaceuticals. Thus, exploiting the diagnostic properties of the gamma-emitting 
radionuclide 99mTc, where labeling can be performed using kit processes, together with the 
‘enhanced permeability and retention’ (EPR) effect of the dendrimer-based ligands will be a 
major contribution to research on nanoparticle based drug delivery systems and cancer 
diagnosis research. 
 




 1.9. Aims and Objectives 
 1.9.1. General aims 
The general aims of this project are: 
  The design and synthesis of bidentate monomeric and dendritic ligands 
  Coordination of these ligands to a aquatricarbonylrhenium(I) core, the fac-
[Re(CO)3H2O]+ isomer, to afford ‘cold’ rhenium complexes as high-performance liquid 
chromatography (HPLC) standards 
  Radiolabeling of the ligands using generator eluted technetium-99m ([99mTcO4]-) and the 
isoLink® kit (fac-[99mTc(CO)3(H2O)3]+) 
  Evaluate the radiolabeled properties of the corresponding complexes 
 1.9.2. Specific objectives 
 1.9.2.1. Synthesis 
 To synthesize a series of monomeric and dendritic ligands from iminopyridyl or bipyridyl 
synthons (Figure 1.16). 
               
Figure 1.16: The synthetic route towards the proposed monomeric and dendritic neutral ligands of 
series 1 and 2. 




  To use the aforementioned ligands in synthesizing ‘cold’ fac-[Re(I)(CO)3]+ complexes in 
Figure 1.17 and devise a chromatographic method to compare the retention times with 
those of radioactive counterparts. 
 
Figure 1.17: The proposed structures of the mononuclear and multinuclear Re(I) tricarbonyl cores 
  To radiolabel the dendritic ligands in Figure 1.16 with 99mTc using reduced pertechnetate 
by direct labeling and/or isoLink® kit method(s). 
 1.9.2.2. Applications 
  Since the ligands are bidentate, the lability or inertness of the aqua ligand in fac-
[Re(CO)3(N,N-bidentate)(OH2)]+ type complexes will be investigated in kinetic studies to 
evaluate the influence of dendritic ligand on the reactivity of the rhenium(I) centre. 
  Develop suitable HPLC and instant thin layer chromatography (iTLC) methods to 
monitor reactions and to determine (radio)chemical purity of intermediates and final 
products 
  Develop methods to determine radiochemical stabilities of the labeled compounds 
  Perform radiobiological studies- i.e. in vitro cell uptake studies will be performed using 
radiolabelled metallodendrimers. 
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Synthesis and characterization of monomeric and dendritic 
bipyridyl (bpy) and picolyl ligands 
 2.1. General introduction 
Current research in the area of technetium-99m (99mTc) is focused towards developing 
diagnostic radiopharmaceuticals that preferentially localize in tumour tissues. The ‘vehicle’ 
that carries the radiotracer to the target site is normally a ‘targeting biomolecule’, with the 
ability to accumulate in neoplastic tissues with high specificity and affinity.1 Dendrimers as 
‘vehicles’ offer possible enhanced targeting efficiency as a result of their proposed 
mechanism of action via the ‘enhanced permeability and retention’ (EPR) effect, a 
phenomenon in which macromolecules accumulate at the tumour site by virtue of an increase 
in blood vessel permeability within diseased tissues compared to healthy tissue.2 Their 
multivalent system of tuneable and controlled size permits complexation of diverse metallic 
ions often resulting in enhanced biological activity compared to their mononuclear 
counterparts.3-7 Such improved activities are attributed to the lipophilicity, solubility and 
favourable modulation of the stability of the organometallic dendritic complexes.7 
Since radiotracers are utilized at nanoMolar to picoMolar concentration, the multivalent 
nature of a dendrimer is likely to permit increased interactions between a dendrimer-
radiotracer complex and a cellular target bearing multiple receptors.8 This may result in 
enhanced sensitivity of an imaging modality (SPECT scan for 99mTc). Since the 
biocompatibility and cytotoxicity of different generations of the diaminobutane 
poly(propylene amine) (DAB-PPI) dendrimer have been reported before9, herein, we report 
the synthesis and characterization of DAB-PPI dendritic scaffolds modified at the periphery 




with N,N’-bidendate donor moieties. These ligands will serve as chelates to ‘cold’ 
rhenium(I), fac-[Re(CO)3]+ isomer , and ‘hot’ fac- [99mTc(CO)3]+ adducts for application as 
potential nuclear imaging agents (in the case of 99mTc). 
The monomeric analogues were synthesized as mononuclear models of the larger dendritic 
ligands. The monomeric and dendritic ligands were characterized using various spectroscopic 
and analytical techniques.  
 2.2. Synthesis and characterization of 4’-methyl-2,2’-
bipyridine-4-carboxaldehyde 
Govender et al. reported on polypyridyl grafted DAB-PPI dendritic scaffolds chelating 
manganese(I) tricarbonyl moieties at the periphery, as new photoactivated CO-releasing 
molecules (PhotoCORMs).10 At the periphery, their first and second generation PPI dendritic 
scaffolds were primarily functionalized with imino conjugated bipyridyl (bpy) moieties via a 
Schiff condensation reaction.10 2,2’-Bipyridyl chelates are known to form inert complexes 
with various transition metals and exhibit favourable photochemistry, photophysical, and 
chemiluminescence properties when coordinated to transition metals such as Ru, Os and 
Re.11-15 In the current study, a series of 2,2’-bipyridyl functionalized dendritic scaffolds were 
synthesized, as potential ‘cold’ Re(I) and 99mTc(I) chelates, for application in nuclear 
medicine. 
The synthetic strategy adopted for the preparation of amino conjugated bipyridyl moieties on 
PPI dendrimers involved 4’-methyl-2,2’-bipyridine-4-carboxaldehyde as the synthetic 
intermediate, a convenient way of introducing functionalized side chains to 2,2’-bipyridyl 
moieties. The functional group transformation of 4,4’-dimethyl-2,2’-bipyridine involved 
partial oxidation of one of the methyl group substituents on the bpy ring using selenium 




dioxide, SeO2 (Scheme 2.1).16-18 This oxidation reaction inefficiently permits optimal 
conversion of the starting material to the desired product since more than 60% of 4,4’-
dimethyl-2,2’-bipyridine is recovered after work-up. In order to isolate 4’-methyl-2,2’-
bipyridine-4-carboxaldehyde from the starting material, 0.3 M Na2S2O5 was used to protect 
4’-methyl-2,2’-bipyridine-4-carboxaldehyde formyl group by converting it to a bisulfite 
adduct, a common industrial procedure for the storage of aldehydes. Under alkaline 
conditions at pH 10, the bisulfite adduct reverts to the desired deprotected formyl form.16,17 
SeO2 is a milder oxidizing agent than potassium permanganate (KMnO4), thus, over-
oxidation of the methyl groups to form undesired (di)carboxylic acid side product(s) is 
negligible.18  
                           
Scheme 2.1: Oxidation of a 4-methyl substituent using selenium dioxide to afford 4’-methyl-2,2’-
bipyridine-4-carboxaldehyde in a 29% yield.16,17 
The compound 4’-methyl-2,2’-bipyridine-4-carboxaldehyde was achieved in 29% yield. The 
reaction scheme is illustrated in Scheme 2.1. 4’-Methyl-2,2’-bipyridine-4-carboxaldehyde 
was isolated as a white solid and is soluble in polar organic solvents such as dichloromethane 
(CH2Cl2), acetone (CH3)2CO, chloroform (CHCl3) and dimethylsulfoxide (CH3)2SO. The 
melting point range of 4’-methyl-2,2’-bipyridine-4-carboxaldehyde is between 130.2 – 132.0 
°C and corresponds accordingly with the reported literature melting point values, 130.9 – 
131.7 °C.16 
 




The 1H NMR spectrum of 4’-methyl-2,2’-bipyridine-4-carboxaldehyde features a singlet at 
10.2 ppm integrating for one proton and is assigned to the formyl functional group at the C4 
position, Figure 2.1. The upfield singlet resonance at 2.59 ppm integrates for three protons 
and corresponds to the methyl substituent at the C4’ position.  
 
Figure 2.1: 1H NMR spectrum of 4’-methyl-2,2’-bipyridine-4-carboxaldehyde in (CD3)2SO 
with the expansion of the aromatic region.  
The 13C{1H} NMR spectrum displays the formyl carbonyl carbon resonance of 4’-methyl-
2,2’-bipyridine-4 at 193.4 ppm. In the IR spectrum, a sharp absorption band at 1705 cm-1 is 
observed, characteristic of α,β-unsaturated aldehyde stretching vibration which is in close 
proximity with the reported literature absorption band at 1709 cm-1, further confirming the 
presence of a formyl group.16,17 The additional IR absorption bands at 1594 and 1557 cm-1 are 
attributed to the C=N bonds present in the bpy ring.  
The elemental analysis output of 4’-methyl-2,2’-bipyridine-4-carboxaldehyde gave C, N and 
H values as 72.1, 5.10 and 14.6%, respectively. These values are comparable to the calculated 
values for this compound. The structural integrity of the compound is supported by the EI-




MS spectrum featuring a molecular ion peak at m/z = 198.00 [M]+. These results are in 
accordance with the reported literature values.19 
 2.3. Synthesis and characterization of N,N’-bipyridyl 
functionalized monomeric and dendritic bidentate ligands 
L1, L2, and L3 
The generation 1 and generation 2 DAB-PPI dendritic scaffolds were functionalized at the 
periphery with 4’-methyl-2,2’-bipyridine-4-carboxaldehyde via a reductive amination 
reaction (the reaction mechanism is shown in Scheme 2.2 (a)), to afford reduced 
poly(pyridyl) functionalized dendritic ligands L2 and L3 (Scheme 2.2 (b)). 
The pure monomeric analogue N-((4’-methyl-2,2’-bipyridin-4-yl)methyl)propan-1-amine 
(L1) was synthesized by condensation between N-propylamine and 4’-methyl-2,2’-
bipyridine-4-carboxaldehyde (Sheme 2.2 (b)), followed by reduction with sodium 
borohydride (NaBH4) to generate L1.14,20 A similar synthetic procedure was used to 











                           
Scheme 2.2: (a) The proposed reductive amination reaction mechanism (of the carbonyl compound) 
or reductive alkylation (of the amines).20 
 
                                
Scheme 2.2: (b) Synthesis of the monomeric and dendritic ligands L1 – L3 via the reductive 
amination of N-propylamine, DAB-G1dendr-(NH2)4 and DAB-G2dendr-(NH2)8 with 4’-methyl-2,2’-
bipyridine-4-carboxaldehyde in a one-pot reaction using literature method.14,20 
 




The dendritic ligands L2 and L3 were isolated as yellow oils and were synthesized in a 54.9 
and 71.4% yield, respectively. L2 and L3 readily dissolve in polar organic solvents such as 
(CH3)2CO, CH2Cl2, CH3Cl, hot MeOH and (CH3)2SO. The monomeric analogue L1 was 
isolated as a yellow oil in 57.2% yield and dissolves in polar organic solvents similar to L2 
and L3. L1 serves as a model in characterization of the dendritic analogues. L1 – L3 were 
found to be stable at room temperature and in the presence of light. The ligands were 
characterized by 1H NMR, 13C{1H} NMR, FT-IR spectroscopy, elemental analysis, and mass 
spectrometry. 
 1H and 13C{1H} NMR spectroscopy 2.3.1.
The 1H and 13C{1H} NMR data were recorded in (CD3)2SO. Figure 2.2 represents the 1H 
NMR spectrum of L1 which was easily interpreted by comparison with the work by Massing 
et al.14 and Yao et al.20 In the aliphatic region between 0.85 – 2.51 ppm, four signals are 
observed, which correspond to the protons of the methyl group at C4’ position and to the 
aliphatic protons on the N-propyl side chain (CH3CH2CH2NH). 
 
Figure 2.2: 1H NMR spectrum of the monomeric ligand L1 in (CD3)2SO. The black square 
accentuates the magnified aromatic region. 




A singlet signal at 3.77 ppm integrating for two protons is assigned to the protons of a newly 
formed methyl (4-CH2NH) group, adjacent to the quaternary carbon on the bipyridyl ring at 
C4 position (Figure 2.2). The 1H NMR spectrum of 4’-methyl-2,2’-bipyridine-4-
carboxaldehyde (Figure 2.1) illustrates the signals for the 2,2’-bipyridyl aromatic protons 
between 9.28 – 7.64 ppm, whereas, in the 1H NMR spectrum of L1, the aromatic protons of 
the 2,2’-bipyridyl ring exist within the 8.56 – 7.24 ppm range. The upfield shift of L1 
aromatic proton signals in the aromatic region, Figure 2.2, may be reasoned through 
inductive contributions from the newly formed methyl bond at C4 position.14 In Figure 2.2, 
the most deshielded protons at 8.51 ppm (H-6’) and 8.56 ppm (H-6) are a result of the 
resonance effect in pyridine rings which renders 2/6 positions as electrophilic sites.  
In Figure 2.3 is the 2D HSQC 13C – 1H correlation spectrum of L1 in (CD3)2SO, the peaks at 
the vertical axis (F1) correspond to the 13C{1H}signals of L1. 
 





Figure 2.3: The 2D HSQC spectrum of L1 in (CD3)2SO. The blue lines correlate the corresponding 
C-H nuclei. Peak assignments in F2 correspond to Figure 2.2. 
The 4’-CH3 carbon atom adjacent to the bipyridyl ring at C4’ position is at 21.0 ppm more 
deshielded than the terminal CH3 group of the N-propyl side chain at 11.7 ppm. The resulting 
methyl (4-CH2NH) carbon atom adjacent to the bipyridyl ring at C4’ position is represented 
by a signal at 51.9 ppm. To confirm the isolation of a pure product, the 13C{1H} NMR signal 
characteristic of the 4’-methyl-2,2’-bipyridine-4-carboxaldehyde carbonyl carbon atom is not 
observed. The quaternary carbon C4 initially at 156.9 ppm—as a result of the formyl electron 
withdrawing effect in 4’-methyl-2,2’-bipyridine-4-carboxaldehyde—shifts to 148.7 ppm 
(Figure 2.3, F1 axis, asterisk) in L1, confirming the integrity of the reductive amination 
product. The 2,2’-bipyridyl ring tertiary carbon atoms resonate between 119.6 – 148.8 ppm. 
In the 2D HSQC 13C – 1H correlation spectrum of L1, the 2,2’-bipyridyl ring quaternary 
* 




carbon atoms are represented by four medium intensity peaks downfield between 148.7 – 
155.3 ppm (C2, C2’, C4 and C4’) and there is a signal overlap corresponding to C2/C2’ at 
155.3 ppm. 
Figure 2.4 displays the 1H NMR spectrum of the dendritic ligand L2 (generation 1 
dendrimer). The 1H NMR spectra of the dendrimers L2 and L3 have the aliphatic protons 
between 1.25 – 3.25 ppm assigned to the dendritic core (diaminobutane) and branches 
(polypropyl chains). In the 1H NMR spectrum of the dendritic ligands, a singlet resonance, 
assigned to the 4-CH2NH (adjacent to the bipyridyl ring) methyl protons, at 3.68 ppm and 
3.67 ppm for L2 and L3, respectively, integrates for two protons and confirms the presence 
of the amino group (as opposed to the imino group by Govender et al).10  The aromatic 
proton resonances observed in L1 1H NMR spectrum (Figure 2.2, magnified region) resonate 
in the same region as the aromatic protons of the dendritic analogues L2 (Figure 2.4) and L3.  
 
Figure 2.4: 1H NMR spectrum of L2 in (CD3)2SO. 




In the 13C{1H} NMR spectra, the aliphatic carbon atoms are between 20.4 – 53.3 ppm and the 
aromatic carbon atoms are in the region of 119.5 – 155.2 ppm for both generations L2 and 
L3. 
 2.3.2. Infrared spectroscopy 
The infrared spectra of L1 – L3 were recorded in Nujol oil using sodium chloride plates. Two 
distinct sharp absorption bands in the region of 1554 – 1597 cm-1, attributed to the vC=N bond 
of the bipyridyl ring, are observed in all ligands. The absence of a diagnostic imine 
absorption band between vC=N ~1650 – 1648 cm-1 infers a successful reductive amination 
reaction. 
 2.3.3. Elemental analysis and mass spectrometry 
Dendrimers are known to encase solvent molecules and chelate inorganic salts. Supported by 
the 1H NMR spectra of L1 – L3, the elemental analysis data for the dendritic ligands L2 and 
L3 were discovered to include CH2Cl2 and MeOH molecules, respectively. The calculated 
values for C, H and N atoms, with inclusion of solvent molecules, correlate with the found 
values. As per EI-MS analysis, a base peak of m/z = 184.00 (calculated mass for [M – 
CH3CH2CH2NH]+ m/z = 184.10, where CH3CH2CH2NH corresponds to the N-propyl-1-
amine chain of L1 in Figure 2.2). The HR-ESI-MS analysis of ligands L2 and L3 ionized 
adducts have prominent peaks corresponding to m/z = 1045.6774 (calculated mass for [M + 
H]+ m/z = 1045.6769) and m/z = 752.0718 (calculated mass for [M + 2H+ Na]3+ m/z = 
752.0393), respectively. 




 2.4. Synthesis and characterization of N,N’-picolyl functionalized 
monomeric and dendritic bidentate ligands L4, L5 and L6 
Picolyl amines and their derivatives are known copper chelators.22-25 Such compounds can be 
synthesized by reacting α, β or γ-pyridinecarboxaldehydes with various alkyl secondary 
amines, via a reductive amination reaction (Scheme 2.2a).25,26 The basic nature of picolyl 
alkyl amines resembles that of naturally occurring class of alkaloids of different biochemical 
and botanical origin.27 Bandyopadhyay et al. synthesized and reported on several picolyl 
alkyl amine derivatives to confer inhibitory activity towards tyrosinase (EC 1.14.18.1), a 
copper-containing polyphenol oxidase responsible for the enzymatic browning of fruits and 
vegetables.25  
Govender et al. reported on a series of periphery functionalized, cationic and neutral PPI 
metallodendrimers, with N,N’-picolyl imine moieties (via a Schiff base condensation 
reaction) coordinated to ruthenium(II)-arene groups.4 In the current study, complexation 
reactions using similar dendritic ligands resulted in the hydrolysis of the imine bond. The 
imine bond was significantly cleaved at high temperatures (during complexation reactions). 
Therefore, a reductive amination reaction was used to achieve ligands L4 – L6 (Scheme 2.3). 
Using a similar synthetic approach to L1 – L3, N-propylamine was reacted with 2-
pyridinecarboxaldehyde to afford the monomeric α-picolyl alkyl amine, N-((pyridine-2-
yl)methyl)propan-1-amine (L4), in the presence of NaBH4 as the reducing agent.25,26 The 
dendritic ligands L5 and L6 were synthetized analogous to the monomer L4. 
 
 





           
Scheme 2.3: Synthesis of the monomeric and dendritic ligands L4 – L6 by reacting  
2-pyridinecarboxaldehyde with either N-propylamine, DAB-G1dendr-(NH2)4 or DAB-G2dendr-
(NH2)8 in a one-pot reaction. 
The picolyl alkyl amine L4 is a yellow liquid and the dendritic ligands L5 –L6 are brown 
oils, the ligands were isolated in 30.0 – 44.0% yield. L4 – L6 are soluble in water and polar 
organic solvents. Apart from the water solubility, these ligands exhibit relative spectroscopic 
features to the bipyridyl ligands L1 – L3, omitting one pyridine ring. The ligands L4 – L6 
were characterized by 1H NMR, 13C{1H} NMR, FT-IR spectroscopy, elemental analysis, and 
mass spectrometry. 
 2.4.1. 1H and 13C{1H} NMR spectroscopy 
The 1H NMR spectrum of L4, in Figure 2.5, has a singlet resonance at 3.76 ppm assigned to 
the methyl protons at the α-position of the pyridine ring. This confirms the formation of an 
amine bond contrary to the imine derivatives synthesized by Govender et al.4 Also, the 
diagnostic singlet resonance for the methyl protons (at the α-position of the pyridine ring) is 
present in the 1H NMR data reported in the literature for L4 in deuterated chloroform.25,26 





Figure 2.5: 1H NMR spectrum of L4 in (CD3)2SO. 
In the 1H NMR spectrum of L4, the aromatic region between 8.50 – 7.00 ppm corresponds to 
the aromatic protons of the picolyl ring, with H-6 being the most deshielded proton at 8.46 
ppm, as a result of the resonance effect of the pyridine ring.26 The alkyl amine side chain (N-
propan-1-amine) is shielded occurring upfield in the region between 2.50 – 0.80 ppm of the 
spectrum. The 1H NMR spectra of the dendritic ligands L5 and L6 only deviate from Figure 
2.5 in the upfield aliphatic region as their spectra feature the dendrimer framework aliphatic 
protons. Figure 2.6 displays the 1H NMR spectrum of L5 which features the overlapping 
dendrimer framework aliphatic proton resonances in the region between 1.25 – 3.00 ppm, 
integrating for 32 protons. 
 
Figure 2.6: 1H NMR spectrum of L5 in (CD3)2SO. 




In addition to the aliphatic and aromatic carbon peaks, the 13C{1H} NMR spectra of L4 – L6 
display a peak between 54.5 – 55.0 ppm which corresponds to the 2-CH2NH (adjacent to C2) 
methyl carbon atom at the α-position of the pyridine ring. 
 2.4.2. Infrared spectroscopy 
In addition to the 1H and 13C{1H} NMR spectra, a sharp absorption band at ~1590 cm-1 is 
observed in the IR spectra of L4 – L6 and is attributed to the pyridyl C=N bond. 
Furthermore, a sharp absorption band at ~1377 cm-1 is observed and is attributed to the 
secondary amine C-N bond. 
 2.4.3. Elemental analysis and mass spectrometry 
The elemental analysis data of L4 – L6 are within the expected values. The EI-MS of L4 
shows a base peak m/z = 93.03 ([M – CH3CH2CH2NH)+] (where CH3CH2CH2NH 
corresponds to the N-propane-1-amine moiety of L4 in Figure 2.5). The ligands L5 and L6 
HR-ESI-MS base peaks are prominent at m/z = 341.2581 ([M + 2H]2+) and m/z = 376.2898 
([M + 4H]4+), respectively. 
 2.5. Summary 
A series of monomeric and dendritic poly(propylene amine) ligands, L1 – L6, functionalized 
with either N,N’-bipyridyl or N,N’-picolyl bidentate moieties have been successfully 
synthesized via a reductive amination reaction. Characterization of these ligands was done 
using spectroscopic (1D and 2D 1H NMR, 13C{1H} NMR, infrared spectroscopy and mass 
spectrometry) and analytical (elemental analysis) methods. The NMR spectra peak 
assignment of the dendritic scaffolds was comparable to the spectra of the monomeric 
analogues. Interestingly, the first and second generation dendritic ligands L5 and L6 were 
discovered to be water-soluble (0.01 mg/µL). In the literature, water-soluble dendrimers such 
as oligoethyleneoxy- modified poly (propylene amine) (POMAM) have been demonstrated to 




encapsulate hydrophilic xathene dyes, accentuating the unlimited possibilities of dendrimer 
binding behaviour.28 The complexation of such ligands with trace amounts of therapeutic or 
diagnostic metals will contribute towards the research of PPI-based dendritic architectures as 
drug delivery vehicles. 
 




 2.6. Experimental 
 2.6.1. Chemical reagents 
All reagents were purchased from Sigma-Aldrich and used without further purification.  
1,4-Diaminobutane poly(propylene amine) octaamine (DAB-PPI-(NH2)8) was purchased 
from SyMO-Chem. All reactions were performed at room temperature using standard 
Schlenk-line techniques, and the reductive amination reactions were performed under 
nitrogen line. Dichloromethane (CH2Cl2) was dried using the molecular sieves (Sigma 
Aldrich, 3Ǻ beads, 4 – 8 mesh) and methanol (MeOH) was dried in the Innovative 
Technology Swagelok® (PS-Micro, PSM-13-564). 
 2.6.2. Purification 
Purification was carried out using deionized water and column chromatography Biotage-KP-
C18-HS, where stated. 
 2.6.3. Spectroscopic and analytical methods 
Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Ultrashield 400 Plus 
spectrometer (1H: 399.95 MHz; 13C{1H}: 100.60 MHz) at ambient temperature. All chemical 
shifts are reported in the standard δ notation of parts per million using tetramethylsilane 
(TMS) as an internal standard and were referenced relative to the signal of correspondinig 
deuterated solvents. The J coupling constants are reported in Hertz (Hz). Spin multiplicities 
are reported in abbreviated conventional format. 
Infrared (IR) absorption bands were measured on a Perkin-Elmer spectrum 100 FT-IR Nujol 
oil. Melting points were determined on a Reichert-Jung Thermovar hot-stage microscope and 
are uncorrected. Elemental analysis were performed using Thermo Flash EA 112 Series 
combustion analyser. Electrospray Ionisation (ESI+) mass spectra were recorded on a Waters 




API Quattro Micro triple quadrupole mass spectrometer by courtesy of the University of 
Stellenbosch. Furthermore, Electron impact mass spectrometry (EI-MS) was carried out on a 
JEOL GCmateII mass spectrometer. 
2.6.4. Synthesis and characterization of N,N’-bipyridyl ligands 
 2.6.4.1. Preparation of 4’-methyl-2,2’-bipyridine-4-carboxaldehyde16,17 
SeO2 (3.31 g, 29.9 mmol) was added to a stirring solution of 4,4’-dimethly-2,2’-bipyridine 
(5.00 g, 27.1 mmol) in 1,4 dioxane (150 mL) and refluxed for 36 hours under nitrogen. The 
reaction mixture was filtered hot through a Celite pad and the solvent of the filtrate was 
removed by rotary evaporation to give an amorphous residue. The residue was suspended in 
EtOAc (3 × 50.0 mL), the organic fractions combined, and filtered by gravity. The filtrate 
was washed with 1M Na2CO3 (2 × 100 mL) and the organic layer subsequently washed with 
0.3 M Na2S2O5 (3 × 100 mL) to form a bisulfide adduct. The combined aqueous extracts 
were adjusted to pH 10 with Na2CO3 and the desired product extracted with CH2Cl2 (4 ×  
100 mL). The combined organic fractions were dried over MgSO4, filtered and evaporation 
of the solvent of the filtrate afforded 4’-methyl-2,2’-bipyridyl-4-carboxaldehyde. 
                                                                    
4’-Methyl-2,2’-bipyridyl-4-carboxaldehyde: White solid, yield: 1.54 g (28.7%). IR: KBr 
pellets, v/cm-1: 1705 (sharp, aldehyde, CO), 1594, 1557 (sharp, bipyridyl, C N). 1H NMR 
(400.22 MHz, (CD3)2SO): δ 2.59 (s, 3H, 4’-CH3), 7.64 (d, 1H, 3J = 5.64 Hz, H-5’), 8.10 (dd, 
1H, 4J = 1.60 Hz,3J = 5.60 Hz, H-5), 8.82 (s, 1H, H-3’), 8.88 (d, 1H, 3J = 5.68 Hz, H-6’), 9.10 




( s, 1H, H-3), 9.28 (d, 1H, 3J =5.4 Hz, H-6), 10.20 (s, 1H, HCO). 13C{1H} NMR (100.60 
MHz, (CD3)2SO): δ = 20.7 (CH3), 119.4 (C-3), 121.4 (C-5), 121.9 (C-3’), 125.5 (C-5’), 142.6 
(C-4’), 148.3 (C-2’) 149.2 (C-6’), 150.7 (C-6), 154.1 (C-2), 156.9 (C-4), 193.4 (CHO). 
Elemental analysis (%): Calc. For C12H10N2O (198.2): C, 72.71; H, 5.09; N, 14.13; Found: 
C, 72.10; H, 5.10; N, 14.62. Mp: 130.2 – 131.9 °C. MS (EI; m/z): 198.00 [M]+. 
 2.6.4.2. Preparation of N-((4’-Methyl-2,2’-bipyridin-4-yl)methyl)propan-1-
amine (L1)14,20 
To a stirring solution of 4’-methyl-2,2’-bipyridyl-4-carboxaldehyde (0.0447 g, 0.760 mmol)) 
in dry CH2Cl2 (30.0 mL), N-propylamine (0.0622 mL, 0.760 mmol) was syringed into the 
flask dropwise. In addition, MgSO4 (0.150 g) was introduced to the mixture. After stirring at 
room temperature for 24 hours, the reaction mixture was filtered by gravity and the solvent of 
the filtrate was removed by rotary evaporation to afford a yellow oil. The crude oil was 
dissolved in MeOH (30.0 mL) and stirred for 30 minutes, under nitrogen. Thereafter, NaBH4 
(0.0333 g, 0.876 mmol) was added to the stirring solution and the reaction proceeded 
overnight at room temperature under nitrogen. The reaction mixture was cooled in an ice bath 
and the excess hydride was quenched with ice cooled water (30.0 mL). The azeotropic 
mixture was reduced by rotary evaporation to afford an aqueous mixture. The desired product 
was extracted with CH2Cl2 (40.0 mL). The organic layer was then washed with H2O (3 × 
50.0 mL) and dried over anhydrous MgSO4. Subsequently, MgSO4 was filtered and rinsed 
with CH2Cl2 (2 × 15.0 mL). The solvent of the filtrate was removed by rotary evaporation to 
afford a pale yellow oil, L1, which was dried in vacuo. 




                                         
Compound L1: Light yellow oil, yield: 0.105 g (57.2%). IR: Nujol between NaCl plates,  
v/cm1 = 1597, 1556 (sharp, bipyridyl, C N). 1H NMR (400 MHz, (CD3)2SO): δ = 0.85 (t, 
3H, 3J = 7.40 Hz, CH3CH2CH2), 1.44 (qn, 2H, 3J = 7.27 Hz, CH3CH2CH2), 2.39 (s, 3H, 4’-
CH3), 2.46 (t, 2H, 3J = 7.10 Hz, CH3CH2CH2), 3.77 (s, 2H, 4-CH2),7.24 (d, 1H, 3J = 4.96 Hz, 
H-5’), 7.37 (d, 1H, 3J = 4.00 Hz, H-5), 8.23 (s, 1H, H-3’), 8.36 (s, 1H, H-3), 8.51 (d, 1H, 3J = 
4.96 Hz, H-6’), 8.56 (d, 1H, 3J = 4.95 Hz, H-6). 13C{1H} NMR (100.60 MHz, (CD3)2SO): δ = 
11.7 (CH3CH2CH2), 21.0 (4’-CH3), 22.6 (CH3CH2CH2), 50.7 (CH3CH2CH2), 51.9 (4-CH2), 
119.6 (C-3), 121.2 (C-3’), 123.1 (C-5), 124.7 (C-5’), 148.7 (C-4), 148.8 (C-6’, C-6), 151.3(C-
4’), 155.2 (C-2, C-2’). Elemental analysis (%): Calculated for C15H19N3 (241.3380): C, 
74.65; H, 7.94; N, 17.41; Found: C, 74.10; H, 7.76; N, 17.05. MS (EI; m/z): Calculated for 
C15H19N3 [M – CH3CH2CH2NH]+,184.10. Found: 184.00. 
 2.6.4.3. Preparation of L2 
A synthetic procedure, analogous to that of compound L1, was followed in the synthesis of 
the dendritic ligands L2 and L3. Synthesis of ligand L2 involved reacting 4’-methyl-2,2’-
bipyridyl-4-carboxaldehyde (0.400 g; 2.02 mmol) and DAB-G1dendr-(NH2)4 (0.160 g, 0.505 
mmol) in dry CH2Cl2 (30.0 mL) and MgSO4 (0.100 g). The workup was carried out as 
outlined in the preparation of L1 with NaBH4 (0.115 g, 3.03 mmol) used as the reducing 
agent. 




                        
Compound L2: Yellow oil, Yield: 0.290 g (54.9%). IR: Nujol between NaCl plates, v/cm-1= 
1596, 1554 (sharp, bipyridine, C N). 1H NMR (400 MHz, (CD3)2SO): δ = 1.23 (br signal, 
4H, NCH2CH2CH2CH2N), 1.47 (m, 8H, NCH2CH2CH2NH), 2.20 – 2.34 (overlapping peak 
signals, 24H, 4’-CH3, NCH2CH2CH2CH2N, NCH2CH2CH2NH), 2.45 (m, 8H, 
NCH2CH2CH2NH), 3.68 (s, 8H, 4-CH2), 7.19 (d, 4H, 3J = 4.35 Hz, H-5’), 7.28 (d, 4H, 3J = 
4.80 Hz, H-5), 8.18 (s, 4H, H-3’), 8.30 (s, 4H, H-3), 8.46 (d, 4H, 3J = 4.88 Hz, H-6’), 8.50 (d, 
4H, 3J = 4.88 Hz, H-6). 13C{1H} NMR (100.60 MHz, (CD3)2SO): δ = 20.6 (4’-CH3), 24.4 
(NCH2CH2CH2CH2N), 27.0 (NCH2CH2CH2NH), 47.3 (NCH2CH2CH2NH), 51.7 
(NCH2CH2CH2NH), 52.1 (4-CH2), 53.4 (NCH2CH2CH2CH2N), 119.6 (C-3), 121.1 (C-3’), 
123.0 (C-5), 124.6 (C-5’), 147.6 (C-4), 148.7 (C-6’, C-6), 151.2 (C-4’), 155.1 (C-2), 155.2 
(C-2’). Elemental analysis (%): Calculated for C64H80N14.CH2Cl2 (1130.3690): C, 69.07; H, 
7.31; N, 17.35; Found: C, 69.18; H, 7.36; N, 17.35. MS (HR – ESI – TOF, m/z): Calculated 
for C64H80N14 [M + H]+, 1045.6769. Found: 1045.6774.  
 2.6.4.4. Preparation of L3 
L3 was prepared by reacting 4’-methyl-2,2’-bipyridyl-4-carboxaldehyde (0.411 g; 2.07 
mmol) and DAB-G2dendr-(NH2)8 (0.195 g, 0.252 mmol) in dry CH2Cl2 (30.0 mL). 




Approximately 0.100 g of anhydrous MgSO4 was added. NaBH4 (0.153 g, 4.03 mmol) in 
MeOH (50.0 mL) was used in the reducing step. 
                
Compound L3. Light red-yellow oil. Yield: 0.401 g (71.4%) IR: Nujol between NaCl plates, 
v/cm-1= 1598, 1560 (sharp, bipyridyl, C N). 1H NMR (400 MHz, (CD3)2SO): δ = 1.20 (m, 
4H, NCH2CH2CH2CH2N), 1.31 (br qn, 8H, NCH2CH2CH2N), 1.45 (qn, 16H, 3J = 6.72 Hz, 
NCH2CH2CH2NH), 2.16 – 2.22 (two overlapping br t, 20H, NCH2CH2CH2CH2N, 
NCH2CH2CH2N), 2.32 (s, 24H, 4’-CH3), 2.43 – 2.47 (m, 32H, NCH2CH2CH2NH, 
NCH2CH2CH2NH), 3.67 (s, 16H, 4-CH2), 7.15 (d, 8H, 3J = 4.92 Hz, H-5’), 7.24 (dd, 8H, 3J = 
4.96 Hz, 3J = 1.48 Hz, H-5), 8.14 (s, 8H, H-3’), 8.27 (s, 8H, H-3), 8.42 (d, 8H, 3J = 4.92 Hz, 
H-6’), 8.46 (d, 8H, 3J = 4.88 Hz, H-6). 13C{1H} NMR (100.60 MHz, (CD3)2SO): δ = 20.4 (4’-
CH3), 24.2, 24.3 (overlapping NCH2CH2CH2N, NCH2CH2CH2CH2N), 26.9 




(NCH2CH2CH2NH),47.1 (NCH2CH2CH2NH), 51.7 – 51.5 (overlapping 
NCH2CH2CH2CH2N, NCH2CH2CH2NH), 51.9 (4-CH2), 53.3 (NCH2CH2CH2N), 119.5 (C-
3), 120.9 (C-3’), 122.8 (C-5), 124.4 (C-5’), 147.3 (C-4), 148.5, 148.6 (overlapping C-6’, C-
6), 150.7 (C-4’), 155.1, 155.2 (overlapping C-2, C-2’). Elemental analysis (%): Calculated 
for C136H176N30.10MeOH (2551.5340): C, 68.73; H, 8.53; N, 16.47; Found: C, 68.35; H, 8.55; 
N, 16.56. MS (HR – ESI – TOF, m/z): Calculated for C136H176N30 [M + 2H + Na]3+, 
752.0393. Found: 752.0718. 
 2.6.5. Synthesis and characterization of N,N’-pyridyl ligands 
 2.6.5.1. Preparation of N-((pyridine-2-yl)methyl)propan-1-amine (L4)24,25 
N-propylamine (0.154 mL, 1.87 mmol) was injected dropwise to a stirring solution of  
2-pyridinecarboxaldehyde (0.178 mL, 1.87 mmol) in dry CH2Cl2 (30.0 mL). Thereafter, 
MgSO4 (0.100 g) was added to the stirred mixture and the reaction proceeded for 24 hours. 
Filtration of the drying agent and evaporation of the solvent of the filtrate afforded a brown 
liquid. The crude liquid was further reacted with NaBH4 (0.142 g, 3.74 mmol) in MeOH (30.0 
mL) under nitrogen for 24 hours. The excess hydride was quenched with ice cooled water  
(20.0 mL). Thereafter, the H2O/MeOH mixture was reduced using a rotary evaporator and the 
crude product was extracted with CH2Cl2 (2 × 30.0 mL). Evaporation of CH2Cl2 from the 
combined organic extracts afforded a yellow liquid which was further purified using reverse 
phase column chromatography eluting with water (100%) then gradually increasing the 
gradient to 100% MeOH. The combined organic extracts were dried over anhydrous MgSO4, 
filtered and L4 was achieved as a light non-viscous yellow oil.  




                                                     
Compound L4: light brown oil, Yield: 0.101 g (35.9%). IR: Nujol between NaCl plates,  
v/cm-1= 1592 (sharp, pyridyl, C N), 1378 (sharp, 2° amine, CN). 1H NMR (400 MHz, 
(CD3)2SO): δ = 0.84 (t, 3H, 3J = 7.38 Hz, CH3CH2CH2), 1.42 (qn, 2H, 3J = 7.18 Hz, 
CH3CH2CH2), 2.46 (t, 2H, 3J = 7.04 Hz, CH3CH2CH2), 3.12 (br s, 1H, NH), 3.76 (s, 2H, 2-
CH2), 7.19 (m, 1H, H-4), 7.39 (m, 1H, H-3), 7.70 (td, 1H, 3J = 7.68 Hz, 4J = 1.83 Hz, H-5), 
8.46 (m, 1H, H-6). 13C{1H} NMR (100.60 MHz, (CD3)2SO): 11.7 (CH3CH2CH2), 22.7 
(CH3CH2CH2), 50.8 (CH3CH2CH2), 54.6 (2-CH2), 121.7 (C-4, C-3), 136.3 (C-5), 148.6 (C-
6), 160.5 (C-2). Elemental analysis (%): Calculated for C9H14N2 (150.2250): C, 71.96; H, 
9.39; N, 18.65; Found: C, 70.79; H, 9.14; N, 17.92. MS (EI; m/z): Calculated for C9H14N2 [M 
– CH3CH2CH2NH]+,93.06. Found: 93.03. 
 2.6.5.2. Preparation of L5 
DAB-G1dendr-(NH2)4 (0.306 mL, 0.930 mmol) was syringed dropwise to a stirring solution 
of 2-pyridinecarboxaldehyde (0.355 mL, 3.73 mmol) in dry CH2Cl2 (50.0 mL). MgSO4 (0.400 
g) was added and the reaction mixture was stirred overnight at room temperature. The drying 
agent was filtered and the solvent evaporated to afford a brown-yellow oil. The oil was 
dissolved in MeOH (60.0 mL) and stirred for 30 minutes while being purged with nitrogen. 
Subsequently, NaBH4 (0.353 g, 9.33 mmol) was added to the stirred solution and the reaction 
proceeded overnight at room temperature under nitrogen. To quench the reaction, ice cooled 
water (70.0 mL) was added and the azeotropic mixture was evaporated by rotary evaporation 
to afford a suspension to which CH2Cl2 (50.0 ml) was added. The organic mixture was 
washed with H2O (2 × 20.0 mL) and evaporation of CH2Cl2 from the combined organic 




extracts afforded a brown oil which was further purified using reverse phase column 
chromatography as outlined in preparation of L4. The combined organic extracts were dried 
over anhydrous MgSO4, filtered off and L5 was achieved as a brown oil.  
                               
Compound L5: Brown oil, Yield: 0.190 g (30.0%). IR: Nujol between NaCl plates, v/cm-1= 
1593 (sharp, pyridyl, C N), 1377 (sharp, 2° amine, C-N). 1H NMR (400 MHz, (CD3)2SO): 
δ = 1.30 (m, 4H NCH2CH2CH2CH2N), 1.53 (br qn, 8H, NCH2CH2CH2NH, 2.29 – 2.38 
(overlapping m, 12H, NCH2CH2CH2CH2N, NCH2CH2CH2NH), 2.54 (br t, 8H, 
NCH2CH2CH2NH), ), 2.81 (br s, 4H, NH), 3.77 (s, 8H, 2-CH2), 7.19 (m, 4H, H-4), 7.38 (d, 
4H, 3J = 7.80 Hz, H-3), 7.69 (br td, 4H, H-5), 8.46 (br d, 4H, H-6). 13C{1H} NMR (100.60 
MHz, (CD3)2SO): 24.4 (NCH2CH2CH2CH2N), 26.7 (NCH2CH2CH2NH), 47.2 
(NCH2CH2CH2NH), 51.7 (NCH2CH2CH2NH), 53.4 (NCH2CH2CH2CH2N), 54.8 (2-CH2), 
121.6 (C-4), 122.7 (C-3), 136.2 (C-5), 148.6 (C-6), 159.9 (C-2). Elemental analysis (%): 
Calculated for C40H60N10.2H2O (717.0200): C, 67.01; H, 9.00; N, 19.54; Found: C, 66.57; H, 
8.92; N, 19.60. MS (HR – ESI – TOF, m/z): Calculated for C40H60N10 [M + 2H]2+, 341.2580. 
Found 341.2581.  
 2.6.5.3. Preparation of L6 
Ligand L6 was synthesized in analogous manner to L5. DAB-G2dendr-(NH2)8 (0.360 mL, 
0.466 mmol) and 2-pyridinecarboxaldehyde (0.400 g, 3.73 mmol) were stirred in dry CH2Cl2 




(40.0 mL) and MgSO4 (0.100 g) was added. Thereafter, the reaction was stirred for 24 hours 
prior to the reducing step using NaBH4 (0.656g, 17.3 mmol) in MeOH (40.0 mL). 
                     
Compound L6. Dark brown oil, Yield: 0.89 g (44.0%). IR: Nujol between NaCl plates, v/cm-
1 = 1592 (sharp, pyridyl, C N), 1377 (sharp, 2° amine, C-N). 1H NMR (400 MHz, 
(CD3)2SO): δ = 1.38 (m, 4H, NCH2CH2CH2CH2N), 1.57 (br qn, 8H, NCH2CH2CH2N), 1.69 
(qn, 16H, NCH2CH2CH2NH), 1.94 (br s, NH), 2.40 (m, 20H, NCH2CH2CH2CH2N, 
NCH2CH2CH2N) 2.50 (t, 16H, 3J = 7.20 Hz, NCH2CH2CH2NH), 2.70 (t, 16H, 3J = 7.02 Hz, 
NCH2CH2CH2NH), 3.90 (s, 16H, 2-CH2), 7.12 (m, 8H, H-4), 7.31 (d, 8H, 3J = 7.68 Hz, H-3), 
7.63 (tdd, 8H, 3J = 7.72Hz, 4J = 1.72 Hz, H-5, 6J = 0,72 Hz, H-5), 8.55 (ddd, 8H, 3J = 4.89 Hz, 
4J = 1.72 Hz, 5J = 0.96 Hz, H-6). 13C{1H} NMR (100.60 MHz, (CD3)2SO):  
20.4 (NCH2CH2CH2N), 24.2 (NCH2CH2CH2CH2N), 27.5 (NCH2CH2CH2NH), 47.8 
(NCH2CH2CH2NH), 51.5 (NCH2CH2CH2CH2N, NCH2CH2CH2N), 51.7 
(NCH2CH2CH2NH,), 51.9 (2-CH2), 119.5 (C-3),  120.9 (C-3’), 121.9 (C-4), 122.8 (C-5), 




124.4 (C-5’) 148.6 (C-6), 160.1 (C-2). Elemental analysis (%): Calculated for 
C88H136N22.CH2Cl2 (1587.1370): C, 67.35; H, 8.76; N, 19.42; Found: C, 66.91; H, 8.76; N, 
19.18. MS (HR – ESI – TOF, m/z): Calculated for C88H136N22 [M + 4H]4+, 376.2908. Found 
376.2898. S25 °C = 0.01 mg/µL in water. 
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Synthesis and characterization of fac-[Re(CO)3(N,N’-
bidentate)X] complexes 
 3.1. General introduction 
Rhenium occurs naturally as a mixture of non-radioactive (‘cold’) isotopes, 185Re (37.4%) 
and 187Re (62.6%).1 By virtue of the ‘lanthanide contraction’—a phenomenon which ensures 
that the complexes of two different metals are similar in terms of their physical properties 
(such as size and lipophilicity)—‘cold’ rhenium complexes are used to characterize (e.g. 
structural elucidation) radioactive (‘hot’) technetium-99m complexes.1 The complexes of Re 
are kinetically inert and harder to reduce than their Tc analogues.1  
Re(I) is a d6 centre and its kinetic behaviour often permits the isolation of intermediates 
which are not the thermodynamic end-products.2 The fac-[M(CO)3]+ (M = Re(I) or 99mTc(I)) 
core is the most versatile and studied adduct as it permits efficient complexation (or labeling) 
under aqueous conditions.3-9 Traditionally, complexes of the general formula fac-
[M(CO)3Ligand] (M = Re or 99mTc, Ligand = tridentate ligand) were prepared from M2CO10 
through high pressure carbonylation, an impractical synthetic route for clinical application.8  
Currently, as part of Green Chemistry, organometallic reactions in aqueous solutions are of 
interest in drug design. Alberto et al. discovered a new method for the synthesis of  
fac-[Re(CO)3]+ containing complexes, derived from the fac-(Et4N)2[Re(CO)3X3] (X = halide) 
precursor.9 Herein, the synthesis and characterization of various fac-[Re(CO)3(N,N-
bidentate)X]n (n = 0, X = Cl or Br and n= +1, X = H2O) monomeric and dendritic complexes 
is described. 




 3.2. Neutral fac-[Re(CO)3X] (X = Cl or Br) core complexes 
A method by Del Guerzo et al. was used for the synthesis of chlorinated Re(I) complexes.10 
Scheme 3.1 displays the reaction between the ligands L1 – L6 with equimolar ratios of 
Re(CO)5Cl in toluene. To remove the traces of the unreacted starting material, the complexes 
C7 – C12 were purified by repeated precipitation and washing with hot benzene. 
                  
                  
                            
Scheme 3.1: Synthesis of the tricarbonylchlororhenium(I) complexes using Re(CO)5Cl.10 
The monomeric tricarbonylchlororhenium(I) complex C7 was isolated as a pale yellow solid 
in 66.7% yield The tricarbonylchlororhenium(I) metallodendrimers, C8 and C9, were 
isolated as yellow-brown amorphous solids in 56.6 and 33.4% yield, respectively. C7 – C9 
are soluble in (CH3)2CO, (CH3)2SO and partially soluble in CH3CN.  
The picolyl metallodendrimers C11 and C12 were isolated as grey amorphous solids in 25.3 
and 43.1% yield, respectively. The monomeric complex C10 was isolated as white flakes in 
49.5% yield. C10 – C12 are soluble in (CH3)2CO, (CH3)2SO and partially soluble CH2Cl2. 




Furthermore, C7 – C12 have melting point ranges greater than 300 °C. The model 
monomeric analogues C7 and C10 were found to be insoluble or rather partially soluble in 
most organic solvents other than (CH3)2SO, notably, at room temperature, making them 
difficult to crystallize. It was suggested that their corresponding brominated counterparts 
might be isolated as solids with the possibility to further crystallize from the appropriate 
solvent(s). 
fac-(Et4N)2[Re(CO)3X3] (X = halide) is a precursor compound that allows facile substitution 
of the X ligands, even under mild conditions, by mono-, bi- or tridentate incoming ligands. 
The brominated complexes were therefore synthesized by reacting the monomeric and 
dendritic ligands L1 – L6 with the rhenium precursor fac-(Et4N)2[ReBr3(CO)3] in dry MeOH 
at room temperature (Scheme 3.2). The desired products were collected as precipitates which 
were further washed with cooled MeOH to afford C13 – C18 as defined solids. 
                         
                       
                              
Scheme 3.2: A synthesis scheme of rhenium(I) tricarbonylbromo complexes C13 – C18. 




The tricarbonylbromorhenium(I) metallodendrimers, C14 and C15, were isolated as yellow 
solids in 79.0 and 61.6% yield, respectively. The monomeric analogue C13 was isolated as a 
pale yellow solid in 76.0% yield. C13 is soluble in polar organic solvents such as EtOH, 
(CH3)2CO, CHCl3, CH2Cl2 and partially soluble in H2O. The complexes C14 and C15 are 
soluble in (CH3)2SO and partially soluble in CH2Cl2. C13 – C15 have melting point range 
less than 200 °C.  
The picolyl monomeric complex C16 was isolated in 57.0% yield as a white solid which was 
further recrystallized from EtOH to afford white needles. C16 is soluble in polar organic 
solvents such as EtOH, (CH3)2CO, (CH3)2SO, CHCl3, CH2Cl2, and warm MeOH. The 
metallodendrimers C17 and C18 were isolated as brown solids in 19.5% and 25.0% yield, 
respectively. C17 is soluble in (CH3)2CO, (CH3)2SO and partially soluble in warm CH2Cl2, 
whereas, C18 is soluble in (CH3)2SO.  
The structural integrity of all the complexes was confirmed using 1H, 13C{1H} NMR, infrared 
spectroscopy, mass spectrometry, elemental analysis and by X-ray diffraction with respect to 
C16. The tricarbonylchlororhenium(I) and tricarbonylbromorhenium(I) complexes 
have similar spectroscopic features. 
 3.2.1. 1H and 13C{1H} NMR spectroscopy 
The NMR spectra were recorded in deuterated dimethyl sulfoxide and the spectroscopic 
features of the Cl complexes translate to Br complexes. 
 3.2.1.1. fac-[Ren(CO)3n(N,N’-bipyridyl)Xn] (n = 1, 4 and 8. X = Cl or Br) 
complexes (C7 – C9 and C13 – C15) 
The 1H NMR spectrum in Figure 3.1 corresponds to the mononuclear complex C7 
and displays a distinctive downfield shift between 9.00 – 7.57 ppm corresponding to the 




bipyridyl ring aromatic protons as a result of tricarbonylbromorhenium(I) coordination 
preference for the bipyridyl N,N’-donor atoms, attesting to the complexation reaction.  
    
Figure 3.1: 1H NMR spectra of the monomeric complex C7 in (CD3)2CO. 
Furthermore, in the 1H NMR spectrum of C7 the CH3CH2CH2NH aliphatic protons 
corresponding to the terminal N-propyl chain appear slightly downfield and overlap with the 
deuterated solvent water signal between 2.75 – 3.00 ppm, the presence of the 
CH3CH2CH2NH aliphatic protons in the spectrum was also confirmed by 2D NMR spectra. 
The deshielding shifts of the aromatic and aliphatic proton resonances in the 1H NMR 
spectrum of C7 were encountered in the 1H NMR spectrum of the 
tricarbonylbromorhenium(I) mononuclear analogue C13. The similarities in the chemical 
shifts of C7 and C13 confirm the complexation reaction. The tricarbonylchlororhenium(I) 
metallodendrimers C8 and C9 have spectral changes analogous to their corresponding 
tricarbonylbromorhenium(I) counterparts, C14 and C15. 
Figure 3.2 illustrates the 1H NMR spectrum of the first generation 
tricarbonylbromorhenium(I) complex C14 in deuterated dimethylsulfoxide.  





Figure 3.2: 1H NMR spectrum of C14 in (CD3)2SO. 
In the 1H NMR spectrum of the multinuclear complex C14, the broadening characteristic of 
the proton resonances corresponding to the dendritic arms and core (DAB), in the aliphatic 
region between 1.50 – 3.00 ppm, is observed as a result of the paramagnetic rhenium(I) 
metal. In general, the presence of an unpaired electron in the paramagnetic metal broadens 
the NMR lines of the nuclei of a compound with which it form a complex.11-13 The magnetic 
field of the paramagnetic ion changes the relaxation time of the magnetically active  
nuclei.11-13 Thus, line broadening is a consequence of the enhanced relaxation time which 
affords the observation of instantaneous NMR signals from all possible orientations (adverse 
broad peaks) of the molecule in solution (isotropic effect), instead of the averaged signals 
normally observed for protracted relaxation events (defined peaks).11-13 The complexation 
reaction is confirmed by the downfield chemical shifts of the bipyridyl ring aromatic protons, 
which were previously observed between 7.19 – 8.50 ppm in the 1H NMR spectrum of L2 
(Chapter 2, Figure 2.4), now resonating between 7.50 – 9.00 ppm in the 1H NMR spectrum 




of C14. In addition to the line broadening of the aliphatic proton signals, peak broadening is 
also observed in the aromatic region of C14 1H NMR spectrum (supported by presence of 
broad doublets and multiplets). The line broadening is observed in the 1H NMR spectra of all 
the bipyridyl metallodendrimers. 
The 13C{1H} NMR confirms the presence of the fac-[Re(CO)3]+ core carbonyl carbon atoms. 
As a result of the low solubility of C7 in deuterated dimethylsulfoxide, (CD3)2CO was used 
to obtain the acquisition of an acceptable 13C{1H} NMR spectrum. The 13C{1H} NMR 
spectra of complexes C7 – C15 show two resonances—as opposed to the three expected 
resonances of the fac-[Re(CO)3]+ core—corresponding to the CO ligands between 189.0 – 
198.0 ppm (for C8/C14) and 190.0 – 197.0 ppm (for C13/C15). In Figure 3.3, is the 13C 
APT spectrum of C9 in (CD3)2SO. 
 
Figure 3.3: 13C APT spectrum of C9. CH3 and CH signals in the negative mode. CH2, C and CO 
signals in the positive mode. Bpy = bipyridyl 




In the 13C APT spectrum of C9, the characteristic 2:1 ratio of the CO carbon atom resonances 
between 190 – 200 ppm signifies that two of the three carbon atoms are magnetically 
equivalent on NMR time scale.14 The aliphatic carbon resonances corresponding to the 
dendritic core and arms coalesce into a broad resonance around ~ 50 ppm. Similarly, the 
overlap of the bipyridyl (C2/C2’ and C4/C4’) resonances between 155 – 160 ppm is 
observed. The presence of overlapping carbon resonances was confirmed by 2D HSQC 13C – 
1H correlation spectrum. 
 3.2.1.2. fac-[Ren(CO)3n(N,N’-picolyl)Xn] (n = 1, 4and 8. X = Cl or Br) complexes, 
(C10 –C12 and C16 – C18) 
The NMR data of tricarbonylbromorhenium(I) and tricarbonylchlororhenium(I) complexes 
were recorded in deuterated dimethylsulfoxide and acetone, respectively. The NMR spectra 
of complexes C10 – C12 are comparable to those of their corresponding analogues C16 – 
C18. Metallation of L4 (Chapter 2, Figure 2.5) with 1 equivalent of fac-
(Et4N)2[ReBr3(CO)3] is confirmed by the set of two doublet of doublets at 4.16 and 4.82 ppm 
(previously observed as singlet at 3.76 ppm in the 1H NMR spectrum of L4, Chapter 2, 
Figure 2.5) present in the 1H NMR spectrum of C16, Figure 3.4.  
 
Figure 3.4: 1H NMR spectrum of C16 in (CD3)2SO. 




The two doublet of doublets at 4.16 and 4.82 ppm are assigned to the 2-CH2NH methyl 
proton resonances adjacent to the pyridyl ring and have 2J coupling constants of ~15.0 Hz, 
consistent with geminal coupling constants.14 The splitting of the 4-CH2NH methyl proton 
resonances is also observed in the 1H NMR spectra of the multinuclear complexes C17 and 
C18, confirming synthesis of the metallodendrimers. The peak splitting patterns in the 1H 
NMR spectra of C17 and C18 appear as multiplets on account of peak broadening influenced 
by the presence of the paramagnetic Re(I). 
The complexation reaction between L6 (Chapter 2) and 8 equivalents of Re(CO)5Cl is 
confirmed by the 1H NMR spectrum of the second generation tricarbonylchloro(I) complex 
C12, in Figure 3.5.  
 
Figure 3.5: 1H NMR spectrum of C12 in (CD3)2CO. 
The previously enantiotopic 2-CH2NH methyl protons adjacent to the pyridyl ring (L6 
spectra, Chapter 2), appear as diastereotopic around the prochiral 2-CH2NH centre post the 
complexation reaction, confirming the chiral nature of [Re(CO)3(N,N’-picolyl)X] (X = Cl or 




Br) complexes.14 The diastereotopic nature is supported by the 1H NMR spectrum of C12 
which shows two broad multiplets in the region between 4.50 – 5.25 ppm assigned to the  
2-CH2NH methyl protons adjacent to the pyridyl ring. Proton integrations in the 1H NMR 
spectrum (Figure 3.5) of C12 account for the total number of protons in the complex. Other 
resonances in Figure 3.5 correspond to solvent molecules. 
The most valuable NMR data were achieved from the 13C{1H} NMR spectra of C10 – C12 
and C16 – C18 supporting a bidentate chelation mode via N,N donor atoms. Figure 3.6 
corresponds to the 2D HSQC 13C – 1H correlation spectrum of C16 in (CD3)2SO. The F1 axis 
corresponds to the carbon signals of C16 and the quaternary carbons in this case are omitted. 
The 2D HSQC spectrum of C16 correlates the chemical shifts of the diastereotopic 2-CH2NH 
protons and N-propyl side chain CH3CH2CH2NH protons with the carbon chemical shift at 
59.7 ppm, the crosspeaks are linked by a black solid line in Figure 3.6. 
 





Figure 3.6: The 2D HSQC spectrum of C16 in (CD3)2SO. The black line correlates the corresponding 
C-H nuclei. Peak assignments in F2 axis correspond to Figure 3.4. 
The presence of the three carbonyl resonances corresponding to the fac-[Re(CO)3]+ moiety is 
observed in the 13C APT spectra of [Re(CO)3(N,N’-picolyl)X] (X = Cl or Br) complexes. 
Figure 3.7 shows the 13C APT spectrum of C16 in (CD3)2CO. 





Figure 3.7: 13C APT spectrum of C16 in (CD3)2SO. CH3 and CH signals in the negative mode. CH2, 
C and CO signals in the positive mode. 
The 13C APT spectrum of C16 in, Figure 3.7, reveals three deshielded CO carbon resonances 
upfield at 191.9, 196.2 and 197.7 ppm. The 13C APT spectrum of the second generation 
tricarbonylchlororhenium(I) complex C12 in deuterated acetone is shown in Figure 3.8. In 
Figure 3.8 the three carbonyl ligands resonate at 192.5, 197.1 and 198.3 ppm, respectively. 
As a result of peak overlap resonances due to broad peaks, the general 13C NMR spectral data 
of the halogenated metallodendrimers does not give the exact number of the carbon signals 
for the proposed structures. 





Figure 3.8: 13C APT spectrum of C12 in (CD3)2CO. CH3 and CH signals in the negative mode. CH2, 
C and CO signals in the positive mode. 
The C4 signal resonating ~ 122.4 ppm in the 13C{1H} NMR spectra of L4 – L6 (Chapter 2, 
Section 2.6.5.1 – 2.6.5.3) shifts downfield by ~20 ppm to ~140.0 ppm upon the formation of 
complexes C10 – C12 and C16 – C18. The carbon atom C4 in picolyl systems is either 
electrophilic or electronegative (e.g. N-oxides). In the case of picolyl complexes, the presence 
of the fac-[Re(CO)3X] (X = Br or Cl) moiety imposes a deshielding effect at C4, confirming 
the successful complexation reactions via N,N’-donor atoms.  
 3.2.2. Infrared spectroscopy 
The IR spectrum of Re(CO)5Cl in KBr pellet displays two absorption bands of different 
intensities corresponding to the carbonyl absorption bands at 1985 and 2046 cm-1, whereas, 
the ATR-FTIR spectrum of fac-(Et4N)2[ReBr3(CO)3] has typical fac-[Re(CO)3]+ carbonyl 
absorption bands at 1846 and 1995 cm-1. 




 3.2.2.1. fac-[Ren(CO)3n(N,N’-bipyridyl)Xn] (n = 1, 4 and 8. X = Cl or Br) 
complexes (C7 – C9 and C13 – C15) 
Table 3.1 summarises the IR and ATR-FTIR frequencies for the complexes C7 – C9 and 
C13 – C15. 
Table 3.1: Summary for the stretching frequencies of CO ligands in [Re(CO)3(N,N’-
bipyridyl)X] (X = Cl or Br) type complexes C7 – C9 and C13 – C15 
a = IR spectrum (KBr), b = ATR-FTIR spectrum 




















The IR spectra of the tricarbonylchloro bipyridyl metal complexes C7 – C9 show three CO 
characteristic asymmetric stretching vibrations between 2019 – 1893 cm-1, indicating the 
presence of fac-[Re(CO)3]+ isomer.14,15 The ATR-FTIR spectra of tricarbonylbromo-
rhenium(I) complexes C13 and C15 have three absorption bands analogous to the bromo 
complexes C7 and C9, as summarized in Table 3.1. Complex C14 ATR-FTIR spectrum 
shows two absorption bands at 2016 and 1877 cm-1, with the latter being broad as a result of 
the symmetric stretching vibrations of the CO ligands in the equatorial plane. The two 
bipyridyl C=N absorption bands, previously observed between 1556 – 1597 cm-1 in the IR 
spectrum of the ligands L1 – L3, shift to higher wavenumbers ranging between 1603 – 1628 
cm-1 in C7 – C15 infrared spectra, indicating that the aromatic N,N’-donor atoms (2,2’-
bipyridyl nitrogen atoms, C=N) are the Re(I) chelate. 
 3.2.2.2. fac-[Ren(CO)3n(N,N’-picolyl)Xn] (n = 1, 4 and 8. X = Cl or Br) complexes 
(C10 – C12 and C16 – C18) 
Table 3.2 summarizes the IR and ATR-FTIR frequencies corresponding to the complexes 
C10 – C12 and C16 – C18. 




Table 3.2: Summary for the stretching frequencies of CO ligands in fac-
[Re(CO)3(N,N’-pyridyl)X] (X = Cl or Br) type complexes C10 – C12 and C16 – C18 
a = IR spectrum (KBr), b = ATR-FTIR spectrum 

















The complexes C10 – C16 exhibit three strong carbonyl absorption bands in the region 
ranging from 2011 – 1875 cm-1. Furthermore, two carbonyl absorption bands are observed in 
the spectra of C17 and C18, Table 3.2, which deviate from 1846 and 1995 cm-1 observed in 
the ATR-FTIR spectrum of the precursor fac-(Et4N)2[ReBr3(CO)3]. These data confirm the 
metallation of L4 – L6 with fac-[Re(CO)3]+, where the carbonyl ligands are coordinated via a 
terminal CO bonding mode around on Re(I) metal center. 
 3.2.3. Elemental analysis and mass spectrometry 
 3.2.3.1. fac-[Ren(CO)3n(N,N’-bipyridyl)Xn] (n = 1, 4 and 8. X = Cl or Br) 
complexes (C7 – C9 and C13 – C15) 
The elemental analysis of the bpy tricarbonylchloro and tricarbonylbromorhenium(I) were 
within the acceptable limits. Notably, the elemental analysis of the complexes C7 – C9 and 
C14 attest the inclusion of water molecules. The water molecules may have resulted from the 
reaction solvents and the starting material DAB-PPI dendrimers which contain 1% (w/v) 
water. Furthermore, Jansen et.al. have previously reported on the capability of dendritic 
architectures to encapsulate small molecules by forming a dendritic box through free rotation 
and folding of the dendritic arms.16 
The identification of the complexes C7 – C9 and C13 – C15 is supported by the HR-ESI-
TOF-MS data and in each case, the base peaks corresponds to a charged complex. 




 3.2.3.2. fac-[Ren(CO)3n(N,N’-picolyl)Xn] (X = Cl or Br) complexes (C10 – C12 and 
C16 – C18) 
The C, H, and N elemental analysis of the complexes C10 – C12 and C16 – C18 were within 
satisfactory ranges. The prominent mass per charge (m/z) spectral data obtained using HR-
ESI mass spectrometry is summarised in Table 3.3. 
Table 3.3: Summary of the mass spectral data corresponding to the fac-
[Re(CO)3(N,N’-picoly)X] (X = Cl or Br) complexes C10 – C12 and C16 – C18 
M = exact mass of the complex excluding the encapsulated solvent molecules 
Complex C10 C11 C12 C16 C17 C18 
Base peak 
(m/z) 
[M + Cl]+ [M + H]+ [M + C7H8 
– 8Cl]8+ 
[M – Br]+ [M + 2H]2+ [M + 3H – 
Br]4+ 
The base peaks corresponding to C11 and C17 adducts exhibited a 1+ and 2+ charge, 
respectively. The base peaks of second generation metallodendrimers C12 and C18 depict 
multivalent adducts 
 3.2.4. Crystallographic studies on fac-[ReBr(CO)3{N-((pyridine-2-yl) 
methyl)propan-1-amine}] (C16) 
The molecular structure of the monomeric model complex, fac-[ReBr(CO)3{N-((pyridine-2-
yl)methyl)propan-1-amine}] (C16), was determined by X-ray diffraction, and is shown in 
Figure 3.9.  
 




                            
Figure 3.9: X-ray structure of fac-[ReBr(CO)3{N-((pyridine-2-yl)methyl)propan-1-amine}], C16. 
Ellipsoids drawn at 50% probability. 
C16 crystallizes in a monoclinic space group, P21/c, with four formula units per unit cell (Z = 
4). The asymmetric unit contains one independent molecule. The molecular structure of C16 
is represented in Figure 3.9 along with the atom numbering scheme. The 1H NMR spectrum 
of C16 (Figure 3.4) illustrates the presence of N(1)-H bond (confirmed by proton integration 
and 2D NMR), whereas, the XRD structure in Figure 3.9 shows the presence of a three 
bonded N(1) atom. This could be attributed to the different forms of C16 in liquid and solid 
state. Table 3.4 and Table 3.5 illustrate the general X-ray diffraction data and geometrical 












Table 3.4: X-ray diffraction data of C16 
empirical formula C12H13BrN2O3Re 
formula weight 499.35 
crystal system monoclinic 
space group P21/c 
a (Å) 8.880(5) 
b (Å) 21.341(5) 
c (Å) 7.693(5) 
α (degrees) 90.000(5) 
β (degrees) 95.410(5) 
γ (degrees) 90.000(5) 
V (Å3)  1451.4(13) 
Z 4 
Dcald (mg.cm-3) 2.285 
µ (mm-1) 11.129 
F(000) 932 
T (K) 293(2)  
crystal colour colourless 
θ range (degrees) 1.91 – 28.00 
completeness of θ (%) 100 
index ranges  h = -11 to 11 
 k = -26 to 28 
 l  = -10 to 8 
reflections collected 39 600 




R1 [I > 2σ(I)]a R1 = 0.0253, wR2 = 0.082 
R1 (all data) R1 = 0.0282, wR2 = 0.0964 
ρmax and ρmin (e Å−3) 1.332, -1.660    














C(12)-Re(1)-N(1)  171.51(18) 
 Bite angle 


















The central rhenium atom coordinates with the nitrogen atoms of N-((pyridine-2-
yl)methyl)propan-1-amine (L4) to form a five-membered ring. Three carbonyl ligands are 
facially coordinated to the metal centre, together with a bromide anion to complete the 
slightly distorted octahedral arrangement around rhenium(I). The trans angles assigned to the 
rhenium–CO (C(10)-Re(1)-Br(1), C(11)-Re(1)-Br(1), C(12)-Re(1)-Br(1)) range between 
171.51(18) – 179.24(14)°, showing a slight deviation from the desirable octahedral limit 
(180.00°).14 The N(2)-Re(1)-N(1) chelate angle of 75.17(16)°, instead of the ideal angle of 
90°, delineates the formation of a geometrically strained 5-membered ring which contributes 
significantly to the angular distortion of the octahedral complex, C16.14,17  
The C(6)–N(1) bond length measures 1.491(6) Å which is consistent with Saw et al. 
observations of 1.46(1) Å for a single bond.18 The bond length assigned to Re(I)-N(1), 
2.220(4) Å, is slightly longer than 2.183(5) Å assigned to Re(I)-N(2). The Re-N bond angles 
are consistent with sp3 and sp2 - hybridized nitrogen donor atoms, respectively.14,18 Also, a 
normal aliphatic trigonal pyramidal geometry around N(1) reflects the amino versus imino 
distinction of sp3 hybridized nitrogen atom. All the bond distances and angles of C16 are 
consistent with the similar structures reported in the literature.14,17-19 The monoclinic crystal 
is stabilized by one C-H---O intermolecular interaction. This is formed between an aromatic 
hydrogen atom (H3) of the pyridine ring and the carbonyl oxygen atom of a neighbouring 
molecule (O11), see Figure 3.10. 
              
Figure 3.10: Hydrogen bonding in C16 




The molecules pack in a head-to-head fashion diagonally across the a-b plane as illustrated in 
Figure 3.11. 
                                        
Figure 3.11: Illustration of C16 molecules across the a-b plane 
As illustrated in Figure 3.12 the two carbon atoms which form part of the five-membered 
ring, C5 and C6, are displaced by 0.229(6) and 0.584(6) Å, respectively, from a plane 
constructed through the central rhenium atom, the two nitrogen atoms coordinated to it and 
the two carbonyl ligands trans to the nitrogen atoms. 
                    
           
Figure 3.12: C5 and C6 lie above the mirror plane. 
(a) 
(b) 




 3.3. Synthesis and characterization of monomeric and dendritic 
cationic fac-[Re(CO)3H2O]+ isomer complexes 
In the current study, one of the aims was to synthesize water soluble dendritic Re(I) aqua 
complexes and to study the substitution kinetic behaviour of the complexes in aqueous 
medium. Different synthetic strategies have emerged from the use of tridentate ligands to a 
combination of a mono- and bidentate ligands (2 + 1 approach) to saturate the coordination 
sphere of fac-[M(CO)3(OH2)3]+ (M = Re(I) or 99mTc(I)).20 As proposed by Mundwiler et al.,21 
the mixed ligand approach comprises a bidentate ligand to substitute two of the three labile 
aqua ligands, and a monodentate ligand to occupy the third aqua coordination site (Scheme 
3.3).20-22  
                                
Scheme 3.3: The concept of the mixed ligand [2 + 1] approach where 2B represents the bidentate 
biomolecule and 1B represents the monodentate biomolecules.21 
A bidentate ligand can control the lipophilicity (e.g. the dendrimer terminal functional 
groups) and a monodentate bifunctional ligand can act as a potential linker to a biomolecule. 




The chemical nature of complexes achieved via the 2 + 1 approach (mixed ligand approach) 
can be tailored and the in vivo properties can be tuned by varying the mono- or bidentate 
ligands (through coordinating a mono- or bidentate biologically active molecule rather than 
coordinating a single tridentate targeting molecule).20-22 The complexes C19 – C21 and C22 
– C24 were synthesized as outlined in Scheme 3.4.  
                  
                           
Scheme 3.4: (a) Synthesis of fac-[Re(CO)3(OH2)3]+. (b) Reaction scheme for the synthesis of 
compounds C19 – C21 and C22 – C24 by reacting fac-[Re(CO2)3(OH2)3]+ with L1 – L3, and L4 – 
L6. 
The dissolution of fac-(Et4N)2[ReBr3(CO)3] in water, Scheme 3.4 (a), results in an 
organometallic aqua cation fac-[Re(OH2)3(CO)3]+, which is stable in water.23 fac-
(Et4N)2[ReBr3(CO)3] was dissolved in water under acidic conditions to minimize 
dimerization as a result of bridging hydroxo ligands.24 The solution was stirred in the 
presence of silver nitrate, for halide extraction, to form fac-[Re(CO)3(H2O)3]+. However, the 
substitution reaction produces Et4N+ as a side product which exhibits similar polarity to fac-
(a) 
(b) 




[Re(CO)3Ligand]+ complexes,25 making the purification of C19 – C24 (Scheme 3.4 (b))using 
silica and alumina chromatography difficult. Furthermore, Et4NBr tends to co-crystallize with 
the desired product(s)25, resulting in inaccurate melting points.  As a result of excess Et4N+, 
calculation of the reaction percentage yields was omitted. 
The complexes C19 – C21 were synthesized by reacting a solution of fac-[Re(CO)3(H2O)3]+ 
with equimolar ratios of ligands L1 – L3. The ligands L1 – L3 (~30 mg) were observed to be 
soluble in 5 mL of water, at pH 2.2. The complexes C19 – C21 were isolated as yellow solids 
which were filtered and rinsed with water. A prolonged exposure to moisture of these 
complexes changes their solid state to oil residues. C19 – C21 are soluble in coordinating 
solvents such as MeCN and (CH3)2CO, (CH3)2SO. In solid state, the melting points range of 
C19, C20 and C21 were found to be 192 – 195 °C, 132 – 135 °C and 179 – 182 °C, 
respectively. 
The complexes C22 – C24 remained in solution after the reaction, hence, water was removed 
using a freeze drier. These complexes, however, are prone to decomposition and/or 
dimerization if placed in vacuo to remove water for a prolonged time limiting their 
characterization, as confirmed using NMR. C22 and C24 were isolated as colourless 
suspensions which turn brown when lyophilized to remove all the water, whereas, C23 was 
isolated as light brown solid. C22 – C24 are soluble in MeOH and in various non-
coordinating polar organic solvents such as CH2Cl2 and CHCl3. Spectroscopic and analytical 
techniques were further utilized for complete characterization of C19 – C24. 
 3.3.1. 1H NMR and 13C{1H} NMR spectroscopy 
Due to the protracted relaxation times of the carbonyl ligands, some of these signals are not 
observed on the 13C{1H} NMR time scale. However, the carbonyl ligands are detected on the 
IR spectra of all complexes. 




 3.3.1.1. fac-[Ren(CO)3n(N,N’-bipyridyl)(OH2)n]n+ (n = 1, 4 and 8) complexes (C19 
– C21) 
The trend observed in the 1H NMR spectra of the fac-[Re(CO)3(N,N’-bipyridyl)X] (X – Br or 
Cl) type complexes is observed in the 1H NMR spectra of C19 – C21, which are 
contaminated with Et4N+. The spectra of C19 – C21 also shows peak broadening and 
contains water. In the 13C{1H} NMR spectra of C20 and C21, the tricarbonyl carbon 
resonances were not observed as a result of the long relaxation time of these carbons atoms. 
Considering the inadequate data obtained using the NMR, other characterization methods 
were considered to be sufficient. 
 3.3.1.2. fac-[Ren(CO)3n(N,N’-picolyl)(OH2)n]n+ (n = 1, 4 and 8) complexes (C22 – 
C24) 
Similarly, the complexes C22 – C24 exhibited similar spectroscopic features to their fac-
[Re(CO)3(N,N’-bipyridyl)X] (X – Br or Cl) type analogues. The monomeric analogue C22 
and the metallodendrimer C23 could be analysed using 13C{1H} NMR. In Figure 3.13 is the 
13C{1H} NMR spectrum of C22 in deuterated chloroform. 
 
Figure 3.13: 13C{1H} NMR spectrum of C22 in non-coordinating CDCl3. * = unreacted L4. 




In the spectrum of C22, Figure 3.13, the carbonyl carbon atoms are observed as three 
resonances with different intensities at 195.1, 196.0 and 206.9 ppm, respectively. The 
spectrum show traces of the unreacted starting material L4 (asterisks). The 13C NMR 
spectrum of C24, the acquisition of an acceptable 13C{1H} NMR spectrum was not obtained. 
 3.3.2. Infrared spectroscopy 
A trend was observed for the IR stretching frequencies of the metal complexes, although 
there are some exceptions. By virtue of the π-backbonding from interaction between π-
acceptor ligand p-orbitals and the Re(I) d-orbitals, complexes with enhanced electron density 
have lower IR stretching frequencies (high wavenumbers).  
 3.3.2.1. fac-[Ren(CO)3n(N,N’-bipyridyl)(OH2)n]n+ (n = 1, 4 and 8) complexes (C19 
– C21) 
The IR absorption bands of complexes C19 – C21 are summarized in Table 3.6. 
Table 3.6: CO stretching frequencies of complexes C19 – C21 
Complex C19 C20 C21 
v(CO)/ cm-1 2022, 1891 2025, 1894 2022, 1884 
The aqua complexes C19 – C21 exhibited two sharp IR absorption bands, of higher 
wavenumbers as compared to their halogenated corresponding complexes (Section 3.2.2.1), 
indicating that the interaction between the anionic counter ion NO3- and the aqua complexes 
is weak.26 
 3.3.2.2. fac-[Ren(CO)3n(N,N’-picolyl)(OH2)n]n+ (n = 1, 4 and 8) complexes (C22 – 
C24) 
Table 3.7: CO stretching frequencies of complexes C22 – C24 
Complex C22 C23 C24 
v/(CO)/ cm-1 2022, 1891 2020,1881 2015, 1863 




The IR spectra of complexes C22 – C24 show two absorption bands. The positively charged 
complexes, where the carbonyls act mainly as sigma donors, display higher frequencies than 
their corresponding neutral complexes, where the carbonyls act as π-donors.27 
The discrimination of the coordinated aqua ligand in complexes C23 and C24 by MeOH and 
DMAP ligands was investigated using IR spectroscopy. The aqua complexes C23 and C24 
were reacted with either MeOH or DMAP as entering ligands (using MeOH as the reaction 
solvent) under reflux for 2 hours to afford the products that were isolated and analysed using 
IR spectroscopy. Table 3.8 and Table 3.9 summarize the IR frequencies of the substitution 
products. 
Table 3.8: CO stretching frequencies of C23 in MeOH and DMAP 
a = 4:1 (Ligand:C23 equimolar ratio), b = 1:1 (Ligand: C23 equimolar ratio) 
Ligand v(CO)/cm-1 
MeOHa 2022, 2000, 1870 
DMAPb 2021, 1901 
DMAPa 2022, 1898 
In Table 3.8, the IR spectra of DMAP complexes display two absorption bands with the 
broad band(s) approximately ~1900 cm-1 representing two equivalent CO ligands. There is a 
progressive decrease in wavenumbers from MeOH complexes to Br- complexes. 
The aqua complex C23 has two absorption bands at 2020 and 1881 cm-1. The IR spectrum of 
the product formed between C23 and DMAPa has two absorption bands at 2022 and  
1898 cm-1, whereas, the monosubstituted (DMAPb) product has two absorption bands at 2022 
and 1901 cm-1. There is no pronounced deviation in the wavelengths indicating that the two 
species, obtained from four DMAP equivalents vs one DMAP equivalent, are similar and that 
there is an increase electron density in each metal centre as the ratio of DMAP increases. The 
IR absorption band corresponding to DMAPb at 2021 cm-1 has a shoulder. Insignificant 
changes are observed in the CO asymmetric absorption band wavenumbers. 




The IR spectrum of the reactions involving C24 display the shifting of absorption bands to 
higher wavenumbers as summarized in Table 3.9. 
Table 3.9: CO stretching frequencies of C24 in MeOH and DMAP 
a = 8:1 (Ligand:C24 equimolar ratio), b = 1:1 (Ligand: C24 equimolar ratio) 
Ligand v(CO)/cm-1 
MeOHa 2022, 1999, 1872 
DMAPb 2018, 1999, 1886 
DMAPa 2021, 1898 
The IR spectra of the product formed between C24 in DMAPa (Table 3.9) has similar CO 
wavenumbers (2021 and 1898 cm-1) to the complex formed in DMAPb (2018, 1999 and 1886 
cm-1). In the presence of the aqua ligands (Table 3.7) the complex C24 has two absorption 
bands at 2015 and 1863 cm-1. By reacting C23 with MeOH or DMAP, the IR spectrum shows 
the shifting of absorption bands to higher wavenumbers as summarized in Table 3.9. This 
observation was unexpected as the wavenumbers are expected to decrease with increasing 
ligand strength.33 As the ligand strength is enhanced, the π-backdonation becomes stronger 
and the CO bond order is reduced resulting in the decrease in the CO stretching frequencies.34  
The IR spectroscopy results illustrate that the N,N-picolyl chelate is a weaker σ-donor and/or 
π-acceptor ligand than the CO ligand. Also, the IR spectra of the complexes support the 
integrity of the chelate around the Re(I) metal centre as the dissociation of the ligand could 
not be observed as confirmed by IR absorption bands of ~1641 cm-1 (this absorption band is 
observed around ~1590 cm-1 in the IR spectra of the free ligands, Chapter 2). 
 3.3.3. Elemental analysis and mass spectrometry 
The elemental analysis of the complexes C19 – C24 were within the acceptable limits and the 
presence of excess nitric acid was detected. The mass spectrometry attests the formation of 
aqua adducts and hydroxy adducts. The hydroxy ligand bridges two rhenium centres from the 




neighbouring dendritic arms (Re-O(H)-Re) thus displacing the aqua ligand. Therefore, a 
stronger acid than nitric acid is necessary to maintain acidic conditions during the storage of 
the complexes and inhibit dimerization. The mass spectrum of C23 and the base peak is 
observed at m/z = 898.7490. The HR-ESI-MS spectral data is consistent with the proposed 
structures of the mononuclear complexes C19 and C22. 
 3.4. Conclusions 
Series of neutral monomeric and new dendritic complexes containing fac-[Re(CO)(N,N-
bidentate)X] have been synthesized and characterized using analytical and spectroscopic 
techniques, namely 1H, 13C{1H} NMR, infrared spectroscopy, elemental analysis and mass 
spectrometry. The Single X-ray diffraction of the monomeric complex C16 elucidates the 
facial geometry of the fac-[Re(CO)3]+ core and the bonding mode of the N,N’-bidentate 
ligand. 
Furthermore, a series of unprecedented cationic monomeric and dendritic aqua complexes 
have been synthesized and characterized. The mass spectrometry shows the possible 
formation of hydroxyl bridged metallodendrimers. The IR data of Re(I) aqua coordinated 
complexes agree with the general observation that anionic ligands (in neutral complexes) 
induce enhanced π-backbonding between the rhenium metal centre and CO ligands, resulting 
in a red shift of the stretching frequencies. 




 3.5. Experimental 
 3.5.1. Chemical reagents 
All reagents were purchased from Sigma-Aldrich and used without further purification. The 
complexation reactions using Re(CO)5Cl as the precursor were performed under nitrogen. 
fac-(Et4N)2[Re(CO)3Br3] was synthesized according to the literature method.28 Methanol was 
distilled and dried over calcium hydride.  
 3.5.2. Spectroscopic and analytical methods 
Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Ultrashield 400 Plus 
spectrometer (1H: 399.95 MHz; 13C{1H}: 100.60 MHz) at ambient temperature. All chemical 
shifts are reported in the standard δ notation of parts per million using tetramethylsilane 
(TMS) as an internal standard and were referenced relative to the signal of corresponding 
deuterated solvents. The J coupling constants are reported in Hertz (Hz).  
Infrared (IR) absorption bands were measured on a Perkin-Elmer spectrum 100 FT-IR Nujol 
oil. Melting points were determined on a Reichert-Jung Thermovar hot-stage microscope and 
are uncorrected. Elemental analysis were performed using Thermo Flash EA 112 Series 
combustion analyser. Electrospray Ionisation (ESI+) mass spectra were recorded on a Waters 
API Quattro Micro triple quadrupole mass spectrometer by courtesy of the University of 
Stellenbosch. Furthermore, Electron impact mass spectrometry (EI-MS) was carried out on a 
JEOL GCmateII mass spectrometer.  
Diffraction data was collected on a Bruker ApexII 4K CCD diffractometer using Mo-Kα 
(0.71073 Å) and ω-scans at 100K. All reflections were merged and integrated with SAINT-
PLUS28 and corrected for Lorentz, polarization, and absorption effects using SADABS.29 
Both structures were solved by the heavy atom method and refined through full-matrix least-




squares cycles using SHELX-9730 as part of the WinGX31 package with Σ(||Fo|-|Fc||)2 being 
minimized. All non-H atoms were refined with anisotropic displacement parameters, while 
hydrogens were constrained to parent atom sites using a riding model [aromatic C–H = 0.95 
Å {Uiso(H) = 1.2Ueq}; aliphatic C–H = 0.98 Å {Uiso(H) = 1.5Ueq}]. The graphics were 
obtained with the visual crystal structure information system software DIAMOND.32 
 3.5.3. Synthesis and characterization of fac-[Re(CO)3(N,N’-bidentate)Cl] 
type complexes, C7 – C12 
3.5.3.1. Preparation of C7 
To a stirring suspension of pentacarbonylchlororhenium(I) (46.0 mg, 0.128 mmol) in toluene 
(12.0 ml), L1 (34.0 mg, 0.141 mmol) was added. The suspension was heated to reflux for 1.5 
hours and the reaction mixture was cooled to room temperature. The solvent was removed by 
suction filtration to afford a solid residue. The resulting residue was dissolved in CH2Cl2 
(8.00 mL) and the solution was filtered by gravity. Thereafter, the solvent was removed by 
rotary evaporation to afford an orange solid which was rinsed with hot benzene. The resulting 
solid was dried under high pressure to afford complex C7 as a yellow powder.  
                                              
Complex C7: Pale yellow solid, Yield: 0.018 g (66.7%). IR: KBr pellet, v/cm-1 = 2020 (s, 
carbonyl, CO), 1919 (br, carbonyl, CO) 1895, (br, carbonyl, CO), 1604, 1615 (w, C=N, 
pyridyl). 1H NMR (400 MHz, (CD3)2CO): δ = 0.99 (t, 3 H, 3J = 7.42 Hz, CH3CH2CH2), 1.66 
(sext,2H, 3J = 7.47 Hz, CH3CH2CH2), 2.59 (s, 3H, 4’-CH3), 2.83-2.87 (overlapping t, 2H, 




CH3CH2CH2), 4.31 (s, 2H,4-CH2), 7.60 (d, 1H, 3J = 5.52 Hz, H-5’), 7.83 (d, 1H, 3J = 5.20 Hz,  
H-5), 8.53 (s, 1H, H-3’), 8.79 (s, 1H, H-3), 8.92 (d, 1H, 3J = 5.60 Hz, H-6’), 9.01 (d, 1H, 3J = 
5.72 Hz, H-6). 13C{1H} NMR (100.60 MHz, (CD3)2CO): δ = 34.8 (CH3CH2CH2), 36.0 (4’-
CH3), 62.1 (CH3CH2CH2), 67.8 (CH3CH2CH2), 70.3 (4-CH2), 133.3, 133.6 (C-3, C-3’), 135.6 
(C-5), 126.4 (C-5’), 135.1 (overlapping peak, C-4’, C-4), 150.1, 162.9 (C-6’, C-6), 170.8, 
172.2 (C-2, C-2’), 202.9, 208.7 (CO). Elemental analysis (%): Calculated for 
C18H19ClN3O3Re.H2O (565.04): C, 38.26; H, 3.75; N, 7.44; Found: C, 37.80; H, 3.89 N, 7.29. 
MS (HR – ESI – TOF, m/z): calculated for C18H19ClN3O3Re [M – Cl]+, 512.0984. Found: 
512.0972. 
Compounds C7 – C12 were prepared using a similar procedure by varying the metal 
precursor to ligand equivalences (1:1 ratio per monomeric analogue, 4:1 ratio per  
first generation PPI dendrimer and 8:1 ratio per second generation dendrimer). 
3.5.3.2. Characterization of C8 
               
Complex C8: Yellow-brown solid, Yield: 0.027 g (56.6%). IR: KBr pellet, v/cm-1 = 2019 (s, 
carbonyl, CO), 1917 (br, carbonyl, CO), 1893 (br, carbonyl,  




CO), 1607, 1621 (w, C=N, pyridyl). 1H NMR (400 MHz, (CD3)2SO): δ = 1.58 – 1.82 (broad 
signals NCH2CH2CH2CH2N, NH), 2.70 (overlapping signals, NCH2CH2CH2NH, 
NCH2CH2CH2NH, NCH2CH2CH2NH, NCH2CH2CH2CH2N), 3.51 (br s, 4’-CH3), 4.09 (m, 
8H, 4-CH2), 7.76 (d, 4H, 3J = 5.08 Hz, H-5’), 7.88 (d, 4H, 3J = 5.84 Hz, H-5), 8.75 – 8.82 (br 
s, 8H, H-3’, H-3), 9.02 – 9.09 (broad dd, 8H, H-6’ and H-6). 13C{1H} NMR (100.60 MHz, 
(CD3)2SO): δ = 26.3 (4’-CH3), 47.3, 51.8 – 52.1 (NCH2CH2CH2NH, NCH2CH2CH2NH, 4-
CH2, NCH2CH2CH2CH2N), 123.5 (C-3), 125.1 (C-3’), 125.7 (C-5), 126.9 (C-5’), 128.6, 
128.8 (overlapping signals, C-4’, C-4), 152.1, 152.9 (overlapping signals C-6’, C-6), 155.3 
(C-2’), 155.7 (C-2’), 190.7, 198.4 (CO). Elemental analysis (%): Calculated for 
C76H80Cl4N14O12Re4.20H2O (2628.49): C, 34.73; H, 4.60; N, 7.46; Found: C, 34.45; H, 4.80; 
N, 7.54. MS (HR – ESI – TOF, m/z): calculated for C76H80Cl4N14O12Re4 [M + H2O – 2Cl]2+, 
1108.1896. Found: 1108.1668. 




3.5.3.3. Characterization of C9 
 
Complex C9: Yellow brown solid, Yield: 0.0358 g (33.4%). IR: KBr pellet, v/cm-1 = 2021 (s, 
carbonyl, CO), 1916 (br, carbonyl,(CO), 1895 (br, carbonyl, CO), 1609, 1628 (w, C=N, 
pyridyl). 1H NMR (400 MHz, CD3)2SO): δ = 1.59 (br m, 12H, NCH2CH2CH2CH2N, 
NCH2CH2CH2N), 2.48 – 2.54 (m, 32H, NCH2CH2CH2NH, NCH2CH2CH2N, NH), 3.31 (br 
signal, 4’-CH3, NCH2CH2CH2N, NCH2CH2CH2CH2N, NCH2CH2CH2NH, 4-CH2), 7.51 – 
7.65 (m, 16H, H-5’, H-5), 8.54 – 8.50 (m, 16 H, H-3’, H-3), 8.78 - 8.85 ( m, 16H, H-6’, H-6). 
13C{1H} NMR (100.60 MHz, (CD3)2SO): δ = 20.9 (4’-CH3), 51.1 – 51.6 (br overlapping 
signals, NCH2CH2CH2NH, NCH2CH2CH2NH, NCH2CH2CH2NH, 4-CH2, 
NCH2CH2CH2CH2N, NCH2CH2CH2N), 122.8 (C-3), 124.8 (C-3’), 126.4 (C-5), 128.3 (C-5’), 




152 (overlapping signals C-4, C-4’), 153.4 (overlapping signals C-6’, C-6), 154.7 (C-2), 
154.9 (C-2’), 190.2, 197.8 (CO). Elemental analysis (%): Calculated for 
C160H176Cl8N30O24Re8.80H2O (6117.81): C, 31.41; H, 5.54; N, 6.87; Found: C, 31.81; H, 
5.37; N, 6.62. MS (HR – ESI – TOF, m/z): calculated for C160H176Cl8N30O24Re8 [M + 4H2O – 
6Cl]6+, 756.8990. Found: 756.4956. 
3.5.3.4. Characterization of C10 
                                                          
Complex C10: White flakes, Yield: 0.065 g (49.5%). IR: KBr pellet, v/cm-1 = 2023, 1920, 
1885 (s, CO), 1604 (s, C=N, pyridyl). 1H NMR (400 MHz, (CD3)2CO): δ = 0.99 (t, 3H, 3J = 
7.42 Hz, CH3CH2CH2), 1.88 (m, 2H, CH3CH2CH2), 3.23 (m, 2H, CH3CH2CH2), 4.26 (d, 1H, 
2J = 14.69 Hz, 2-CH2), 4.99 (d, 1H, 2J= 14.65 Hz, 2-CH2), 7.49 (m, 1H, H-5), 7.69 (d, 1H, 3J 
= 7.92 Hz, H-3), 8.04 (td, 1H, 3J = 7.76 Hz, 4J = 1.56 Hz, H-4), 8.76 (m, 1H, H-6). 13C{1H} 
NMR (100.60 MHz, (CD3)2CO): 11.6 (CH3CH2CH2), 23.1 (CH3CH2CH2), 60.6 
(CH3CH2CH2), 60.8 (2-CH2), 123.7 (C-3), 126.1 (C-5), 140.5 (C-4), 153.5 (C-6), 161.3 (C-
2), 198.3, 202.5, 207.0 (CO). Elemental analysis (%): Calculated for C12H14ClN2O3Re 
(455.91): C, 31.61 H, 3.10; N, 6.14; Found: C, 31.69; H, 3.06; N, 5.97. MS (HR – ESI – 
TOF, m/z): Calculated for C12H14ClN2O3Re [M – Cl]+, 421.0562. Found 421.0561. 




3.5.3.5. Characterization of C11 
                                
Complex C11: Grey solid, Yield: 0.053 g (25.3%) IR: KBr pellet, v/cm-1 = 2011 (s, CO), 
1905, 1892 (br, CO), 1600 (s, C=N, pyridyl). 1H NMR (400 MHz, (CD3)2CO): δ = 1.69 (br 
signal, 4H, NCH2CH2CH2CH2N), 2.09, 2.84, 3.37 – 3.44 (br signals, NCH2CH2CH2NH, 
NCH2CH2CH2NH, NCH2CH2CH2NH), 4.48 (m, 4H, 2-CH2), 4.68 – 4.53 (br signal, 4H, 
NCH2CH2CH2CH2N), 5.06 (d, 4H, 2J = 11.16 Hz, 2-CH2), 7.53 (m, 4H, H-5), 7.73 (m, 4H, 
H-3), 8.06 (m, 4H, H-4), 8.82 (br dd, 4H, H-6). 13C{1H} NMR (100.60 MHz, (CD3)2CO): 
25.0 (NCH2CH2CH2CH2N), 26.3 (NCH2CH2CH2NH), 52.5 (NCH2CH2CH2NH), 54.3 
(NCH2CH2CH2NH), 57.4 (NCH2CH2CH2CH2N), 60.7 (2-CH2), 123.7 (C-3), 126.1 (C-5), 
140.5 (C-4), 153.4 (C-6), 161.2 (C-2), 193.3, 197.8, 199.1 (CO). Elemental analysis (%): 
Calculated for C52H60Cl4N10O12Re4 (1903.74): C, 32.81; H, 3.18; N, 7.36; Found: C, 32.44; 
H, 3.22; N, 6.98. MS (HR – ESI – TOF, m/z): Calculated for C52H60Cl4N10O12Re4 [M + H]+, 
1905.1455. Found: 1905.0795. 




3.5.3.6. Characterization of C12 
                 
Complex C12: Grey solid, Yield: 0.0793 g (43.1%). IR: KBr pellet, v/cm-1 = 2015 (s, CO), 
1903, 1897 (br, CO), 1607 (s, C=N, pyridyl). 1H NMR (400 MHz, (CD3)2CO): δ = 1.69 – 
1.88 (br signal, 4H, NCH2CH2CH2CH2N), 2.60 – 3.45 (broad, overlapping signals, 
NCH2CH2CH2NH, NCH2CH2CH2NH, NCH2CH2CH2N, NCH2CH2CH2N), 4.22 (m, 8H, 2-
CH2), 4.65 (br s, 4H, NCH2CH2CH2CH2N), 5.08 (d, 8H, 2J = 11.92 Hz, 2-CH2), 7.51 (br t, 
8H, H-5), 7.74 (br s, 8H, H-3), 8.05 (m, 8H, H-4), 8.80 (d, 8H, 3J = 4.48 Hz, H-6). 13C{1H} 
NMR (100.60 MHz, (CD3)2CO): 25.8 (NCH2CH2CH2CH2N), 51.5 – 52.3 
(NCH2CH2CH2NH, NCH2CH2CH2NH, NCH2CH2CH2N, NCH2CH2CH2N), 57.1 
(NCH2CH2CH2CH2N), 59.8 (2-CH2), 122.8 (C-3), 125.3 (C-5), 139.0 (C-4), 152.5 (C-6), 
160.1 (C-2), 192.5, 197.1, 198.3 (CO). Elemental analysis (%): Calculated for 
C112H136Cl8N22O24Re8.4C7H8 (4316.27): C, 38.96; H, 3.92; N, 7.14; Found: C, 38.84; H, 
4.48; N, 7.55. MS (HR – ESI – TOF, m/z): Calculated for C112H136Cl8N22O24Re8 [M + C7H8 – 
8Cl]8+, 470.0898. Found 470.0565. 




3.5.4.  Synthesis and characterization of [Re(CO)3(N,N’-bidentante)Br] 
type complexes, C13 – C18 
3.5.4.1. Preparation of C13 
A dissolved amount of fac-(Et4N)2[Re(CO)3Br3] (0.329 g, 0.427 mmol) in MeOH (5.00 mL) 
was added to a stirring MeOH (5.00 mL) solution of L1 (0.103 g, 0.427 mmol). The reaction 
proceeded at room temperature for 3 hours and a yellow precipitate was filtered, washed with 
MeOH and CH2Cl2. Thereafter, the solid product was dried under high vacuum.  
                                             
Compound C13: Pale yellow solid, yield: 0.192 g (76.0%). IR: ATR, v/cm-1: 2027 (s, 
carbonyl, CO), 1914 (s, carbonyl, CO), 1867 (s, carbonyl, CO). 1H NMR (400 MHz, 
(CD3)2SO): δ = 0.84 (m, 3 H, CH3CH2CH2), 1.46 (m ,2H, CH3CH2CH2), 2.38 (s, 3H, 4’-
CH3), 2.44 (overlapping t, 2H, CH3CH2CH2), 3.75, (s, 1H, 4’-CH3), 3.91 (s, 2H, 4-CH2), 7.53 
(d, 1H, 2J = 5.84 Hz, H-5’), 7.68 (d, 1H, 2J = 5.68 Hz, H-5), 8.61 (s, 1H, H-3’), 8.67 (s, 1H, 
H-3), 8.81 (d, 1H, 2J = 5.68 Hz, H-6’), 8.88 (d, 1H, 2J = 5.68 Hz, H-6).13C{1H} NMR 
(100.60 MHz, (CD3)2SO): δ = 11.6 (CH3CH2CH2), 20.9 (4’-CH3), 23.5(CH3CH2CH2), 61.8 
(CH3CH2CH2), 62.4 (4-CH2), 122.0 (C-3), 125.1 (C-5), 126.5 (C-5’), 128.3 (C-3’), 152.2 (C-
6), 152.3 (C-4), 152.6 (C-6’), 152.8 (C-4’), 155.0 (C-2, C-2’), 189.8, 197.6 (CO). Elemental 
analysis (%): Calculated for C18H19BrN3O3Re (591.48): C, 36.55; H, 3.24; N, 7.40; Found: 
C, 36.83; H, 3.33; N, 6.81. MS (HR – ESI – TOF, m/z): Calculated for C18H19BrN3O3Re [M 
– Br]+, 512.0984. Found 512.0985. MP: 193 – 195 °C. 




 3.5.4.2. Preparation of C14 
A synthetic procedure analogous to that of C13 was followed for the synthesis of C14. fac-
(Et4N)2[Re(CO)3(Br)3] (0.221 g, 0.287 mmol) and L2 (0.750 g, 0.0718 mmol) were reacted to 
afford. C14 as a yellow precipitate. 
               
Compound C14: Yellow solid, yield: 0.139 g (79.0%). IR: ATR, v/cm-1: 2016 (s, carbonyl,  
CO), 1877 (br, carbonyl, CO). 1H NMR (400 MHz, (CD3)2SO): δ = 1.54 – 1.78 (broad 
signals NCH2CH2CH2CH2N, NCH2CH2CH2N), 2.54 – 2.88 (overlapping signals, 
NCH2CH2CH2NH, NCH2CH2CH2NH, NCH2CH2CH2CH2N, NH, 4’-CH3), 3.98 (br s, 8H, 4-
CH2), 7.58 (br d, 4H, H-5’), 7.72 (br d, 4H, H-5), 8.65 (br s, 4H, H3’), 8.75 (br s, 4H, H-3), 
8.85 (br d, 4H, H6’), 8.93 (br d, 4H, H-6). 13C{1H} NMR (100.60 MHz, (CD3)2SO): δ = 21.4 
(4’-CH3), 31.1 (NCH2CH2CH2CH2N), 46.9, 49.1 – 52.9 (NCH2CH2CH2NH, 
NCH2CH2CH2NH, NCH2CH2CH2N, 4-CH2, NCH2CH2CH2CH2N), 123.7 (C-3), 125.3 (C3’). 
127.2, 127.1 (C-5, C-5’), 128.8 (C4), 152.7, 152.8 (overlapping signals C-6’, C-6), 153.1 
(C4’), 154.7 (C-2), 154.9 (C-2’), 189.5, 197.8, (CO). Elemental analysis (%): Calculated for 
C76H80Br4N14O12Re4.10H2O (2626.16): C, 34.76; H, 3.84; N, 7.47; Found: C, 34.76; H, 3.53; 




N, 7.36. Calculated for C76H80Br4N14O12Re4 [M + 3H – Br]4+, 592.0524. Found 592.0241. 
MP: 182 – 184 °C. 
 3.5.4.3. Preparation of C15 
To achieve C15, fac-(Et4N)2[Re(CO)3Br3] (0.525 g, 0.0681 mmol) in MeOH (3.00 mL) was 
added to a stirring solution of L3 (0.0380 g, 0.0170 mmol) in MeOH. The reaction proceeded 
at room temperature for 3 hours and the yellow precipitate was filtered, washed with MeOH 
and CH2Cl2, and dried under reduced pressure. Complex C15 was isolated as a yellow solid. 
                          
Compound C15: Yellow solid, Yield: 0.0553g (64.6%). IR: ATR, v/cm-1: 2010 (s, carbonyl,  
CO), 1960, 1879 (br, carbonyl, CO). 1H NMR (400 MHz, (CD3)2SO): δ = (400 MHz, 
CD3)2SO): δ = 1.35 - 161 (br m, NCH2CH2CH2CH2N, NCH2CH2CH2N), 2.35 – 2.37 (m, 
32H, NCH2CH2CH2NH, NCH2CH2CH2N, NH), 3.31 (br signal, 4’-CH3, NCH2CH2CH2N, 
NCH2CH2CH2CH2N, NCH2CH2CH2NH), 3.89 (s, 16H, 4-CH2), 7.54 – 7.65 (br d,16H, H-5’, 
H-5), 8.58 – 8.66 (m, 16H, H-3’, H-3), 8.82 - 8.88 ( m, 16H, H-6’, H-6). 13C{1H} NMR 




(100.60 MHz, (CD3)2SO): δ = 21.16 – 21.37 (overlapping peaks 4’-CH3, 
NCH2CH2CH2CH2N, NCH2CH2CH2N, NCH2CH2CH2NH), 47.3, 51.6 – 52.0 (overlappig 
peaks NCH2CH2CH2CH2N, NCH2CH2CH2N, NCH2CH2CH2NH, NCH2CH2CH2CH2N), 
51.4 (4-CH2), 123.5 (C-3), 125.2 (C-3’), 126.9 (C-5), 128.8 (C-5’), 147.0 (C-4’), 147.3 (C-4), 
152.6 (C-6’), 152.9 (C-6), 155.3, 155.5 (overlapping peaks C-2, C-2’), 190.1, 197.8, 
(CO). Elemental analysis: Calculated for C160H176Br8N30O24Re8 (5032.24): C, 38.19; H, 
3.53; N, 8.35; Found: C, 38.20; H, 4.68; N, 8.00. MS (HR – ESI – TOF, m/z): Calculated for 
C160H176Br8N30O24Re8 [M + 4MeOH – 4Br]4+, 1210.0929. Found 1210.0341. MP: 
 158 – 161 °C.  
 3.5.4.4. Preparation of C16 
fac-(Et4N)2[Re(CO)3Br3] (0.862 g, 1.12 mmol) was dissolved in MeOH (5.00 mL) and added 
to a stirring solution of L4 (0.168 g, 1.12 mmol) in MeOH (5.00 mL). The reaction was 
stirred for 3 hours and a white precipitate was filtered. Thereafter, the precipitate was washed 
with warm water ( ̴ 30 °C) and recrystallized from EtOH to afford C16 as colourless needles. 
                                                          
 Compound C16: White solid, yield: 0.321 g (57.0%). IR: ATR, v/cm-1: 2012 (s, carbonyl,  
CO), 1912 (s, carbonyl, CO), 1875 (s, carbonyl, CO), 1672 (s, pyridyl,  
C N). 1H NMR (400 MHz, (CD3)2SO): = 0.96 (t, 3H, 3J = 7.41 Hz, CH3CH2CH2), 1.98 – 
1.66 (m, 2H, CH3CH2CH2), 3.04 (m, 2H, CH3CH2CH2), 4.16 (dd, 1H, 2J = 15.68 Hz, 3J = 
8.72 Hz, 2-CH2 ), 4.82 (dd, 1H, 2J =15.72 Hz, 3J = 5.08 Hz, 2-CH2), 5.07 (br m, NH), 7.57 (t, 
1H, 3J = 6.06 Hz, H5), 7.75 (d, 1H, 3J = 7.84 Hz, H3), 8.09 (td, 1H, 3J =7.75 Hz, 1.53 Hz, 




H4), 8.77 (d, 1H, 3J = 5.52 Hz, H6). 13C{1H} NMR (101 MHz, (CD3)2SO): 11.0 
(CH3CH2CH2), 21.6 (CH3CH2CH2), 59.7 (CH3CH2CH2, 2-CH2), 122.6 (C-3), 125.1 (C-5), 
139.6 (C-4), 152.4 (C-6), 160.4 (C-2), 191.9, 196.2, 197.7 (CO). Elemental analysis (%): 
Calculated for C12H14BrN2O3Re (500.37): C, 28.81; H, 2.82; N, 5.60; Found: C, 28.92; H, 
2.77; N, 5.42. MS (HR – ESI – TOF, m/z): Calculated for C12H14BrN2O3Re [M – Br]+, 
421.0562. Found 421.0549. MP: 211 – 213 °C. 
 3.5.4.5. Preparation of C17 
Complex C17 was synthesized analogous to C16. fac-(Et4N)2Re(CO)3Br3] (0.765 g, 0.993 
mmol) and L5 (0.169 g, 0.248 mmol) were used. A brown precipitate, C17, was filtered off, 
washed with warm water and dried under reduced pressure. 
                                   
Compound C17: Brown powder, yield: 0.169 g (19.5%). IR: ATR, v/cm-1: 2014 (s, carbonyl,  
CO), 1863 (br, carbonyl, CO), 1609 (s, pyridyl, C N). 1H NMR (400 MHz, 
 (CD3)2SO): δ = 1.53 (br signal, 4H, NCH2CH2CH2CH2N), 1.97 (br signal, 8H, 
NCH2CH2CH2NH), 2.91 – 3.25 (br m, 16 H, NCH2CH2CH2NH, NCH2CH2CH2NH), 4.17 
(m, 4H, 2-CH2), 4.47 (m, 4H, NCH2CH2CH2CH2N), 4.83 (m, 4H, 2-CH2), 5.16 (br s, 4H, 
NH), 7.54 (m, 4H, H-5), 7.73 (m, 4H, H-3), 8.10 (m, 4H, H-4), 8.79 (br dd, 4H, H-6).13C{1H} 
NMR (101 MHz, (CD3)2SO): 24.1 (NCH2CH2CH2CH2N), 25.5 (NCH2CH2CH2NH), 51.1, 
52.9 (NCH2CH2CH2NH. NCH2CH2CH2NH), 57.4 (NCH2CH2CH2CH2N), 59.6 (2-CH2), 




123.1 (C-3), 125.7 (C-5), 140.2 (C-4), 153.0 (C-6), 160.0 (C-2), 191.8, 196.2, 197.6  
(CO). Elemental analysis (%): Calculated for C52H60Br4N10O12Re4 (2081.93): C, 30.01; H, 
2.91; N, 6.73; Found: C, 30.18; H, 3.33; N, 6.65. MS (HR – ESI – TOF, m/z): Calculated for 
C52H60Br4N10O12Re4 [M + 2H]2+, 1041.8850. Found 1041.9767. MP: 148 – 151 °C.  
 3.5.4.6. Preparation of C18 
A 3.00 mL of MeOH was added in L6 (0.0480 g, 0.0320 mmol) and allowed to stir until the 
ligand was dissolved completely. Thereafter, fac-(Et4N)2[Re(CO)3Br3] (0.0980 g, 0.128 
mmol) was then dissolved in MeOH (1.00 mL) and added to the stirring solution. The 
resulting precipitate was maintained in the stirring solution for 3 hours and subsequently 
filtered to afford a brown solid. The solid was washed with warm water and dried under 
reduced pressure to afford C18. 
                
Compound C18: Brown powder, yield: 0.0248 g (18.0%). IR: ATR, v/cm-1: 2014 (s, 
carbonyl, (CO), 1865 (br, carbonyl, CO), 1610 (s, pyridyl, C N). 1H NMR (400 MHz, 
(CD3)2SO): δ = 1.70 – 1.88, 2.98 – 3.32 (br signals, 40H , NCH2CH2CH2CH2N, 




NCH2CH2CH2NH, NCH2CH2CH2NH, NCH2CH2CH2N, NCH2CH2CH2N, 
NCH2CH2CH2CH2N), 4.19 (br m, 8H, NH), 4.50 (m, 8H, 2-CH2), 5.07, 4.85 (br d, 8H, 2-
CH2), 7.55 (br t, 8H, H-5), 7.70 (br s, 8H, H-3), 8.07 (m, 8H, H-4), 8.74 (m, 8H, H-6). 
13C{1H} NMR (100.60 MHz, (CD3)2SO): 25.9 (NCH2CH2CH2CH2N), 49.4, 50.1 – 57.0 
(NCH2CH2CH2NH, NCH2CH2CH2NH, NCH2CH2CH2N, NCH2CH2CH2N, 
NCH2CH2CH2CH2N), 60.4 (2-CH2), 123.2 (C-3), 125.7 (C-5), 140.3 (C-4), 152.9 (C-6), 
160.9 (C-4), 192.5, 196.7, 198.3 (CO). Elemental analysis (%): Calculated for 
C112H136Br8N22O24Re8 (4303.34): C, 31.26; H, 3.19; N, 7.16; Found: C, 31.35; H, 3.77; N, 
7.30. MS (HR – ESI – TOF, m/z): Calculated for C112H136Br8N22O24Re8 [M + 3H – Br]4+, 
1056.6145. Found 1056.5388. MP: 140 – 143 °C 
 3.5.5. Synthesis and characterization of fac-[Re(CO)3(N,N’-bidentate) 
OH2]+ type complexes, C19 – C24 
 3.5.5.1. Preparation of C19 
fac-(Et4N)2[Re(CO)3Br3] (0.100 g, 0.130 mmol) was dissolved in water (6.00 mL) and the 
solution was adjusted to pH 2.2 using HNO3. Silver nitrate (0,066g, 0.389 mmol) was added 
to the solution and the suspension was stirred for 24 hours to afford a fac-
[Re(CO)3(H2O)3]NO3 solution. Subsequently, AgBr was filtered and the filtrate was 
transferred to a round bottomed flask containing L1 (0.0314g, 0.130 mmol). The solution was 
stirred for 4 hours and C19 was filtered as a yellow solid. 
Compound C19: Yellow solid, yield: 0.972 g. IR: ATR, v/cm-1: 2022 (s, carbonyl,  
CO), 1891 (s, carbonyl, CO), 1618 (br, bipyridyl, C N). 1H NMR (300 MHz,  
(CD3)2SO): δ = 0.95 (m, 3 H, CH3CH2CH2), 1.69 (m ,2H, CH3CH2CH2), 2.59 (s, 3H, 4’-
CH3), 3.05 (br signal, 2H, CH3CH2CH2), 4.44, 4.46 (overlapping signal, 2H,4-CH2), 7.79 (m, 
1H, H-5’), 8.53 –  9.19 (m, 5H, H-5, H-3’, H-3, H-6’, H-6). Elemental analysis (%): 




Calculated for C18H21N3O4Re.2HNO3 (655.61): C, 32.98; H, 3.54; N, 10.68; Found: C, 33.06; 
H, 4.17 N, 10.45. MS (HR – ESI – TOF, m/z): Calculated for C18H21N3O4Re [M – H2O]+, 
512.0984. Found: 512.0986. MP: 192 – 195 °C 
 3.5.5.2. Preparation of C20 
fac-[Re(CO)3(H2O)3]NO3 (0.130 mmol) was synthesized in a similar manner as stated above. 
After filtering AgBr, the filtrate and L2 (0.034g, 0.0325 mmol) were combined to form a 
mixture that was stirred for 4 hours. The resulting yellow precipitate was filtered to afford 
C20 
Complex C20: Light brown solid, Yield: 0.109 g. IR: ATR, v/cm-1: 2025 (s, carbonyl, 
CO), 1894 (s, carbonyl, CO), 1620 (br, bipyridyl, C N). 1H NMR (300 MHz,  
(CD3)2SO): δ = 1.74 – 2.14 (br overlapping signals, 6H, NCH2CH2CH2CH2N, 
NCH2CH2CH2NH), 2.57 (s, 12H, 4’-CH3), 3.64 (br m, NCH2CH2CH2NH, 
NCH2CH2CH2NH, NCH2CH2CH2CH2N), 4.50 (m, 8H, 4-CH2), 7.74 – 7.89 (m, 8H, H-5’, H-
5), 8.54 – 9.38 (m, 16H, H-3’, H-3, H-6’ and H-6). Elemental analysis (%): Calculated for 
C76H88N14O16Re4.4HNO3.Et4N.35H2O (3211.28): C, 31.42; H, 5.71; N, 8.29; Found: C, 
31.18; H, 5.52; N, 8.78. MS (HR – ESI – TOF, m/z): Calculated for C76H88N14O16Re4 [M + 
2H2O + Et4N+]5+, 472.5291. Found: 472.0348. MP: 132 – 135 °C. 
 3.5.5.3. Preparation of C21 
L3 (0.0363 g, 0.0163 mmol) was stirred in a fac-[Re(CO)3(H2O)3]NO3 (0.130 mmol) solution 
for 4 hours. The resulting yellow precipitate was filtered to give C21. 
Complex C21: Yellow solid, Yield: 0.109 g. IR: ATR, v/cm-1: 2022 (s, carbonyl, 
CO), 1884 (s, carbonyl, CO), 1620 (br, bipyridyl, C N). ). Elemental analysis (%): 
Calculated for C160H192N30O32Re8.4HNO3.Et4N (5645.34): C, 41.20; H, 4.43; N, 9.97; Found: 




C, 41.40; H, 4.33; N, 10.29. MS (HR – ESI – TOF, m/z): calculated for C160H192N30O32Re8 
[M + HNO3 + 8Et4N+]16+, 352.8338. Found: 352.9930. MP: 179 – 182 °C. 
 3.5.5.4. Preparation of C22 
fac-(Et4N)2[Re(CO)3(Br)3] (0.100 g, 0.130 mmol) was dissolved in water (6.00 mL) and the 
solution was adjusted to pH 2.2 using HNO3. Silver nitrate (0.066g, 0.389 mmol) was added 
to the solution and the suspension was stirred for 24 hours to afford fac-[Re(CO)3(H2O)3]NO3  
(0.130 mmol) in solution. Subsequently, AgBr was filtered off and L4 (0.0195g, 0.130 mmol) 
dissolved in the filtrate, the solution was stirred for 10 hours. The product remained in 
solution and water was removed using a freeze drier to afford a colourless suspension. 
Compound C22: Colourless suspension, yield: 0.674 g. IR: ATR, v/cm-1: 2022 (s, carbonyl,  
CO), 1891 (s, carbonyl, CO), 1624 (s, pyridyl, C N). 1H NMR (300 MHz,  
(CD3)2SO): = 0.83 (t, 3H, 3J = 7.46 Hz, CH3CH2CH2), 1.59 (m, 2H, CH3CH2CH2), 2.94 (t, 
2H,  3J = 7.71 Hz, CH3CH2CH2), 4.26 (br m, 2H, 2-CH2 ), 7.47 – 7.55 (m, 2H, H5, H3), 7.96 
(td, 1H, 3J =7.77, 1.73, H4), 8.52 (d, 1H, 3J = 5.13, H6). 13C{1H} NMR. Elemental analysis 
(%): Calculated for C12H16N2O4Re (438.48): C, 32.87; H, 3.86; N, 6.39; Found: C, 32.23; H, 
3.45; N, 7.00. MS (HR – ESI – TOF, m/z): Calculated for C12H16N2O4Re [M – H2O]+, 
421.0562. Found 421.0560.  
 3.5.5.5. Preparation of C23 
A fac-[Re(CO)3(H2O)3]NO3 (0.130 mmol) solution was added to L5 (0.0221 g, 0.0325 
mmol), the reaction was stirred for 10 hours. The resulting solution was freeze dried 
(minimally) to give a colourless suspension. 
Compound C23: colourless suspension, yield: 0.107 g. IR: ATR, v/cm-1: 2020 (s, carbonyl,  
CO), 1881 (s, carbonyl, CO), 1644 (s, pyridyl, C N). 1H NMR (400 MHz, 
 (CD3)2SO): = 1.71 (br signal, 4H, NCH2CH2CH2CH2N), 2.09 (br signal, 8H, 




NCH2CH2CH2NH), 2.83 – 3.13 (br m, 16 H, NCH2CH2CH2NH, NCH2CH2CH2NH), 4.94 – 
5.00 (br signal, 16H, NCH2CH2CH2CH2N, 2-CH2, NH), 7.45 – 7.53 (m, 8H, H-5, H-
3), 7.93 (m, 4H, H-4), 8.67 (m, 4H, H-6). Elemental analysis (%): Calculated for 
C52H68N10O16Re4.5HNO3 (2149.06): C, 29.06; H, 3.42; N, 9.78; Found: C, 29.39; H, 3.13; N, 
9.60. MS (HR – ESI – TOF, m/z): Calculated for C52H60N10O14Re4 [M + 2H]2+, 898.6299. 
Found 898.7490.  
 3.5.5.6. Preparation of C24 
A fac-[Re(CO)3(H2O)3]NO3 (0.130 mmol) solution was added to L6 (0.0244 g, 0.0163 
mmol), the reaction was stirred for 10 hours. The product was freeze-dried to afford C24 as a 
brown suspension. 
Compound C24: brown suspension. IR: NaCl cell, v/cm-1: 2015 (s, carbonyl, CO), 1863 (s, 
carbonyl, CO), 1621 (s, pyridyl, C N). Elemental analysis (%): Calculated for 
C112H152N22O32Re8.15HNO3.Et4N (4883.66): C, 29.90; H, 3.89; N, 10.75; Found: C, 29.54; 
H, 3.43; N, 10.54. MS (HR – ESI – TOF, m/z): Calculated for C112H152N22O32Re8 [M + 
30H2O + 2Et4N+]10+, 460.9781. Found 461.0756.  
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Substitution kinetic investigations 
 4.1. Rationale behind the study 
This chapter forms part of a preliminary investigation into the intimate mechanism of the 
ligand substitution processes of dendritic complexes containing more than one rhenium metal 
centre. Herein, the intention is to find out if the metal ions ‘communicate’ with each other 
through dendrimer ligands and overall complex charge, in spite of being substantially 
removed from each other via the dendritic branches (in terms of distance). To perform this, a 
monomeric complex, LM1 (M1 = one fac-[Re(CO)3MeOH]+ core) was chosen as a model, 
after which dendritic complexes, LM4 (four fac-[Re(CO)3MeOH]+ cores) and LM8 (eight 
fac-[Re(CO)3MeOH]+ cores) were synthesized and the substitution of methanol with various 
ligands were attempted.  
A systematic attempt to describe the kinetics, starting with the model complex LM1 and 
moving towards the highest dendrimer generation will be discussed. 
 4.2. General introduction 
The understanding of the dynamics of the Re–MeOH/H2O bond, bond substitution and 
stability in a controlled environment may give a predictive kinetic pattern of [2 + 1]1 labeled 
metallodendrimers in biological environments. In vivo, nucleophiles of varying basicity are 
ubiquitous and can readily compete for the ‘labile site’ in fac-[M(N,N-bidentate)(CO)3OH2]+ 
(M = 99mTc or 188/186Re) systems. Kinetic studies give an indication of the rate at which a 
chemical reaction proceeds permitting the identification of the intimate mechanism (i.e. 
associative interchange (Ia) or dissociative interchange (Id) mechanism) of the reaction. The 
labeling of biomolecules, such as dendrimers, with the isoLink® kit requires the substitution 




of at least one of the relatively labile aqua ligands from fac-[99mTc(CO)3(OH2)2]+.2 By far, the 
kinetic behaviour of Re(I) metallodendrimers (metal containing dendrimers) as models for 
99mTc(I) labeled complexes and the rate of aqueous substitution on fac-[Re(N,N-
dendrimer)(CO)3OH2]+ complexes by different nucleophiles, has not been reported in the 
literature.  
 4.3. Experimental 
4.3.1. Chemical reagents 
All chemicals were purchased from Sigma-Aldrich and Merk and were used without further 
purification. MeOH was dried in calcium hydride. The synthesis of the aqua complexes is 
reported in Chapter 3, Section 3.5.5.4 – 6. 
4.3.2. Spectroscopic methods 
The kinetic measurements were initially performed on a Varian Cary 50 Conc UV/vis 
spectrophotometer equipped with a Julabo F12-mV temperature cell regulator (accurate 
within 0.1 °C). The kinetic reactions of coordinated methanol substitution were observed to 
occur rapidly under UV/vis. Thus, rapid kinetic reactions (reaction half-lives shorter than 20 
seconds) were monitored at four different temperatures 5.00 °C, 15.0 °C, 25.0 °C and 35.0 °C 
(accurate within 0.1 °C) on Kinet AsystTM Hi-Tech Scientific M300 SHU-615X2 Stopped 
Flow Spectrophotometer attached to a Julabo MPV thermostat water bath (accurate within 
0.1 °C). The third generation stopped-flow system has a thermostatic  sample handling unit 
and can be operated in the diode-array mode with a dead time < 5.00 microseconds, yielding 
400 nm spectral width scans at < 5.00 microseconds per complete scan. The Scientist 
Micromath, Version 2.01 program and Microsoft Office Excel 2014 were used to fit the 
output data to the specific functions.  




4.3.3. Data treatment 
In all linear and non-linear plots, the individual experimental data points are correlated by the 
solid line representing the computer least-squares fits of data and the kinetic data points 
reported per concentration represent an average of 7 individual traces. All the kinetic runs 
were performed under pseudo first-order conditions with the ligand in excess.3 It was 
assumed that all the aqua complexes (C22, C23 and C24 in Chapter 3) are converted to their 
corresponding methanol complexes (LM1, LM4 and LM8, respectively) upon dissolution in 
methanol, as observed in previous studies.2-7 Also, the UV/vis spectra of LM1, LM4 and 
LM8 are analogous to their corresponding large scale MeOH complexes, characterized by IR 
spectroscopy in Chapter 3.  
The simple equilibrium for a monomeric complex undergoing substitution under pseudo first-
order conditions is given in Scheme 4.1. The rate constants k1 and k-1 are calculated from the 
graph of kobs vs [L], where k1 is the gradient and k-1 is the intercept as given by Equation 
4.2.4 The pseudo first-order observed rate constant, kobs, is determined by a least square fit of 
the absorbance versus time for a corresponding reaction.4 The stability constants, K1, were 
kinetically determined using Equation 4.1 in Scheme 4.1.4  
 
Scheme 4.1: The parameters of a pseudo first-order reaction. K1 represents the stability constant, k1 
denotes the rate constant and kobs represents the ‘observed’ rate constant (obtained experimentally).4 
The charge of the complex is represented by m and is dependent on the nature of the 
monodentate ligand (X) in the final product. Investigations under pseudo first-order 
conditions eliminate difficulties encountered when two reagents are investigated 




simultaneously. The sum of the orders of the reactants gives the total order of the rate law. 
The order is the way in which the reaction rate varies with a change in concentration of one 
or both of the reacting species. These values can only be determined experimentally and it is 
often not trivial. Thus under pseudo first-order conditions, one reactant concentration is kept 
constant throughout the experiment and the other is varied (i.e. [L] >>> [Re]).8,9 To obtain 
the standard entropy change of activation, ∆Sǂ, and the standard enthalpy change of 
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obtained, hence ∆Sǂ and ∆Hǂ can be solved. The Eyring equation substantiates the type of 
substitution mechanism involved.  
Since Re(I)-aqua complexes often polymerize in less acidic aqueous solutions,4,10 and 
because they are able to form different species in solution (hydroxo versus aqua), the aqua 
ligand was substituted with MeOH ligand to eliminate the subtle uncertainties associated with 
pH factors. Furthermore, the dendritic complexes are not soluble in water, making 
comparison with the monomeric complex kinetics not viable (if different solvents are used). 
Therefore, the rates obtained in this study correspond to the Re(I)-methanol complexes which 
were characterized by IR spectroscopy (Chapter 3). 




 4.3.4. Substitution reactions of fac-[ReN-((pyridine-2-yl)methyl)propan-1-
amine)(CO)3(OH2)]+ (C22) in methanol with monodentate ligands. 
The synthesis of C22 was described in detail in Chapter 3. The stabilities of the complex as 
well as the entering ligands in methanol were tested and found to be stable for several hours 
by monitoring the solutions on a UV/vis spectrophotometer. The monodentate entering 
ligands chosen for the substitution reactions were pyridine (Py), bromide ion (Br-) and 4-
dimethylaminopyridine (DMAP). For these monodentate ligands, the reactions were followed 
at 5.0 °C, 15.0 °C, 25.0 °C and 35.0 °C to obtain the standard enthalpy change of activation 
(∆Hǂ) and standard entropy change of activation (∆Sǂ) for the reactions with DMAP and Py. 
The monomeric Re(I)-complex fac-[ReN-((pyridine-2-yl)methyl)propan-1-amine)(CO)3 
(OH2)]+, C22, was dissolved in dry MeOH to afford the proposed corresponding Re(I)-
methanol complex LM1 in Figure 4.1.  
                                                     
Figure 4.1: The proposed structure of fac-[ReN-((pyridine-2-yl)methyl)propan-1-amine)(CO)3 
(MeOH)]+ LM1. 
Figure 4.2 represents a typical UV/vis spectrum shift for the slow reaction between fac-
[ReN-((pyridine-2-yl)methyl)propan-1-amine)(CO)3(MeOH)]+ (LM1 and in this case ) 
pyridine. The insert in Figure 4.2 represents the change in absorbance versus time. 





Figure 4.2: Typical UV/vis spectral change for the MeOH substitution reaction of fac-[ReN-
((pyridine-2-yl)methyl)propan-1-amine)(CO)3(MeOH)]+ (LM1) with pyridine in MeOH at  
15.0 °C. [LM1] = 5.00 × 10-4 M, [Pyridine] = 0.035 M, λ = 317 nm. 
 4.3.4.1. LM1 + pyridine (Py) 
The methanol substitution reactions between fac-[ReN-((pyridine-2-yl)methyl)propan-1-
amine)(CO)3(MeOH)]+ (LM1) and pyridine as entering ligand were investigated. The 
reactions were followed at 317 nm at four temperatures 5.0 °C, 15.0 °C, 25.0 °C and 35.0 °C. 
A kobs versus [Py] plot yielded a straight line displayed in Figure 4.3 and the data were fitted 








                       
Figure 4.3: Plots of kobs versus [Ligand] (Ligand = Pyridine) obtained using [LM1] = 5.00 ×  
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  to afford the activation parameters is illustrated in Figure 
4.4. The solid line represents the best linear fit.  
 






  for the reaction between LM1 and pyridine  
The rate data were obtained from least square fits of the kobs vs [Py] data to Equation 4.2 
while ∆Sǂ  and ∆Hǂ , in Table 4.1, were obtained from least square fits to Equation 4.3. 
Table 4.1: Rate data for the reaction between LM1 and Py between 5.0 – 35.0 °C. 
Temperature 5.0 °C 15.0 °C 25.0 °C 35.0 °C 
k1 (M-1s-1) 1.80(1) 3.68(3) 10.2(1) 20.4(5) 
k-1 (s-1) 0.025(7) 0.0382(1) 0.062(4) 0.24(3) 
K1 (M-1) 72(1) 96.3(6) 164(7) 85(3) 
 
 4.3.4.2. LM1 + 4-Dimethylaminopyridine (DMAP) 
Similarly, the MeOH substitution reactions between LM1 and 0.005 – 0.05 M  
4-dimethylaminopyridine (DMAP) were monitored between 5.0 – 35.0 °C. Figure 4.5 

















1/T (K-1)  
∆Sǂ   -34.1(10)JK-1mol-1 
∆Hǂ 57(3) KJmol-1 





Figure 4.5: Plots of kobs versus [Ligand] (Ligand = DMAP) obtained using [LM1] = 5.00 ×  
10-4 M and [DMAP] = 0.005 – 0.05 M. 
Based on Figure 4.5, the experimental data to give kobs versus [Ligand] plots is in accordance 





  to afford the activation parameters is 
shown in Figure 4.6. The solid line represents the best linear fit. 
 




  for the reaction between LM1 and DMAP at temperatures  
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The kinetic data was again fitted in Equation 4.1 and the resulting rate constants were 
determined (summarized in Table 4.2). 
Table 4.2: Summarized rate data for the reaction between LM1 and DMAP between 
5.0 – 35.0 °C.  
Temperature 5.0 °C 15.0 °C 25.0 °C 35.0 °C 
k1(M-1s-1) 8.57(7) 13.81(9) 28.7(1) 51.9(4) 
k-1 (s-1) 0.202(8) 0.287(4) 0.301(3) 0.322(9) 
K1(M-1) 42.4(4) 48.0(9) 95.3(6) 161(9) 
 4.3.4.3. LM1 + Bromide ion (Br-) 
The MeOH substitution kinetic reactions between 5.00 × 10-4 M LM1 and 0.005 – 0.05 M 
tetraethylammonium bromide (Br- ions) were monitored at 317 nm using a stopped-flow 
spectrophotometer. The Br- ion was chosen to understand the influence of the anionic charge 
on cationic LM1. In Figure 4.7, the plot of kobs vs [Br-] at 25.0 ˚C, to afford the kinetic data 
summarised in Table 4.3, is displayed.  
 
Figure 4.7: Plots of kobs versus [Ligand] (Ligand = Br-) at 25.0 ˚C obtained using [LM1] = 5.00 ×  














∆Sǂ   -79.1(9) JK-1mol-1 
∆Hǂ 40(2) KJmol-1 




Table 4.3: Reaction rate data for the reaction between LM1 and Br- at 25.0 °C.  
Temperature 25.0 ˚C 
k1(M-1s-1) 34.8(4) 
k-1 (s-1) 0.165(1) 
K1(M-1) 211(2) 
 
Since the reactions were monitored at a constant temperature, the activation parameters ∆Sǂ 
and ∆Hǂ were not determined. 
4.3.4.4. Observations 
At 25.0 °C, the second order rate constant, k1, for the reactions of LM1 with DMAP and Br- 
are almost a factor of 3 faster than the comparative reactions with pyridine and is illustrated 
by Figure 4.8. 
 
Figure 4.8: Plots of kobs versus [Ligand] (Ligand = Pyridine, DMAP or Br-) obtained using [LM1] = 
5.00 × 10-4 M and [Ligand] = 0.005 – 0.05 M. 
Such observations can be attributed to the favourable charge-charge interactions between the 
Br- ion and the corresponding cationic complex LM1. Furthermore, the increased basicity of 
the entering ligand DMAP (pKa = 9.8011) than pyridine (pKa = 5.2311), suggests an increased 


















In theory, the high negative entropy values obtained are associated with an associative (A) 
mechanism8,9 and in this case -34.1(10) JK-1mol-1 and -79.1(9) JK-1mol-1 were obtained for 
the Py and DMAP reactions, respectively. However, more information using high pressure 
kinetic studies which investigate the activation volume, ∆Vǂ, needs to be undertaken to 
achieve this.12 The variations in k-1 and k1 suggest that the reactions are dependent on the 
nucleophilicity of the entering ligand. 
In general, it seems as if the kinetically obtained values for stability constants, K1, for Py as 
entering ligand are slightly higher than that of DMAP. Due to the small absorbance changes 
observed under our reaction conditions, it was not possible to gather reliable data to 
determine K1 also thermodynamically for comparison with the tabled values. 
Having investigated the effect of the monomeric N,N-bidentate ligand around the  
fac-[Re(CO)3MeOH]+ core, the degree of the methanol labilising effect conferred by 
dendritic structures around the fac-[Re(CO)3MeOH]+ core was also of interest. 
 4.3.5. Substitution reactions of dendritic complexes C23 and C24 with 
monodentate ligands (Pyridine, DMAP and Br-) 
Preliminary stability and kinetic studies of fac-[Re4(N,N’-G1picolyl)(CO)12(OH2)4]4+ (LM4) 
and fac-[Re8(N,N’-G2picolyl)(CO)24(OH2)8]8+ (LM8) with Py, DMAP and Br- ligands were 
performed in dry methanol. All the reactions were found to be too fast for conventional 
UV/vis spectroscopic studies and could only be followed on a stopped-flow apparatus. Under 
pseudo-first order conditions, only one reaction was observed for all the reactions studied and 
the rates of these reactions were increased systematically with the increase in ligand 
concentration. 




In order to describe the general mechanism for the reaction of a dendrimer with monodentate 
entering ligands, the following simplified approach, Scheme 4.2, will first be followed in 
which the situation of a dendrimer containing two metal centres is used. 
Scheme 4.2: Proposed MeOH substitution overall equilibrium for a complex with two facial metal 
cores. 
The rate of the reaction is given below. 
 
Where k1, and k2 represent the forward reactions and k-1 and k-2 the reverse. By employing 
the pseudo first-order conditions with [X] >>> [total metal concentration], Equation 4.4 is 
reduced to Equation 4.5: 
 
From this, it means the overall rate second order constant, k1’ = (k1 + k2), can be obtained 
from plots of kobs vs [X]. 
Similarly, for a dendritic complex containing n number of metal centres, the overall second 
order rate constant can be obtained as: 
 
In the current study, all rates and concentration dependencies correspond to the methanol 
substituted complexes LM4 and LM8 (Figure 4.9). The dendritic analogues 1.00 × 10-4 M 
LM4 and 1.00 × 10-5 M LM8, and their substitution kinetic behaviour was investigated to 
determine the equilibrium constants and rate constants of the substitution of the 




aqua/methanol ligand at the sixth coordination site by DMAP, pyridine and Br- at 25.0 °C. 
All experiments were performed in dry methanol with the entering ligands having 
concentrations ranging from 0.005 – 0.05 M. 
 
Figure 4.9: Schematic representation of methanol substituted complexes, LM4 and LM8, studied in 
methanol substitution kinetics. 
A UV/vis spectrum of the reaction between LM4 and Br- is shown in Figure 4.10. In the 
UV/vis spectra of LM8, a similar trend is observed.  




       
Figure 4.10: Typical UV/vis spectral change for the reaction between fac-[Re4(N,N-
G1picolyl)(CO)3(MeOH)]4+ (LM4) and Br- at 25.0 ºC. [LM4] = 1.00 × 10-4 M, [Br-] = 0.025 M, λ = 
317 nm. 
The insert in Figure 4.10 represents the absorbance change versus time at 317 nm, 
confirming the first order behaviour. 
 4.3.5.1. LM4 and LM8 + Pyridine at 25.0 ˚C. 
The evaluation of the substitution kinetics of methanol by pyridine for [Re4(N,N’-
G1picolyl)(CO)12(MeOH)4]4+ (LM4) and [Re8(N,N’-G2picolyl)(CO)24(MeOH)8]8+ (LM8) 
supported by the plots of kobs vs [Pyridine] in Figure 4.11.  





Figure 4.11: The plots of kobs versus [Pyridine] for the reactions between 1.00 × 10-4 M fac-
[Re4(N,N’-G1picolyl)(CO)12(MeOH)4]4+ (LM4) and 1.00 × 10-5 M fac-[Re8(N,N’-
G2picolyl)(CO)24(MeOH)8]8 + (LM8). [Pyridine] = 0.005 – 0.05 M, λ = 317 nm. 
The linear relationship of kobs vs [Pyridine] suggests these reactions occur via a similar 
substitution mechanism as the monomeric analogue LM1, as illustrated by Equation 4.5. 
The kinetic data of the reactions represented in Figure 4.11 is summarized in Table 4.4. 
Table 4.4: Rate constants for the reactions between LM4 and LM8 with pyridine  
Pyridine LM4 (n = 4) LM8 (n = 8) 
kn (M-1s-1) 19.9(8) 22.7(4) 
k-n (s-1) 0.0749(2) 0.105(5) 
Kn (M-1) 265(9) 216(4) 
 
 4.3.5.2. LM4 and LM8 + 4-Dimethylaminopyridine at 25.0 ˚C 
The methanol substitution kinetics between DMAP and complexes LM4 and LM8 were 
performed using a stopped-flow spectrophotometer. The reactions were monitored at 312nm.  
The Re(I) metal concentrations were kept constant at 5.00 × 10-4 M LM4 and 1.00 × 10-5 M 
LM8, whereas, the incoming ligand DMAP concentration was varied from 0.005 – 0.05 M. A 






















Figure 4.12: The plots of kobs versus [DMAP] for the reactions between 1.00 X 10-4 M fac-[Re4(N,N’-
G1picolyl)(CO)12(MeOH)4]4+ (LM4) and 1.00 X 10-5 M fac-[Re8(N,N’-G2picolyl)(CO)24(MeOH)8]8+ 
(LM8). [DMAP] = 0.005 – 0.05 M, λ = 312 nm. 
The rate data are listed in Table 4.5. 
Table 4.5: Rate constants for the reactions between LM4 and LM8 with DMAP at  
25.0 °C 
DMAP LM4 (n = 4) LM8 (n = 8) 
kn (M-1s-1) 46.0(2) 50.7(6) 
k-n (s-1) 0.205(2) 0.255(3) 
Kn (M-1) 224(5) 199(1) 
 
 4.3.5.3. LM4 and LM8 + Bromo- ion (Br-) at 25.0 ˚C. 
The Br- ligand was chosen to understand the influence of the anionic charge on cationic 
dendritic ligands. The bromide ions were obtained from Et4NBr. In Figure 4.13, the plots of 






















Figure 4.13: The plot of kobs vs [Ligand] (Ligand = Br-) obtained using fac-[Re4(N,N’-
G1picolyl)(CO)12(MeOH)4]4+  (LM4) = 1.00 × 10-4 M and fac-[Re8(N,N’-G2picolyl)(CO)24(MeOH)8]8+ 
(LM8) = 1.00 × 10-5 M [Br-] = 0.005 – 0.05 M and T = 25.0 ˚C. 
The second generation dendritic complex has an increased kobs value compared to the other 
complexes and the linear plots is a good indication that the correct mechanism is assigned 
(Equation 4.6).  
Table 4.5: Rate data for the reaction between LM4 and LM8 with Br- at 25.0 ˚C 
Br- LM4 (n = 4) LM8 (n = 8) 
kn (M-1s-1) 60.8(2) 60.7(2) 
k-n (s-1) 0.274(4) 0.346(7) 
Kn (M-1) 222(3) 175(6) 
The increase in the polydispersity of a complex results in a faster reaction rate, however, the 
k1 values for LM4 and LM8 are comparable. This may be attributed to the increased 
inductive effect, by virtue of the dendritic arms, which influences the electron density around 





















 4.4. Discussion and conclusions 
Table 4.6 summarizes the rate data for the reactions of LM1, LM4 and LM8 with various 
nucleophilic ligands at 25.0 ºC. 
Table 4.6: Rate data for the reactions between LM1, LM4 and LM8 with various 
entering monodentate nucleophiles at 25.0 ˚C. 
LM1 (n = 1) kn (M-1s-1) k-n (s-1) Kn (M-1) 
Py 10.2(1) 0.062(4) 164(7) 
DMAP 28.7(1) 0.301(3) 95.3(6) 
Br- 34.8(4) 0.165(1) 211(2) 
LM4 (n = 4) kn (M-1s-1) k-n (s-1) Kn (M-1) 
Py 19.9(8) 0.0749(2) 265(9) 
DMAP 46.0(2) 0.205(2) 224(5) 
Br- 60.8(2) 0.274(4) 222(3) 
LM8 (n = 8) kn (M-1s-1) k-n (s-1) Kn (M-1) 
Py 22.7(4) 0.105(5) 216(4) 
DMAP 50.7(6) 0.255(3) 199(1) 
Br- 60.7(2) 0.346(7) 175(6) 
Based on the second order rate constants (kn) in Table 4.6, the LM1 reactions are slower than 
LM4 and LM8 reactions by a factor of ~2, hence, as the number of metal centres increase the 
reaction rate increases. Twala and co-workers investigated the formation of monomeric  
fac-[Re(CO)3(N,N-bidentante)Py]+ type complexes at 25.0 ºC and obtained rate constants of 
2.93(9) × 10-3 and 2.39(5) × 10-3 M-1s-1 (typical metal concentration 4.00 × 10-4 M – 1.00 × 
10-4 M).5 These rate constants are significantly lower (the reactions are ~6000 – 8000 times 
slower) than those obtained in the current study for the substitution of MeOH by Py in 
dendritic complexes LM4 (19.9(8) M-1s-1) and LM8 (22.7(4) M-1s-1). The increase in the rate 
accentuates the strong labilising effect of the dendritic N,N-bidentate ligands than the 
monomeric N,N-bidentate ligands. Therefore, the dendritic architecture on N,N-picolylamino 
moieties in complexes LM4 and LM8, has labilising effect on the generally inert Re(I)-
tricarbonyl core.  




The second order rate constants (k1) for LM4 and LM8 with Br- as the entering ligand (~60.0 
M-1s-1, Table 4.6 and Figure 4.14) are comparable and the pre-equilibrium constants (K1) are 
almost similar (LM4 = 222(3) M-1 and LM8 = 175(6) M-1).  
 
Figure 4.14: Overlap plot of kobs vs [Br-] for the reactions between LM1, LM4 and LM8 with Br- ion 
at 25.0 ºC. 
Therefore, it can be postulated that the k1 values for LM4 account for all four steps involved 
when the MeOH ligand is substituted by the monodentate nucleophiles. This demonstrates 
the ability of the dendritic arms to ‘communicate’ with each other. As the metal concentration 
increases, the rate increases by a factor of 2 (LM1 to the dendritic complexes), however a 
limit is reached thereafter (supported by comparable rate constants of LM4 and LM8) and 
this phenomenon will have to be investigated further. 
At 25.0 ˚C, the k1 value corresponding to LM1 brominated complex (Table 4.6) is  
34.8(4) M-1s-1 comparable to 28.7(1) M-1s-1 in the presence of DMAP. However, the stability 
constant, K1, in the presence of Br- ions increases to 211(2) M-1 compared to 95.3(6) M-1 in 
DMAP. The great increase in K1, compared to the constants shown in Table 4.1 – 4.2 at 





















Br- ion and corresponding cationic complexes. This suggest an associative mode of activation 
to form neutral complexes as the Br- ions have a greater affinity for the electrophilic 
Re(I)tricabornyl core.  
The flexibility of the dendritic arms permit faster reaction rates as the second order 
equilibrium constants increase with the dendrititc generations. When there is greater 
deviation on the k-1 values than the k1 values, there is less dependence on the entering ligand 
suggesting a dissociative type reaction mechanism.14,15 In the current study, the IR data 
corresponding to LM4 in DMAP (C23 + DMAPa in Chapter 3) cannot distinguish between 
single steps of substitution, therefore, it is proposed that the measured substitution rate of 
MeOH by 4 equivalents of DMAP is the overall rate of the reaction. 
 4.5. Summary 
The preliminary kinetic studies of the monomeric and dendritic complexes 5.00 × 10-4 M fac-
[ReN-((pyridine-2-yl)methyl)propan-1-amine)(CO)3(MeOH)]+ (LM1), 1.00 × 10-4 M fac-
[Re4(N,N’-G1picolyl) (CO)12(MeOH)4]4+ (LM4) and 1.00 × 10-5 M fac-[Re8(N,N’-
G2picolyl)(CO)24(MeOH)8]8+ (LM8) with varying ligands (Br- ions, Py and DMAP) were 
investigated. By comparing the rate constants at 25.0 °C, the following can be deduced: 
  The second order rate constants for the reactions with Br- ions are greater than those 
of N- donor ligands (Table 4.6). 
  The second order rate constants for the reactions LM1, LM4 and LM8 with DMAP 
(Table 4.6) are ~2 times higher than in the case where pyridine is used (Table 4.6). 
 The increase in rate constants from LM1 to LM4/8 indicates that the DAB-PPI 
dendrimer architecture does influence the rate of substitution reactions, but this effect is less 




dramatic as the generation increases from LM4 to LM8 (the reason for this is unknown but 
more studies are necessary to investigate this)  
  The stability constants K1 of the reactions at 25.0 ºC do not show a definite trend 
moving from a charged ligand to a neutral ligand. However, the dendritic complexes are 
notably stable in the presence of N-donating ligands. 
  Since the activation parameters for the complexes LM4 and LM8 with the ligands at 
varying temperatures were not investigated, high pressure studies are required in order to 
investigate the mode of activation of these complexes as it becomes more obvious whether 
the rate increases or decreases as the pressure in varied i.e. whether the activation volume 
∆Vǂ is positive or negative.16 
  The activation entropy values for LM1 reacted with pyridine and DMAP are negative 
but are not as high enough to infer pure associative mechanism.3 Entropy decreases as the 
entering ligand and complex come together in the rate-determining step (indicative of less 
disorder in the transition state). In a D process, the loss of the leaving ligand in the rate-
determining step increases entropy, resulting in positive entropy of activation. Experimental 
errors are inherent in the long extrapolation needed to estimate ∆Sǂ values from plots.16 
  Previous substitution kinetic studies involving the fac-[Re(CO)3(H2O)3]+ complex— 
in other instances the two aqua ligands substituted by O,O’- , N,O – and N,N’- bidentate 
ligands—in the presence of Br- ions, pyridine or DMAP suggested a dissociative 
interchange mechanism.2,3,8,14,17 
  The IR data of the complexes attests that the kinetic reactions observed corresponded 
to the MeOH substitution and not the dissociation of the bidentate ligand. 
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Technetium-99m and gallium-68 radiolabeling studies 
 5.1. General introduction 
Dendrimers are known to encapsulate multitude species such as metal ions1-5, anions6,7 and 
solvent molecules (neutral substrates8,9). Stephen and co-workers investigated the extraction 
of sodium pertechnetate (Na99mTcO4), a common nuclear waste contaminant10, by benzo-
crown-modified poly(propylene amine) (POMAM) dendrimers of varying generations 
(Figure 5.1) in chloroform.3  
                
Figure 5.1: Constitution of the benzo-crown-modified poly(propyleneamine) dendrimers of different 
generations.3 
The metal-binding affinity results demonstrated an increased [99mTcO4]- binding efficiency 
with increasing dendrimer generation.3 Also, during liquid-liquid extraction processes the 
analysis of the organic phase under basic conditions revealed low binding affinity of 
[99mTcO4]-,3 reflecting a pH dependent factor of dendrimer-based radiochemical interactions. 
 




Technetium-99m (Chapter 1, Section 1.4.2.) is a gamma (γ)-emitting radionuclide 
commonly used in imaging medical conditions using Single Photon Emission Computed 
Tomography (SPECT) scan, a nuclear imaging methodology that allows real-time monitoring 
of organ function in vivo, diagnose medical conditions and follow up disease progression.11,12 
The 6 hour half-life of 99mTc is favourable for monitoring the disease hours post injection 
Gallium-68 (68Ga, β+, 88.9%, half-life = 68 minutes) emits two with a radiopharmaceutical. 
divergent gamma-photons per decay allowing for the construction of three dimensional (3D)–
diagnostic images through a Positron Emission Tomography (PET) scan.12,13 The 68 minutes 
half-life is favourable for radiolabeling, and for the biodistribution of small molecules and 
biomolecules such as peptides.12 The PET scans are more sensitive but expensive than 
SPECT scans. 
The unique topology of dendrimers permits various possibilities of metal-binding behaviour 
within the dendritic framework or functionalized periphery.3 In nuclear imaging, the 
radiolabeling of higher generation dendrimer ligands with radiotracers such as 99mTc and 68Ga 
for disease diagnosis is of current interest. The multivalent nature, ‘enhanced and 
permeability retention’ effect14 and favourable generation-dependent biodistribution profiles 
of dendrimers in diseased tissues15-17, may enhance the sensitivity of imaging modalities 
through multitude attachment of diagnostic radioisotopes per dendrimer (lowering the 
injection dose to a patient) leading to enhanced image quality and resolution.  
In the current study, the 99mTc and 68Ga radiolabeling of first generation diaminobutane 
poly(propylene amine) (DAB-PPI) dendrimers grafted with 2-picolylamino (Figure 5.2) 
moieties at the periphery is reported.  




 5.2. Preliminary studies: radiolabeling of L5 using 99mTc 
Labeling of the first generation 2-picolylamino functionalized DAB-PPI dendrimer with 
99mTc radiotracer was performed using direct labeling ([99mTcO4]-), and ‘kit’ methods (fac-
[99mTc(CO)3(H2O)3]+ obtained from the isoLink® kit). The first generation dendritic ligand 
L5 (Figure 5.2) was purposely selected for direct labeling studies as a result of its water 
solubility.  
                                        
Figure 5.2: Proposed structure of L5. 
5.2.1. Direct radiolabeling studies using [99mTcO4]- 
The feasibility of labeling ligand L5 (Figure 5.2) was investigated using modified literature 
methods.18-21 In preparation of the labeling formulation, a generator eluted solution of 
Na99mTcO4 (22.2 mCi) was reduced with a 0.1 M solution of stannous chloride (SnCl2) in the 
presence of L5. Different dendritic formulations at pH 4.5, 5.5, 6.0 and 7.0 were investigated. 
The labeling pH was adjusted using a buffer solution (NaHPO4/citric acid). Other 
reduces the inert +7 oxidation state of experimental parameters such as the amount of SnCl2 (
99mTc in [99mTcO4]- to reactive oxidation states < +7), incubation temperature (80.0 ˚C) and 
radiochemical reaction time (15 minutes) were kept constant.  




The labeling efficiency of the radioactive dendritic formulations were measured through a 
gamma detector using instant thin-layer chromatograpy silica gel (iTLC-SG) and Whatmann 
cellulose fibre sheets passed through saline and acetone, respectively (Figure 5.3). 
 
Figure 5.3: A chromatographic system for analysing radiochemical purity of 99mTc-
radiopharmaceuticals.22-24 When the mobile phase reaches the solvent front line, the chromatogram is 
cut into two equivalent halves. Thereafter, each segment is placed in a gamma detector to measure the 
radioactivity. 
The available literature reports suggest that the amount of SnCl2 as a reducing agent 
influences the labeling efficiency and the formation of 99mTc colloids.18,19 The iTLC-SG gives 
an estimate of bound and hydrolized 99mTc at the origin and free 99mTc at the solvent 
front.22,23 Copious amounts of SnCl2 influence the formation of adverse radiocolloids as a 
result of free, reduced or hydrolysed [99mTcO4]-.18 Moreover, inadequate amounts of SnCl2 
result in poor labeling efficiency as a result of incomplete reduction of [99mTcO4]- from its 
inert heptavalent oxidation state.18,19  
In Figure 5.3, on the iTLC-SG paper base line the radiocolloids (hydrolized/reduced) are 
retained, whereas, the labeled complex (bound) together with ‘free’ [99mTcO4]- migrate 
towards the solvent front.18 In order to obtain the amount of labeled complex (bound), the 
activity migrating with acetone towards the solvent front corresponds to the ‘free’ [99mTcO4]- 










B (%) = 100 – F (%) – H (%) 




and is subtracted from the activity corresponding to the labeled formulation comprising L5 
and [99mTcO4]- (Figure 5.3, free + bound) on iTLC-SG paper.18 The obtained activity 
amounts (in mCi units) are substituted in the equations revealed in Figure 5.3 to obtain the F 
(‘free’ 99mTc), H (hydrolysed or reduced 99mTc/ colloids) and B (L5 bound 99mTc) 
variables.18,19,22 The retention factor (Rf) values were not measured. The properties of L5 
labeled at pH 4.5 – 7.0 using the direct method are summarized in Table 5.1. 
Table 5.1: Effect of pH on labeling efficiency of L5 at T = 80.0 ˚C and time = 15 
min. 





Free % 99mTc 
F 
4.5 60 40 0 
5.5 72.1 27.9 0 
6.5 21 79 0 
7.0 21 74 5 
From Table 5.1, at labeling pH 4.5 the labeling yield is 60% and the 40% difference is 
attributed to the radiocolloids. At pH 6.5 and 7.0, the labeling efficiency decreases to 21% 
attesting that the pH needs to be critically controlled in radiolabeling of L5. At pH 7, 
colloidal 99mTc precipitated in the reaction mixture. The highest labeling efficiency of 72.1% 
is obtained at pH 5.5.  
In the work done by Stephen and co-workers, the liquid-liquid extraction studies of 
[99mTcO4]- by third generation crown ether PPI dendrimer (Figure 5.1) revealed a highest 
metal-binding efficiency of 54.1% at pH 5.4, independent of the buffer composition.3 This 
group reasoned that the decrease in [99mTcO4]- binding affinity to the dendrimers at higher pH 
occurs as a result of low protonation state of the interior tertiary amine groups within the 
polyamine framework25, which render the coordination to [99mTcO4]- via electrostatic 
interactions possible.3 Based on their experimental findings, Stephen et al. reported the crown 




ether functionalities to have lower binding affinity to Na+ and [99mTcO4]-.3 Thus, in the 
present study it is possible that at pH 5.5, all the nitrogen atoms in L5 including the periphery 
moieties get protonated with the possibility to coordinate anionic 99mTc species. 
The radio-HPLC analysis gamma ray (Gina star, Raytest Gabi) of the aliquot at pH 5.5 
afforded the chromatogram in Figure 5.4 with a peak having retention time ranging from 
1.92 – 2.01 minutes (mobile phase: acetonitrile(ACN)/H2O – 55/45%, stationary phase: 
Phenomenex Luna C18 100 Å (4 × 250 mm × 5 µm), flow rate: 0.5 mL/min). Such results 
are inconclusive as ‘free’ [99mTcO4]- was found to elute around 2.00 minutes, possibly co-
eluting with the 99mTc+L5 complex formulation. Although the formulation at pH 5.5 was not 
used for further studies, the current study elucidates the feasibility of labeling L5 with 99mTc. 
                            
Figure 5.4: radio-HPLC chromatogram of L5 in pertechnetate [99mTcO4]- using a Luna C18 column. 
Mobile phase: acetonitrile(ACN)/H2O – 55/45%, stationary phase: Phenomenex Luna 
C18 100 Å (4 × 250 mm × 5 µm) column and flow rate: 0.5 mL/min 
It is important that a radiopharmaceutical has a radiolabeling efficiency of 95% and 
above.22,23 Also, the ideal pH of a radiopharmaceutical is 7.4, which corresponds to the blood 
pH. However, due to the buffer capacity of the blood, the ideal pH can vary between 2 and 
9.23 




5.2.2. Radiosynthesis studies using the fac-[99mTc(CO)3(OH2)3]+ 
5.2.2.1. isoLink® kit activation 
The combination of boranocarbonate (carbonylation reagent), disodium tartrate dehydrate and 
borax decahydrate under elevated temperatures reduces the heptavalent oxidation state of 
[99mTcO4]- to a univalent oxidation state leading to the synthesis of fac-[99mTc(CO)3(OH2)3]+ 
complex (isoLink® kit).26 The lyophilized isoLink® kit was activated as described in the 
literature27-29 and kit protocol (Centre of Radiopharmaceutical Research at the Paul Scherrer 
Institute in Switzerland). The kit activation was monitored using ultrahigh-performance 
liquid chromatography (UHPLC) Ultimate 3000 Thermofisher Dionex equipped with a UV 
spectrophotometer and a Berthold LB509 radiodetector. The chromatogram is displayed in 
Figure 5.5. The retention time of fac-[99mTc(CO)3(OH2)3]+  was found to be 2.02 ± 0.2 
minutes, possibly co-eluting with minute traces of [99mTcO4]-.  
                     
Figure 5.5: Radiometric analysis (UHPLC-Gamma detector) of the active isoLink® kit has a retention 
time of 2.13 minutes corresponding to fac-[99mTc(CO)3(OH2)3]+ co-eluting with [99mTcO4]-. Stationary 
phase: Phenomenex Luna C18 column (4.6 × 250 mm × 5 µm). Gradient mobile phase: acetonitrile 
(ACN)/water (20/80 – 70/30%). Flow rate: 1.1 mL/min 
In radiopharmaceutical developmental chemistry of fac-[99mTc(CO)3]+ isomer containing 
complexes, non-radioactive (‘cold’) fac-[Re(CO)3]+ adducts are used as characterization 
surrogates on account of corresponding isostructural properties of the two metal cores.12 In 
the framework of the current study, the synthesis and characterization of first generation (G1) 




DAB-PPI fac-[99mTc(CO)3(N,N-G1DAB-PPI)OH2]+ complexes is reported. The ‘cold’  
fac-[Re(CO)3OH2]+ DAB-PPI analogues, C20 and C23 complexes, have been synthesized 
and characterized using spectroscopic and analytical techniques as reported in Chapter 3. 
These non-radioactive Re(I) complexes served as models in characterization of the 
radioactive 99mTc(I) dendritic complexes by ultra-high performance liquid chromatography 
(UHPLC Ultimate 3000 Thermofisher Dionex). 
5.2.2.2. Radiolabeling experiment of L5 using fac-[99mTc(CO)3(OH2)3]+ and 
structural elucidation of the radiosynthesis product 
(Poly/di)Picolylamines are commonly reported as stable tridentate chelates orientated in a 
di(2-picolyl)-amine framework around fac-[99mTc(CO)3]+ isomer, displacing three aqua 
ligands from fac-[99mTc(CO)3(H2O)3]+.30-35 The di(2-picolyl)-amine frameworks are known to 
facilitate facile radiochemical synthesis of 99mTc complexes. In the current study, the 
picolylamine type dendritic ligand L5 was used as a bidentate chelate in the radiochemical 
synthesis of fac-[99mTc(N,N-L5)(CO)3OH2]+ (C23*, * = a radioactive 99mTc complex) 
complex. The UHPLC UV/vis (Ultimate 3000 Thermofisher Dionex equipped with a UV 
spectrophotometer and a Berthold LB509 radiodetector) chromatogram of the free ligand L5 
is shown in Figure 5.6 and L5 has a retention time of 3.20 ± 0.2 minutes using a Luna C18 
column using acetonitrile/H2O mixture as gradient mobile phase (20/80% – 70/30%). 
 
Figure 5. 6: UHPLC UV-vis trace of L5 (Rt = 3.20 min). Stationary phase: Phenomenex Luna C18 
(4.6 × 250 mm × 5 µm) column. Gradient mobile phase: acetonitrile (ACN)/H2O (20/80% – 
70/30%). Flow rate: 1.1 mL/min. 




The radiosynthesis of the radioactive complex C23* was performed using a devised 
procedure. Briefly, a 100 µL solution of fac-[99mTc(CO)3(H2O)3]+ (654 MBq) precursor was 
added to 0.21µmol solution of L5 in H2O. At pH 6, radioactive mixture was heated to 100 °C 
for 15 minutes to afford a 210 MBq radiochemical formulation. This experiment was 
performed in triplicate by varying only the pH to pH 2 and pH 8 in the other two vials using a 
PBS/HCl buffer. The formulation at pH 6 gave interpretable results. The activity at pH 2 and 
8 was 158 and 142 MBq, respectively.  
Purification of the L5-isoLink® kit formulations through a Sep-Pack C18 Light Cartridge 
(GE Healthcare) using EtOH/H2O gradient mobile system resulted in loss of radioactivity and 
some of the activity was retained in the column (~21.7 MBq at pH 2 and 6; ~ 50.3 MBq at pH 
8). The co-elution of the undesired impurities with the product(s) was also observed upon 
UHPLC analysis and this can be attributed to the enhanced lipophilicity of L5 or 99mTc-L5 
labeled complex and the hydrophilic mobile system. The use of the appropriate purification 
method is important for accurate radiochemical purity, specific activity and labeling 
reproducibility.13 Furthermore, radiolabeling of L5 is pH dependent.  
In Figure 5.7, the degree of radiochemical synthesis of C23* was verified by separately 
injecting the fac-[Re(CO)3(OH2)3]+ medium (the top chromatogram in mAU units), the ‘cold’ 
Re(I) analogue C23 (the middle chromatogram in mAU units) and the crude L5-isoLink® kit 
formulation at pH 6 (the bottom chromatogram in mV units) in a UHPLC equipped with 
UV-vis and a gamma-ray detector. 
 





Figure 5.7: Comparative chromatograms of Re(I)-aqua precursor fac-[Re(CO)3(H2O)3]+ (top), Rt = 
2.25 ± 0.2 minutes and λ = 238 nm; the rhenium model complex C23 (centre), Rt = 6.23 ± 0.2 
minutes and λ = 258 nm; and the technetium-99m formulation, desired L5-isoLink® kit formulation 
(bottom), at Rt = 6.23 ± 0.2 minutes (λ = 258 nm). Stationary phase: Phenomenex Luna C18 (4.6 × 
250 mm × 5 µm) column. Gradient mobile phase: acetonitrile/H2O (20/80% – 70/30%). Flow rate: 
1.1 mL/min. 
The chromatogram corresponding to the fac-[Re(CO)3(H2O)3]+ complex (Figure 5.7, top 
chromatogram) has two peaks at 2.07 ± 0.2 and 2.25 ± 0.2 minutes assigned to Et4N+ and  
fac-[Re(CO)3(H2O)3]+, respectively. The chromatogram at the centre, in Figure 5.7, 
corresponds to the crude complex C23 (Figure 5.8 and Chapter 3). 
 




                            
Figure 5.8: Proposed structure of C23. 
In the second chromatogram (Figure 5.7, middle chromatogram), a peak with a retention 
time of 6.23 ± 0.2 minutes is assigned to the complex C23 (characterization data in Chapter 
3), where four equivalents of the fac-[Re(CO)3]+ core coordinated at the periphery of the 
dendritic arms. Other peaks are attributed to the unreacted metal precursor and impurities 
from the crude mixture injected. 
At least, three radioactive species are detected in the radio-UHPLC chromatogram (in mV 
units) of the L5-isoLink® kit formulation (Figure 5.7, bottom chromatogram). The peak with 
the retention time of 2.41 ± 0.2 minutes is assigned to the unreacted metal precursor, 
identified as either fac-[99mTc(CO)3(H2O)3]+ or 99mTcO4-. The possible slow conversion of  
fac-[99mTc(CO)3(OH2)3]+ via oxidation to form [99mTcO4]- over the duration of 
experimentation, is reported in the literature.36 The gamma detector chromatogram displays a 
peak at 6.23 ± 0.2 minutes assigned to the target complex C23* wherein four equivalents of 
the fac-[99mTc(CO)3]+ core are coordinated at the periphery of the dendritic arms via the N,N-
picolylamine donor atoms. The radioactive species between 4.00 – 6.50 minutes, although 
unexpected, may correspond to 99mTc-L5 labeled complexes of different nuclearity, based on 
the capability of the dendritic periphery (picolyl pendants) and framework (Chapter 1, 
Figure 1.11) to compete for the fac-[99mTc(CO)3OH2]+ precursor. 
Based on the comparative chromatographic retention times of the ‘cold’ Re(I) complex C23 
(6.23 ± 0.2 min) and the radioactive 99mTc(I) complex C23* at 6.23 ± 0.2 minutes (Figure 




5.7, bottom chromatogram in mV units), the translation of Re chemistry to 99mTc at a 
radiotracer level using a dendritic N,N-picolyamine type ligand was successful. The proposed 
molecular structure of the radioactive complex at 6.23 ± 0.2 minutes considers the possibility 
of forming a mixture of bridged dimeric or oligomeric hydroxy complexes via the aqua 
ligand and substitution of the aqua ligand by nucleophilic solvent molecules.  
5.3. Preliminary studies: radiolabeling experiment of L2 using 
fac-[99mTc(CO)3(OH2)3]+ and structural elucidation of the 
radiosynthesis product 
The radiolabeling of the ligand L2 (Figure 5.9 and Chapter 2) was performed analogous to 
the L5-isoLink® kit formulation.  
                            
Figure 5.9: Constitution of C20 
In acetonitrile/H2O (50/50% – 80/20%) gradient mobile phase system, the ‘cold’ complex 
C20 (Chapter 3) has a retention time of 7.15 ± 0.2 min. This retention time does not 
correlate with that of the radioactive fac-[99mTc(N,N-L2)(CO)3OH2]+ complex which is 4.01 
± 0.2 minutes. The differences in retention times are not attributed to the sequential 
configuration of the UV-vis and gamma ray detectors. As in most cases, the deviation in the 
HPLC retention factors of 99mTc radiolabeled complexes from Re complexes is due to the 
dead time as the analyte migrates in the pipe line to the ultraviolet and gamma-ray 
detectors.37 These adverse radiosynthesis results may be attributed to the poor solubility of 




L2 in labeling aqueous media, reaction time or pH, resulting in inefficient labeling of the 
dendrimer. Also, the purification of the crude formulation by a Sep-Pack C18 Light Cartridge 
using EtOH/H2O gradient mobile system resulted in a drastic loss of radioactivity from the 
collected fractions. The activity post purification, was found to be retained in the cartridge, 
possibly radioactive degradation products.  
Based on the translatable radiolabeling results on L5 + technetium-99m preliminary studies, 
the radiolabeling of L5 in aqueous media was further attempted using radioactive 
gallium(III)chloride, [68Ga]GaCl3. 
5.4. Preliminary studies: 68Ga radiolabeling experiment of L5  
Figure 5.10 displays UHPLC-UV/vis and gamma-detector chromatograms of L5 (top 
chromatogram), ‘free’ [68Ga]GaCl3 (centred chromatogram), L5-[68Ga]GaCl3 purified 
formulation (bottom chromatogram).  




                  
Figure 5.10: Top: UV/vis chromatogram of L5, Rt = 3.20 ± 0.2 min. Centre: radio-UHPLC 
chromatogram of purified 68Ge/68Ga generator eluted [68Ga]GaCl3, Rt = 2.12  ± 0.2 min. Bottom: 
radio-UHPLC chromatogram of the reaction mixture post purification. Stationary phase: 
Phenomenex Luna C18 (4.6 × 250 mm × 5 µm) column. Gradient mobile phase: ACN/H2O (20/80% 
- 70/30%). Flow rate: 1.1 mL/min. 
The generator-eluted [68Ga]GaCl3 was purified using a cation ion exchange cartridge 
(CHROMABOND® PS-H+). In Figure 5.10 (middle chromatogram) The radiodetector 
chromatogram of [68Ga]GaCl3, after purification, displays a peak with a retention time of 2.12 
± 0.2 minutes assigned to [68Ga]GaCl3. In this chromatogram, there is peak broadening and 
splitting, possibly as a result of adverse chromatographic parameters (flow rate, stationary 
phase and mobile phase).  




Currently, no work has been reported on the radiolabeling of 2-picolylamine functionalized 
PPI dendrimers using 68Ga. The radioactive L5-68Ga formulation was purified through a 
Sephadex® G-10 cartridge (molecules of ≤ 700 g/mol are retained within the cartridge). The 
chromatogram at the bottom in Figure 5.10 corresponds to the fraction with the highest 
radioactivity (30.7 MBq) after purification which was eluted from the cartridge using 0.6 M 
PBS mobile phase. This chromatogram is inconclusive to whether the free [68Ga]GaCl3 is not 
present or its peak signal overlaps with the signal at 2.41 ± 0.2 minutes. Thus, injection of the 
crude medium prior to purification might give interpretable results.  
Since this is a nascent study, the challenge within this work was to find optimum reaction 
conditions for a successful radiolabeling of the dendritic ligand L2 using [68Ga]GaCl3. 
Labeling parameters like incubation temperature, labeling pH, reaction time duration, starting 
materials concentration, choice of buffer solutions and UHPLC mobile phase will have to be 
investigated for optimum labeling efficiency. Ebenhan et al., radiolabeled NOTA conjugated 
peptides (~10mg/ml) using 68Ga and the radiolabeling method used is partially similar to the 
current study.13 Radiolabeling adjustments in the current study are most likely to yield 
sufficient radiolabeling yields. Alternatively, the labeling of DAB-PPI dendrimers with 
bifunctional chelators at the periphery (as opposed to N,N-chelates in the current study) will 
have to be investigated as it has been reported in the literature that bi-functional chelators 
chelate the 68Ga(III) ion with greater affinity and stability.13,37,38 
5.5. Summary 
In the current study, the first generation DAB-PPI dendrimers, with different functionality at 
the periphery, were radiolabeled with 99mTc. The direct labeling procedure demonstrated pH 
dependent radiolabeling of PPI type dendrimers. Among the different options investigated in 
optimizing labeling conditions, successful labeling of L5 using the isoLink® kit was obtained. 




The ‘cold’ Re(I) surrogate C23 was used to elucidate the structure of the fac-
[99mTc(CO)3(N,N-L5)OH2]+ complex, C23*. The characterization of C23* (99mTc complex) 
was performed by UHPLC-Gamma detector and the desired complex was found to have a 
retention time of 6.23 ± 0.2 minutes (comparable to ‘cold’ Re(I) complex C23 at 6.23 ± 0.2 
minutes). These results attest the similarity in fac-[99mTc(CO)3]+ and fac-[Re(CO)3]+ 
containing complexes. Furthermore, the results show that the N,N-2-picolylamine type 
ligands selectively coordinate to 99mTc and Re in a similar manner. The major divergences in 
‘cold’ and radioactive N,N-bipyridyl complexes were observed with respect to the different 
retention times of the ‘cold’ complex C20 and the radioactive 99mTc complex(es). This may 
be attributed to the inadequate labeling reaction time and/or poor solubility of L2 in aqueous 
labeling solution. Such findings highlight the difference in experimental conditions for 
chemical and radiolabeling reactions. The [68Ga]GaCl3 labeling study on L5 was a challenge 
and optimum reaction conditions for a successful radiolabeling are required. Labeling parameters 
like incubation temperature, labeling pH, reaction time duration, starting materials’ concentration 
and choice of buffer solutions will have to be investigated for optimum labeling efficiency. The 
simple organometallic labeling studies performed accentuate the possibility of labeling higher 
generation dendrimers of L5 type with 99mTc—if purification, prominent labeling yields and 









5.6.1. Materials and methods 
5.6.1.1. Direct radiolabeling studies 
The solvents used were of high performance liquid chromatography (HPLC) grade and were 
purchased from Sigma-Aldrich. Analytical reverse phase HPLC was carried out on an 
Agilent Series 1200 instrument coupled to a diode array UV/vis detector and radiodetector 
(Gina star, Raytest Gabi Gamma Detector Benzstrasse 4, D-75334 Straubenhard) using 
Phenomenex Luna C18 column (4 × 250 mm × 5 µm) with a flow rate of 0.5 mL/min. All 
HPLC procedures isocratic mobile phase system comprised 45% H2O and 55% acetonitrile 
(ACN). HPLC-grade water was produced in-house using a Simplicity 185 Millipore system 
(resistivity = 18.2 MΩcm). Instant thin layer chromatography silica gel (iTLC-SG) was 
purchased from PALL Life Science. [99mTcO4]- was obtained from an in-house generator at 
South African Nuclear Energy Corporation (Necsa, NTP). The activity was measured in a 
Scionix 25B25/1.5-E2 gamma counter. All vials were evacuated with argon. 
5.6.1.2. isoLink® kit radiolabeling studies 
The analytical solvents were purchased from Advanced Biochemical Compounds (ABX) and 
used as received. The isoLink kit was purchased from Centre of Radiopharmaceutical 
Research at the Paul Scherrer Institute, Switzerland. The ultrahigh performance liquid 
chromatography (UHPLC) chromatograms were obtained from a Thermofisher Dionex 
equipped with a UV/vis spectrophotometer and a Berthold LB509 radioactivity detector using 
a Phenomenex Luna C18 column 100 Å (4.6 × 250 mm × 5 µm) and a flow rate of 1.1 
mL/min. Sep-Pack C18 Light Cartridges (78.6 µm) were obtained from GE Healthcare. The 
pH test papers were purchased from MACHEREY-NAGEL. Radiolabeling and purification 




experiments were performed in a LEMER PAX INNOVATIVE glove box integrated with a 
dose calibrator. [99mTcO4]- used was obtained from a 4 GBq Generator purchased from Cis-
Bio IBA. 
5.6.1.3. 68Ga radiolabeling studies 
The radiolabeling studies were performed in an automated General Electric Medical Systems 
(Tracelab FX F-N) radiosynthesizer. [68Ga]GaCl3 was eluted from a 1GBq SnO2-based 
68Ge/68Ga generator (iThemba LABS, SA) and purified through a CHROMABOND® PS-H+ 
cartridge purchased from MACHEREY-NAGEL. The pH test papers were purchased from 
MACHEREY-NAGEL. The analytical solvents were purchased from Advanced Biochemical 
Compounds (ABX). The crude dendritic formulation was purified using 0.6 M PBS, as the 
mobile phase, through a Sephadex® G-10 Medium (55 – 165 μm, 1.3 × 4.0 cm, 5.3 mL) size 
exclusion cartridge purchased from GE Healthcare. Purification processes were performed in 
a LEMER PAX INNOVATIVE glove box integrated with a dose calibrator. UHPLC 
chromatograms were obtained from a Thermofisher Dionex equipped with a UV/vis 
spectrophotometer and a Berthold LB509 radioactivity detector using a Phenomenex Luna 
C18 column 100 Å (4.6 × 250 mm × 5 µm) and a flow rate of 1.1 mL/min. 
5.6.2. Direct radiolabeling protocol 
5.6.2.1. Buffer preparation 
The reagents sodium phosphate (NaHPO4) and citric acid were weighed for the preparation of 
buffer solutions of pH 4.0, 5.5, 6.5 and 7.0. In all preparations, 200 µL of ultrapure water 
collected at 18.2 MΩcm was used to dissolve the reagents using a vortex. 




5.6.2.2. Sample preparation 
In a vial, L5 (1.00 mg, 0.210 µmol) was dissolved in 250 µL ultrapure water (collected at 
18.2 MΩcm resistance) to afford a pH 10 solution. The solution was adjusted to pH 4.0 by a 
200 µL NaHPO4/citric acid buffer solution. 
5.6.2.3. Preparation of the reducing agent 
To a vial containing SnCl2 (10.0 mg, 0.0527 mmol), a 100 µL solution of 0.1 M HCl was 
added. Subsequently, 9.90 mL of ultrapure water was introduced.  
5.6.2.4. ‘Kit’ formulation 
The evacuated vial containing the reducing agent was further pipetted with 250 µL solution 
of L5 in ultrapure water. Contents were vortexed. Thereafter, 100 µL aliquot of the solution 
was pipetted into a shielded vial for radiolabeling studies. 
5.6.2.5. Radiolabeling of the dendritic formulation 
A direct labeling method using sodium pertechnetate (Na99mTcO4) was formulated at varying 
pH values of the ‘kit’ formulation. Briefly, 500 µL of [99mTcO4]- (22.2 mCi; obtained from an 
in-house 99Mo/99mTc generator) in saline was added to 100 µL (1.00 mg/mL) of each ‘kit’ 
formulation. The resulting solutions were heated at 80.0 °C for 15 minutes and stored in 
sterile evacuated sealed vials for labeling efficiency studies. 
5.6.2.6. Determination of radiochemical labeling efficiency and colloid forming by 
iTLC-SG 
Whatmann paper and Instant Thin-Layer Chromatograpy-silica gel (iTLC-SG) 
Radiochemical purity of the radiolabeled material was evaluated using a Whatmann cellulose 
and iTLC-SG (dimensions: paper strips 1 cm × 10 cm, both stationary phases). Briefly, 
each crude radioactive formulation (3 – 6 µL) was spotted at the baseline of iTLC 




impregnated silica gel paper (iTLC-SG) and Whatmann cellulose strip using an 
insulin needle (Hamilton). Following 4 – 5 minutes exposure to mobile phase, acetone 
nn cellulose strip and saline for iTLC-SG, the strips were immediately dried and. for Whatma
divided into two segments, demarcating the solvent front from the solvent origin. 
Subsequently, the activity in each segment was measured using a gamma radiation counter 
(Scionix 25B25/1.5-E2). 
5.6.3. Synthesis of fac-[99mTc(CO)3OH2]+ core complexes 
5.6.3.1. ‘Kit’ activation 
The isoLink® kit was activated according to the protocol packaged with the kit. The activity 
of the generator-eluted [99mTcO4]- used to activate the kits ranged betweem 5.00 – 4.00 GBq. 
5.6.3.2. Radiolabeling of L2 using the isoLink® kit to afford C20* 
                               
A 100 µL aliquot of [99mTc(CO)3(H2O)3]+ (858 MBq) was added into a vial containing 224 
µL L2 (0.21 µmol, 1 mg/mL) in acetonitrile and 350 µL of 0.6 N HCl/PBS buffer solution 
(3:2). The mixture was heated to a 100 °C for 15 minutes where a 20 µL aliquot of the 
reaction mixture was analysed using UHPLC-Gamma photon detector every 5 minute time 
interval. The spectra obtained by HPLC have shown that the labelling reaction is achieved 




after 15 min. The crude reaction mixture (~500 µL, 108 MBq, pH 6) was then passed through 
a 3.5 mL short cartridge (Sep-Pack C18 Light Cartridge) where 2 – 3 mL of 100% H2O, 
EtOH/H2O (1:1) and 100% EtOH were used as mobile phase. Following the purification, the 
fractions collected (0.2 mL per vial) were analysed using a γ-ray detector and those with 
higher activity (~30 MBq) were further analysed by UHPLC-Gamma photon detector. 
C20: Rt = 7.15 ± 0.2 min. C20*: Rt = 4.02 ± 0.2 min. Gradient mobile phase: 
acetonitrile/H2O (50/50% - 80/20%). Stationary phase: Phenomenex Luna C18 column (100 
Å, 4.6 × 250 mm × 5 µm). Flow rate: 1.1 mL/min. 
 Radiolabeling of L5 using the isoLink® kit to afford C23*5.6.3.3.  
                                         
A 100 μL solution of [99mTc(CO)3(H2O)3]+ (654 MBq) was added into a vial containing 146 
μL L5 (0.21 μmol, 1 mg/mL) in water and 350 μL of 0.6 N HCl/PBS buffer solution (3:2). 
The mixture was heated to 100 °C for 15 minutes. After 15 minutes, the crude reaction 
mixture (~500 μL, 210 MBq, pH 6 - 7) was then passed through a 3.5 mL short cartridge 
(Sep-Pack C18 Light Cartridge) where 2 – 3 mL of 100% H2O, EtOH/H2O (1:1) and 100% 
EtOH were used as the mobile phase. Following the purification, the fractions collected (0.2 
mL per vial) were analysed using a γ-ray detector and those with higher activity (>25.5 MBq) 
were further analysed by UHPLC-Gamma photon detector. 




C23: Rt = 6.23 ± 0.2 min. : Rt = 6.23 ± 0.2 min. Gradient mobile phase: C23*
acetonitrile/H2O (20/80% - 70/30%). Stationary phase: Phenomenex Luna C18 column (100 
Å, 4.6 × 250 mm × 5 µm). Flow rate: 1.1 mL/min. 
 Preliminary radiolabeling studies on L5 using 5.6.4. 68Ga 
5.6.4.1. Reagents preparation 
L5 (0.21 μmol, 1mg/ml) was dissolved in 1.00 mL solution of 2.5 M sodium acetate buffer to 
give a final solution of pH 5 – 6. Under acidic conditions, 2.00 – 3.00 mL 0.6 N HCl was 
used to elute 68Gallium(III)chloride (68Ga) (571.1 MBq) from a SnO2-based 68Ge/68Ga 
generator. The initial eluent collected at 1.00 mL 0.6 N HCl was discarded in a waste vial. 
The [68Ga]GaCl3 solution was passed through a CHROMABOND® PS-H+ (200 mg. cation 
exchange cartridge) and 68Ga desorbed using 1.00 mL 0.5 M saline as the mobile phase for 
pH adjustment and preliminary purification from potentially co-eluted 68Ge. 
5.6.4.2. 68Ga radiolabeling procedure 
In the automated radiosynthesize, 146 μL L5 was injected in a reactor containing 1.00 mL 
[68Ga]GaCl3 (111.4 MBq) in 0.5 M NaCl. The reaction proceeded at room temperature for 20 
minutes. An aliquot of the reaction mixture was retained for UHPLC-Gamma ray detector 
analysis prior to the purification step. 
[68Ga]GaCl3: Rt = 2.12 ± 0.2 min. Gradient mobile phase: acetonitrile/H2O (20/80% - 
70/30%). Stationary phase: Phenomenex Luna C18 column (100 Å, 4.6 × 250 mm × 5 µm). 
Flow rate: 1.1 mL/min. 
 




5.6.4.3. Purification procedure 
The crude reaction mixture (104.9 MBq) was passed through a Sephadex® G-10 Medium (55 
– 165 μm, 1.3 × 4.0 cm, 5.3 mL) size exclusion cartridge using 0.6 M PBS as the mobile 
phase. The collected fractions (pH 2, 0.200 mL each) with radioactivity ≤ 20.0 MBq were 
evaluated for small scale sample purification using UHPLC-Gamma ray detector. 
[68Ga]GaCl3 + L5: Rt = 2.12 – 2.41 ± 0.2 min. Gradient mobile phase: acetonitrile/H2O 
(20/80% - 70/30%). Stationary phase: Phenomenex Luna C18 column (100 Å, 4.6 × 250 
mm × 5 µm). Flow rate: 1.1 mL/min. 
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General Conclusions and Future Work 
6.1. Conclusions 
The N,N-bidentate monomeric and dendritic (DAB-PPI) ligands integrated with 2,2’-
bipyridyl and 2-picolylamino entities, L1 – L6, were synthesized using a reductive amination 
reaction. The 2-picolylamino functionalized ligands, L4 – L6, were found to be water 
soluble, S25 °C = 0.01 mg/µL.  
Subsequently, Re(I) complexes were synthesized from three Re(I) precursors Re(CO)5Cl, fac-
(Et4N)2[Re(CO)3Br3] and fac-[Re(CO)3(OH2)3]+ to afford complexes C7-C24. Several 
complexes were characterized using spectroscopic and analytical methods. The molecular 
structure of C16, a Re(I) bromo- complex, was further confirmed by X-ray diffraction 
analysis to investigate the mode of bidentate ligands coordination in macromolecular 
structures of the same family. The XRD structure of C16 revealed the mode of coordination 
of CO ligands around the Re(I) centre as being facial. Also, the crystal structure confirmed 
the pseudo octahedral conformation, supported by the bite angles of the N,N-donor atom 
chelates. 
The dissolution of fac-[Re(CO)3(N,N-2-picolylamino)OH2]+ type complexes, C22, C23 and 
C24, in MeOH to afford fac-[Re(CO)3(N,N-2-picolylamino)MeOH]+ type complexes, LM1, 
LM4 and LM8, respectively. The Re(I) methanol complexes were investigated in 
substitution kinetic studies. The incredible reactivity of the MeOH ligand in dendritic Re(I) 
complexes LM4 and LM8 towards nucleophilic substitution by monodentate ligands (Br-, Py 
and DMAP) in solution indicate prominent prospects for the ‘2+1’ radiolabeling of these 
macromolecules. It was observed that the dendrimer labilizing effect did not increase with the 




MeOH substitution; however, to a certain extent, in spite of the metals being substantially 
removed from each other via the dendritic branches.  
In the preliminary radiolabeling studies, the first generation dendritic ligands L2 and L5 were 
tested for their regioselective radiolabeling ability with 99mTc in aqueous media. The direct 
labeling studies of L5 using [99mTcO4]- accentuated the feasibility of chelating 99mTc with 
N,N-donor atoms present in macromolecular structures, a confirmed by labeling efficiency 
analysis using iTLC-SG and Whatmann cellulose strips. In this study, pH and the amount of 
SnCl2 used may have contributed in the formation of the undesired 99mTc radiocolloids. 
Furthermore, the radiolabeling of L5 with fac-[99mTc(CO)3(OH2)3]+, a fac-[Re(CO)3(OH2)3]+ 
congener, was successfully achieved and the comparison of the chromatographic results 
corresponding to the ‘cold’ Re(I) complex C23 and radioactive 99mTc analogue C23* 
suggested a similar mode of metal coordination, at the periphery. However, efficient 
purification of the labeled formulation could not be achieved as a result of similar enhanced 
lipophilicity of the product(s) and impurities in the mobile phase. 
Translatable chromatographic results for the radiolabeling of L2 with fac-
[99mTc(CO)3(OH2)3]+ and L5 with [68Ga]GaCl3 were not observed, supporting the need to 
explore different experimental parameters when radiolabeling macromolecular structures (as 
 opposed to chemical reactions), in general.
6.2. Future Work 
Since the activation parameters for the complexes LM4 and LM8, in the presence of Py, 
DMAP and Br-, at varying temperatures were not investigated, high pressure stopped-flow 
studies are required in order to investigate the mode of activation of these complexes, as it 
becomes more obvious whether the rate increases or decreases as the pressure in varied (i.e. 




phenomenon that results in negligible increase of rate constants with increasing generation 
number (LM4 to LM8). In radiolabeling studies, an effective purification method must be 
devised in order to determine the labeling yields and purity of fac-[99mTc(CO)3OH2]+ isomer 
dendritic complexes. If a purification methodology can be achieved, the labeled 
metallodendrimers can be biologically tested as potential diagnostic 99mTc 
radiopharmaceuticals. In L5 + [68Ga]GaCl3 radiolabeling studies, labeling must be 
investigated at various pH ranges, temperatures and at high ligand mass. 
 
